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A new methodology is introduced in which engineering-based tools and 
techniques are adapted to quantitative microbial risk assessment (QMRA) in order to 
offer a more systematic solution to food safety problems.  By integrating available 
microbial data and adapted engineering techniques within the traditional QMRA 
framework, this new methodology addresses some of the deficiencies of traditional 
approaches.  Through the use of a hierarchical structure, the system is decomposed 
into its most basic elements so that the interrelationships and interdependences of 
these basic elements are captured.  This hierarchical structure also identifies 
variability throughout the process, resulting in a risk model in which multiple 
scenarios can be analyzed.  In addition, the engineering approach adapts methods for 
characterizing and propagating uncertainties.  Unlike the traditional approaches in 
food safety, the engineering-based methodology relies on mathematical models; the 
uncertainties about these models (both aleatory and epistemic), as well as the 
uncertainties about the model parameters, are formally quantified and properly 
considered.  This separation and characterization of uncertainties results in a more 
powerful risk model, so that assessments can be made as to whether additional 
information or changes to the physical system will reduce the total uncertainty.  
Finally, this research characterizes the validity of the various dose-response models.  
Comparison of actual outbreak observations to model predictions lends credibility 
and assesses uncertainty of the developed dose-response models.  Thus, the results of 
the risk model can be used both as an absolute assessment of risk and as a relative 
measurement of mitigation and control strategies.     
As a case study, the engineering-based methodology is applied to the problem 
of Escherichia coli O157:H7 contamination in cheese.  While it has been assumed 
that pathogenic microorganisms in raw milk die during cheese-making, several 
studies on the survival of E. coli O157:H7 in cheese have demonstrated growth 
during cheese manufacturing.  Furthermore, E. coli O157:H7 has been linked to 
several outbreaks involving cheese, thereby establishing the need to investigate this 
route of transmission.  The successful application of the engineering-based approach 
to the problem of E. coli O157:H7 contamination in cheese suggests that this new 
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1.  INTRODUCTION 
 
1.1  Dissertation Overview 
Foodborne disease is a serious cause of illness in the United States and is 
estimated to affect over 76 million people each year and cost the economy several 
billion dollars.  While many different pathogens can cause foodborne illness, 
Escherichia coli O157:H7 has emerged as a primary food safety concern in recent 
years.  Many estimates of the severity of E. coli O157:H7 cases have been made over 
the last decade.  While these figures vary, an estimated 62,000 cases of symptomatic 
E. coli O157:H7 infections occur annually in the United States due to foodborne 
exposures.  These infections result in approximately 1,800 hospitalizations and 52 
deaths (Mead et al., 1999).  In addition, the annual cost to the United States economy 
for foodborne E. coli O157:H7 cases has been estimated to be as high as $659 million 
(Buzby, 2002).  Thus, E. coli O157:H7 has emerged as a foodborne pathogen with 
major public health significance in the United States.   
E. coli O157:H7 was first isolated by the Centers for Disease Control (CDC) 
in 1975; however, it was identified as a cause of human illness in 1982, after it was 
associated with a severe outbreak of hemorrhagic colitis in Oregon and Michigan that 
was traced back to undercooked ground beef (Riley et al., 1983).  Since that time, 
numerous outbreaks of E. coli O157:H7 infections associated with beef products have 
been reported, establishing cattle as the primary reservoir of E. coli O157:H7 (Griffin 
and Tauxe, 1991).  These ground beef related outbreaks prompted the Food Safety 
and Inspection Service (FSIS) and others to conduct risk assessments of E. coli 
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O157:H7 in ground beef (Cassin et al., 1998; FSIS, 2001; Ebel et al., 2004).  
Although fecal contamination of carcasses during slaughter and processing of beef 
has been established as route of transmission, investigations have shown that fecal 
contamination of milk is an important route of transmission as well (Marek et al., 
2004).  Multiple outbreaks of E. coli O157:H7 linked to the ingestion of both raw and 
pasteurized milk have been reported (Keene et al., 1997; Martin et al., 1986; Upton 
and Coia, 1994), and this association with milk raises the possibility of E. coli 
O157:H7 survival in other dairy products such as cheese.   
Cheese was originally developed as a means of preserving raw milk in times 
of excess production, and has generally been considered a relatively “safe” food.  
Traditionally, it has been assumed that pathogenic microorganisms in raw milk die 
during the cheese manufacturing process due to the production of high acidity (i.e., 
low pH value) and competition from starter cultures (Fox, 1993).  However, studies 
on the survival of E. coli O157:H7 in hard cheese indicate that the pathogen can grow 
during the cheese manufacturing process and survive for up to 70 days post-
manufacturing (Hudson et al., 1997; Maher et al., 2001; Reitsma et al., 1996; Teo et 
al., 2000).  Therefore, the indications are that the additional hurdles imposed during 
the cheese manufacture are insufficient to prevent the growth and survival of the 
pathogen in cheese produced from milk contaminated with the pathogen.   
In recent years, several outbreaks of E. coli O157:H7 infection have been 
linked to cheese.  Five cases of gastroenteritis in Wyre, England were linked with the 
consumption of cheese made from unpasteurized milk in November 1997 (Strachan et 
al., 2005).  In 1998, an outbreak affecting 55 people in Wisconsin was linked with the 
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consumption of fresh Cheddar cheese curds contaminated with E. coli O157:H7 
(CDC, 2000).  Finally, 13 cases of E. coli O157:H7 infection associated with the 
consumption of Gouda cheese were identified in Alberta, Canada in 2003.  Two of 
these cases involved children who later developed hemolytic uremic syndrome (HUS) 
as a result of infection (Hornish et al., 2005). 
Not only has E. coli O157:H7 been shown to survive the cheese 
manufacturing and ripening process, but it has also been linked to several outbreaks 
involving cheese, thereby establishing the need to investigate this route of 
transmission.  This research develops a risk model using probabilistic-based 
engineering tools and techniques in order to describe the behavior of E. coli O157:H7 
in cheese during production, distribution, and consumption and estimate the overall 
human health risk.  The framework upon which the model is based organizes and 
links the data to a user-interface, allowing for scenario development and sensitivity 
analysis.  In addition, the inclusion and recognition of variation within the process 
and data, parameter, and model uncertainty allows for the consideration of both 
aleatory and epistemic uncertainty when assessing the societal impacts, identifying 
control strategies, and weighing risk management options.   
 Despite the introduction of engineering tools and techniques, the risk 
assessment described herein is consistent with other food safety risk assessments 
(Cassin et al., 1998; Bemrah et al., 1998; FSIS, 2001; Ebel et al., 2004).  These risk 
assessments follow the basic guidelines set forth in the “Application of Risk Analysis 
to Food Standards Issues” prepared by the Food and Agriculture Organization/World 
Health Organization (FAO/WHO) Expert Consultation at the request of the Codes 
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Executive Committee during the 41st Session of the Codex Alimentarius Commission 
(CAC) (WHO, 1995).  Although risk assessment terminology varies slightly among 
the various regulatory agencies and organizations, the key elements of a risk 
assessment are the same (Buchanan, 1997; Hoornstra and Notermans, 2001; Potter, 
1996).  This research uses a framework consisting of four components, as outlined by 
Buchanan (1997), to establish the risks associated with E. coli O157:H7: 
(1) Hazard Identification:  Identification of known or potential health 
effects associated with a particular agent in food. 
(2) Exposure Assessment:  Evaluation of the degree of intake likely to 
occur. 
(3) Dose-Response Assessment:  Determination of the relationship 
between the quantity of the biological agent consumed and the 
magnitude and frequency of adverse health effects.  
(4) Risk Characterization:  Integration of the results from the exposure 
and dose-response assessments to provide an overall estimate of 
the likelihood and magnitude of the hazard; includes aleatory and 
epistemic uncertainties associated with the assessment.  
 
1.2  Risk Assessment Overview 
   1.2.1  History of Risk Assessment in Food Safety 
Risk analysis is a process composed of three elements:  risk assessment, risk 
management, and risk communication.  Risk assessment is the use of scientific 
information to describe the likelihood and magnitude of harm attributed to a specific 
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hazard.  Risk management consists of all activities undertaken to control a hazard.  
Risk communication is the exchange of information and opinions about a hazard 
among concerned parties (Dennis et al., 2001).  Thus, risk analysis may be described 
as a framework to analyze, manage, and communicate any activity that may have 
negative consequences (Lindqvist et al., 2002), and is accomplished through the 
efforts of separate but integrated assessment, management, and communication teams 
(Dennis et al., 2001).   
The concept of risk analysis has been applied to many areas including 
transportation, energy, aerospace, chemical processing, etc.  In addition, the Food and 
Drug Administration (FDA) has more than 30 years experience conducting and using 
safety and risk assessments for food additives and chemical contaminants.  However, 
only recently have these techniques been applied to microbial food safety issues 
(Dennis et al., 2001).  With the emergence of newly identified human pathogens, such 
as E. coli O157:H7, risk analysis has become an increasingly important activity in the 
area of microbial food safety.  A joint consultation of the WHO/FAO was held in 
1995 to address the application of risk analysis to food standards issues.  This 
consultation was convened at the request of the 41st Session of the CAC Executive 
Committee which recognized the need to promote consistency and transparency in the 
establishment of Codex standards, guidelines, and recommendations.  The main 
objective of the joint WHO/FAO consultation was to provide FAO, WHO, CAC, and 
member countries with advice on practical approaches for the application of risk 
analysis, with a focus on risk assessment, to food standards issues (WHO, 1995).  
Since that time, WHO, FAO, and CAC have developed an international strategy and 
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identified mechanisms required to support risk assessment of microbial hazards in 
foods.  Additionally, several risk assessments for different food-pathogen 
combinations have been undertaken, thus advancing microbial risk assessment as an 
important discipline for addressing complex food safety issues.   
   1.2.2  Components of Microbial Risk Assessment 
Although there are some differences in risk assessment terminology among 
various regulatory and international agencies/organizations, the framework used to 
accomplish the task of microbial risk assessment generally includes four components:  
hazard identification, exposure assessment, dose-response assessment, and risk 
characterization (Buchanan, 1997; Hoornstra and Notermans, 2001; Potter, M.E., 
1996).  This framework is consistent with elements adopted by CAC and defined in 
the FAO/WHO report (FAO/WHO, 1995).  These four steps provide a systematic 
process for identifying and evaluating the significance of microbial hazards in the 
food of concern, with the outcome of this process being an estimate of risk (i.e., the 
measure of the magnitude of the risk), based on current scientific knowledge and 
understanding (Lammerding and Fazil, 2000).  These four components are often 
combined with problem statement that describes the purpose and scope of the 
assessment and establishes the key assumptions and goals.  The four main 
components of a microbial risk assessment are described in detail in the following 
sections.   
      1.2.2.1  Hazard Identification 
Epidemiological, biological, and other information about the pathogen, the 
food, and the adverse health outcomes associated with the consumption of 
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contaminated foods is gathered in the hazard identification step (Dennis et al., 2001).  
In many cases, the hazard is well established and information about the pathogen and 
food can be found in biological surveillance, process evaluations, epidemiological 
surveillance, and epidemiological investigations (Buchanan, 1997).   
      1.2.2.2  Exposure Assessment 
The exposure assessment provides an estimate of the levels of the pathogen 
consumed.  This requires estimation of the probability that the pathogen will be 
present in the food, the levels of the pathogen in the food consumed, the impact of 
food handling, processing, and storage conditions on the pathogen, and the duration 
and frequency of exposure (Dennis et al., 2001).  In addition, host population 
demographics, consumption patterns, consumer handling practices, pathogen 
distributions, and predictive models for estimating the effects of processing, 
distribution, and preparation may need to be considered (Buchanan, 1997). 
      1.2.2.3  Dose-Response Assessment 
Also known as hazard characterization, the dose-response assessment 
estimates the relationship between the exposure level (i.e., dose) and the frequency of 
illness or other adverse health effect (i.e., response).  In addition, the severity of the 
health effect, squelae, and secondary infections must also be considered (Dennis et 
al., 2001).  The information used to develop the dose-response relationship includes 
human volunteer feeding studies, epidemiological data, and animal model data 
(Buchanan, 1997).   
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      1.2.2.4  Risk Characterization 
Risk characterization mathematically integrates the results from the exposure 
and dose-response assessments to determine the likelihood of the adverse health 
outcomes from exposure to the pathogen.  This step also involves the determination 
of the degree of uncertainty in relation to the results and distinguishes this from the 
inherent biological variation (Dennis et al., 2001).  In addition, an effort should be 
made in this step to identify areas in which additional data could enhance the 
accuracy of the model (Buchanan, 1997).   
   1.2.3  Quantitative Microbial Risk Assessment (QMRA) 
While there are two general approaches to risk assessment, qualitative and 
quantitative, this research focuses on quantitative microbial risk assessment (QMRA).   
Dennis et al. (2001) define the QMRA approach as the combination of existing 
laboratory and surveillance databases with computational techniques to yield models 
that predict public health outcomes.  This approach takes the microbial aspect of the 
process into account, as it evaluates the likelihood of adverse human health effects 
due to exposure to a pathogenic microorganism; however, it also takes the 
quantitative aspect into consideration, as the magnitude of the risk is expressed as a 
mathematical statement.  According to Lammerding and Fazil (2000), quantitative 
risk assessment can be divided into two categories:  deterministic and stochastic.   
The deterministic, or point-estimate, approach uses single values such as the average 
or worst-case as inputs to the risk assessment, while the stochastic, or probabilistic, 
approach considers all of the available data and uses probability distributions to 
describe the parameters that contribute to the risk.  Thus, the probabilistic approach 
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produces a distribution of risk that characterizes the range of risk that might be 
experienced by an individual or population (Lammerding and Fazil, 2000).  
      1.2.3.1  Probabilistic Approach to QMRA 
 Although the probabilistic approach is more complex than point-estimate 
calculations, it is becoming the choice for quantitative risk assessments.  This is 
partially due to the recommendations of the 1994 National Research Council that 
wrote “Science and Judgment in Risk Assessment” emphasizing the need to address 
both the variability and uncertainty of risks (Thompson, 2002).  Variability, or 
aleatory uncertainty, refers to the real and identifiable differences in nature, 
represents the diversity in a well-characterized population or parameter, and is 
irreducible (Lammerding and Fazil, 2000).  In contrast, epistemic uncertainty arises 
from a lack of knowledge and may be related to the model used to characterize the 
risk, the parameters used to provide values for the model, or both (Thompson, 2002).  
In some cases, epistemic uncertainty can be reduced through the attainment of better 
information, but this is not always possible.  Thus, there is a clear distinction between 
aleatory and epistemic uncertainty.  Recognizing and characterizing both aleatory and 
epistemic uncertainty in a risk assessment is important, as these uncertainties have 
different implications in the risk assessment results, and therefore, the risk 
management decisions (Lammerding and Fazil, 2000).   
A quantitative risk assessment uses mathematical models to estimate risk as a 
function of several inputs.  A point-estimate assessment largely ignores aleatory and 
epistemic uncertainties, as a single point-estimate or worst-case value is used to 
represent a given data set for an input.  In contrast, a probabilistic assessment 
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substitutes probability distributions for the single point-estimate values to describe the 
inputs.  The probability distributions assigned to input values are based on empirical 
data, knowledge of underlying biological phenomena, or derived from expert opinion 
(Vose, 1998).  Thus, in the probabilistic assessment, a range of values is used and the 
frequency with which different values occur is also characterized (Lammerding and 
Fazil, 2000).  As stated by Lammerding and Fazil (2000), the importance of 
acknowledging the range of possible values is emphasized by the recognition that it is 
unlikely that microbial risks to human health are uniformly distributed, nor that 
“average” occurrences of events are likely to cause significant problems.   
Probabilistic risk assessments (PRA) can be evaluated using analytical 
techniques such as the method of moments or exact algebraic solutions; however, 
these techniques have limitations and can be quite tedious (Vose, 2000).  An 
alternative to analytical techniques is Monte Carlo simulation, which offers a 
powerful and precise method for incorporating both the aleatory and epistemic 
uncertainty of a problem (Vose, 2000).  In Monte Carlo simulation, a single value is 
randomly selected from each of the probability distributions assigned to each input 
parameter involving epistemic uncertainty.  These randomly selected single values 
are then used to calculate a mathematical solution, as defined by the risk assessment 
model.  This result is stored, and this sequence is repeated several thousand times 
(i.e., iterations).  During each iteration, a different set of values for the inputs is 
selected with values that are more likely to occur, as defined by the probability 
distribution, selected more frequently.  The end result is a probability distribution for 
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the output of interest, represented by the combination of ranges and frequencies of the 
input parameters (Lammerding and Fazil, 2000).  
      1.2.3.2  Examples of Previous Probabilistic QMRAs 
The number of published quantitative microbial risk assessments, examining a 
variety of different food-pathogen combinations, has increased in recent years due in 
part to the proliferation of personal computers and availability of commercial 
software modeling tools (Dennis et al., 2001).  Much work has been done to 
characterize and quantify the factors contributing to exposure to various foodborne 
pathogens.  Duffy and Schaffner (2002) have developed a model to examine the risk 
of contamination of apples with E. coli O157:H7.  Lindqvist et al. (2002) performed a 
quantitative risk assessment of Staphlyococcus aureus in unripened cheese made from 
raw milk.  In addition, several studies have examined the contamination of milk with 
various bacterium (Peeler and Bunning, 1994; Zwietering et al., 1996; Notermans et 
al., 1997; Nauta and van der Giessen, 1998).  However, these risk assessments have 
not attempted to quantify the associated human health risk.  In fact, there are 
relatively few published comprehensive quantitative microbial risk assessments.  
Table 1.1 contains references of recent QMRAs, along with the food and pathogen of 
interest.  
 
Table 1.1:  Summary of Food-Pathogen QMRAs 
Reference Food Pathogen 
Cassin et al., 1998 
Marks et al., 1998 
FSIS, 2001 
Ebel et al., 2004 
Ground Beef E. coli O157:H7 
Nauta et al., 2001 Steak Tartare E. coli O157:H7 
Baker et al., 1998 
Whiting and Buchanan, 1997 
Shell/Liquid Eggs Salmonella enteritidis 
Bemrah et al., 1998 
Sanaa et al., 2004 
Soft Cheese Listeria monocytogenes 
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The references listed in Table 1.1 take similar approaches to quantitative 
microbial risk assessment in that all include the major components of a formal 
quantitative microbial risk assessment; however, these risk assessments differ in the 
approach used to address the aleatory and epistemic uncertainty associated with the 
process investigated.  A brief literature review of three of these risk assessments 
follows.   
         1.2.3.2.1  Salmonella enteritidis in Shell Eggs and Egg Products 
Baker et al. (1998), under the direction of FSIS, develop a comprehensive 
quantitative model to characterize the public health effects associated with the 
consumption of Salmonella enteritidis infected shell eggs and egg products; this 
research is prompted by the increasing number of human illnesses attributed to the 
consumption of shell eggs.  Baker et al. (1998) present the risk assessment in the 
farm-to-table context, and follow the guidelines for microbial risk assessments (i.e., 
hazard identification, exposure assessment, dose-response assessment, and risk 
characterization).  Finally, the main objectives of the risk assessment are identified:  
establish the unmitigated risk of foodborne illness from S. enteritidis, identify and 
evaluate potential risk reduction strategies, identify data needs, and prioritize future 
data collection efforts (Baker et al., 1998).   
Baker et al. (1998) provide an explanation of the evidence, the expected value, 
and the distribution for each influencing factor in the model.  In addition, the output 
of the model is a prediction of various health effects given the simulated number of 
eggs contaminated with S. enteritidis.  Aleatory and epistemic uncertainty are 
separated within the risk assessment.  This enables the identification of data gaps and 
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future research needs when the risk estimate is driven by epistemic uncertainty, and 
the identification of areas needing better process control when the risk estimate is 
driven by aleatory uncertainty.  This research also attempts to validate the risk 
assessment model by comparing the simulated distribution of the number of illnesses 
due to S. enteritidis positive eggs with a distribution of illnesses from S. enteritidis 
positive eggs prediction from national public health surveillance data; the result is a 
substantial overlap between these distributions.  Finally, a number of input variables 
are reduced in order to investigate how changes in module variables affect the model 
output (Baker et al., 1998).   However, it should be noted that there are limitations to 
the scope, resulting in important restrictions in terms of the overall conclusions of the 
model (Schlundt, 2000).  For example, only S. enteritidis contamination from egg 
contents is included even though it is stated that S. enteritidis contamination from 
external sources (i.e., shell contamination) would significantly change the outcome.   
         1.2.3.2.2  Listeria monocytogenes in Soft Cheese 
Bemrah et al. (1998) study the risk of listeriosis from the consumption of soft 
cheese made from raw milk by modeling the process from milking to consumption.  
Again, this risk assessment takes a farm-to-table approach and considers the four 
components of a comprehensive microbial risk assessment.  The scope of this work is 
limited to analyzing the risk created only by the raw milk itself.  To this end, the 
probability of temperature abuse is not considered during the various phases of the 
model and the model is “limited to what is good hygienic practice” (Bemrah, et al., 
1998).  These assumptions have important implications on the results, as many risk-
contributing factors are potentially ignored or overlooked (Schlundt, 2000).   
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The results of the model are given in terms of the annual cumulative risk of 
listeriosis based on estimates of the number of servings/capita/year with the premise 
that only a proportion of the Listeria monocytogenes strains in the cheese are virulent; 
however, these results are not compared to epidemiological evidence.  In addition, 
while attempts are made to address the aleatory and epistemic uncertainty of the input 
parameters, it is unclear as to whether the uncertainty and variability have been 
separated in the risk estimates.  Finally, no risk management options/mitigation 
strategies are explored.   
         1.2.3.2.3  Escherichia coli O157:H7 in Ground Beef 
 Cassin et al. (1998) apply quantitative risk assessment techniques to E. coli 
O157:H7 contamination in ground beef in order to calculate the human health risk.  
Again, like Baker et al. (1998) and Bemrah et al. (1998) this study follows the 
guidelines for microbial risk assessments; however, this risk assessment differs in that 
it uses scenario analysis and predictive microbiology to assess the hygienic 
characteristics of a manufacturing process as well.  This work introduces the idea of a 
process risk model (PRM) that integrates the application of the quantitative risk 
assessment methodology with scenario analysis and predictive microbiology to 
provide an assessment of a process (Cassin et al., 1998).  This results in a prediction 
of the probability of illness attributable to E. coli O157:H7 in a particular ground beef 
manufacturing scenario.  Because this model is limited to a particular food production 
system, the annual number of illness is not estimated.     
Another aspect of the model developed by Cassin et al. (1998) is that it 
incorporates two mathematical sub-models.  The first described the behavior of the 
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pathogen through the various phases of processing, handling, and consumption in 
order to predict human exposure.  This exposure estimate is then used as an input to 
the second sub-model, the dose-response model, in order to estimate the health risk 
associated with consumption.  In addition, this risk assessment also investigates and 
identifies intervention procedures that potentially mitigate the risk.  Three strategies 
for controlling contamination and their influence on the final outcome of human 
health risk are examined, demonstrating how the PRM concept can be useful to risk 
managers (Cassin et al., 1998).  Finally, this research acknowledges that confidence 
limits and uncertainty bounds cannot be put on the expected value of risk, as the final 
distribution represents both aleatory and epistemic uncertainty.  Treatment of aleatory 
and epistemic uncertainty separately would be necessary to estimate uncertainty 
bounds on the risk estimate, and this would require a more sophisticated simulation 
technique (Cassin et al., 1998).  
 
1.3  Engineering-Based Approach to QMRA 
  The model developed in this research has similarities to previous QMRAs,  
and builds upon many of the ideas introduced in Bemrah et al. (1998), Cassin et al. 
(1998), and Baker et al. (1998).  However, this work differs significantly in that it is 
performed from an engineering perspective with the main goal being the adaptation of 
probabilistic-based engineering risk assessment techniques to a food safety project.  
As a case study, this research develops a probabilistic risk assessment model to study 
E. coli O157:H7 contamination in cheese using tools and techniques adapted from 
various engineering disciplines.        
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   1.3.1  Similarities:  Traditional QMRAs vs. Engineering Approach 
As stated, the engineering-based approach to QMRA has similarities to the 
traditional approach used in prior works (Bemrah et al., 1998, Cassin et al., 1998; 
Baker et al., 1998).  First, the engineering approach taken in this research works 
within the framework of traditional quantitative microbial risk assessments in that it 
employs the four components of a risk assessment (i.e., hazard identification, 
exposure assessment, dose-response assessment, and risk characterization) in the 
development of the model.  Second, the goals of the engineering approach remain the 
same as those of traditional QMRA:  1) quantitatively model and account for the 
uncertainty of E. coli O157:H7 contamination in cheese, 2) estimate the likelihood 
and magnitude of E. coli O157:H7 contamination occurring at various locations along 
the exposure pathway, 3) estimate various adverse human health effects due to E. coli 
O157:H7 exposure, 4) determine risk-significant contributors/activities, 5) identify 
possible control and/or mitigation strategies, and 6) identify data gaps and future 
research needs to reduce uncertainty.  Finally, while difficult to implement, both 
approaches recognize the need for the separation of aleatory and epistemic 
uncertainty within the model, and attempt to accomplish this separation through the 
use of Monte Carlo methods to simulate the output distributions of interest.   
   1.3.2  Differences:  Traditional QMRAs vs. Engineering Approach 
The differences between the engineering approach employed in this research 
and traditional QMRA approach are significant.  Obviously, the most important 
difference between these approaches is the adaptation of probabilistic model-based 
engineering tools and techniques to a food-pathogen combination.  The use of 
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methods, such as Dynamic Master Logic (DML), Multiplicative Factors (MF), and 
Analytical Hierarchy Process (AHP), allow for consideration of data, parameter, and 
model uncertainty, as well as variability, generally not accounted for in traditional 
QMRAs.  Thus, this research has the additional goal of adapting non-traditional 
models and methods to a quantitative microbial risk assessment.  The utilization of 
these methods is briefly described below; however, a detailed discussion of these 
methods is reserved for Chapters 2 and 3. 
      1.3.2.1  Dynamic Master Logic (DML) method 
The DML methodology is the main technique by which the decomposition, or 
“reduction”, of the problem is performed.  It is used not only to structure the overall 
cheese model, but also to develop the Probabilistic Risk Assessment of E. coli 
O157:H7 in Cheese (PRAEC) software interface.  The DML modeling concept is a 
knowledge management methodology, relying on the fact that complex systems can 
generally be decomposed hierarchically.  Once the system is broken down into its 
basic elements, it is easier to understand how and why those basic elements exist and 
are interrelated.  This hierarchy structure then lends itself to the development of the 
user-interface which, in turn, allows for the consideration of process variability and 
model uncertainty.  
For example, in terms of cheese production, there are several key steps in the 
production of cheese; however, there are many different cheese types and each 
variety is produced differently.  The DML methodology not only identifies the 
various steps of the cheese-making process and establishes the interdependencies, but 
also identifies basic elements for each step and the various options for each basic 
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element in order to account for the variability within the cheese-making process.  It 
should be noted that this decomposition approach can be applied to the exposure 
assessment, dose-response assessment, and risk characterization elements of the 
problem.  By using this same concept to develop the PRAEC interface, any number of 
different scenarios can be analyzed.  Thus, the DML concept builds on the idea of the 
PRM introduced by Cassin et al. (1998) by integrating the quantitative microbial risk 
assessment methodology with scenario analysis.  However, while PRM investigates 
one specific scenario, the DML model is structured to examine any number of 
different scenarios.   
In addition to identifying the variability throughout the model, the DML 
structure also considers model uncertainty.  Developing a dose-response model for E. 
coli O157:H7 is a difficult task and presents a number of challenges due to both 
model and data uncertainty.  There are a number of different dose-response models 
that describe the relationship between the level of microbial exposure and the 
likelihood of occurrence of an adverse health consequence.  However, within the 
literature there is no consensus on which specific model is most applicable to E. coli 
O157:H7.  Furthermore, due to the severe nature of E. coli O157:H7, volunteer 
human dose-response studies are not possible resulting in much uncertainty about the 
data used for parameter estimation of the dose-response model.  The DML structure 
recognizes this uncertainty and identifies various options for both the dose-response 
model and the data sets from which the parameters of the model are estimated.  
Consequently, the results from various dose-response models or data sets can be 
compared.   
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      1.3.2.2  Multiplicative Factors (MF) 
The multiplicative factor is a mathematical predictive model that allows 
contamination to propagate through production phase of the DML-structured model.  
As the model for E. coli O157:H7 contamination in cheese is based solely on 
information and data available in the open literature, the MF concept attempts to 
address data gaps and data inconsistencies among the available experimental 
research.  Furthermore, due to the assortment of cheeses, the variability in the cheese-
making process, and the number of influencing factors (i.e., pH, temperature, salt 
content, moisture content, fat content, starter cultures, etc.) on microbial growth, data 
relating to the kinetics of E. coli O157:H7 throughout the cheese-making process is 
somewhat limited.  Since there is not enough data available to develop microbial 
predictive models based on all of these influencing factors, the DML method is used 
to identify which of these influencing factors are most critical to the growth and 
survival of E. coli O157:H7.  MFs are then developed for the critical factors at each 
step in order to propagate the contamination through the cheese-making process.   
The MF is essentially a “multiplier” that allows the contamination to be 
increased or decreased throughout the production phase.  A distribution is created for 
each MF by calculating the multiplier based on the contamination level at the input 
and output of a step.  Hence, if a selection increases the contamination, the multiplier 
will be greater than 1; if a selection decreases the contamination, the multiplier will 
be between 0 and 1.  Bayesian updating is used not only to develop the distributions 
for the MF, but also to account for the parameter uncertainty.   
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      1.3.2.3  Analytical Hierarchy Process (AHP) 
The AHP method is a powerful and flexible decision making process that 
helps set priorities and compares alternative concepts when both qualitative and 
quantitative aspects of a decision need to be considered.  It is a comprehensive, 
logical, and structured framework that helps to improve the understanding of complex 
decisions by decomposing the problem in a hierarchical structure.  Again, developing 
a dose-response model for E. coli O157:H7 is difficult as there is both model and data 
uncertainty.  The AHP methodology is extended to the dose-response model to 
account for the data uncertainty.   
The AHP method is used to develop a weighted-average dose-response model 
by comparing alternative data sets on several criteria.  A pair-wise comparison of the 
various criteria is completed for each alternative and the comparisons are synthesized 
to get the absolute weights of the alternatives with respect to each criterion.  The 
weights of each criterion with respect to the goal are obtained from a matrix 
operation, with the end result being the overall priority of each alternative.  Thus, by 
developing a weight for each data set, a new “weighted-average” model is developed 
which accounts for the uncertainty associated with the E. coli O157:H7 dose-response 
data.  The model uncertainty is then addressed through the DML structure, which 
allows for selection among three previously proposed dose-response models as well 





1.4  Contributions of Engineering-Based Approach to QMRA 
Traditional QMRAs have focused on identifying various steps in the exposure 
assessment of a pathogen; these steps are typically quantified with either a point 
estimate or a distribution representing the best-case, most-likely, and worst-case 
values.  The dose-response data judged most relevant is selected in order to determine 
the parameters of a single dose-response model.  Finally, based on the results of the 
exposure and dose-response assessments, risks are characterized using point-
estimates of adverse health outcomes.  This research differs in several ways and 
provides a number of advancements to the area of food safety risk assessment.  Three 
main contributions are summarized below.   
 First, the engineering approach proposed is a decomposition, or reductionist, 
approach to risk assessment.  This approach offers a more systematic solution to food 
safety problems.  A hierarchy, in this case, encompasses important elements (i.e., 
constituents) of the exposure assessment, dose-response assessment, risk 
characterization, and their relationships.  The hierarchy is divided into multiple levels 
of interrelated constituents, each of which can be studied in relative isolation from the 
rest.  These constituents can be a combination of diverse entities involving human 
activities, processes, events, equipment, software errors, etc.  Thus, a “systems” 
approach to a food safety problem, which captures the interdependencies and 
interrelationships of the entire problem, is attained through the decomposition 
process.  Because the traditional PRA techniques applied to engineering systems are 
not directly applicable to food safety problems, a major advancement of this research 
 22
is the adaptation of the reductionist thinking of engineering PRAs resulting in a new 
modeling paradigm.   
Second, the proposed engineering food safety assessment approach relies on 
mathematical models.  Unlike the traditional approaches in food safety, the 
uncertainties about these models (both aleatory and epistemic), as well as the 
uncertainties about the model parameters, are formally quantified and properly 
considered in the risk assessment.  The methods used for characterizing and 
propagating these uncertainties are adapted to the proposed engineering-based risk 
assessment methodology, resulting in another advancement.  Again, the traditional 
risk assessments use either point estimates or simplified distributions representing the 
minimum and maximum values or the best-case, most-likely, and worst-case values.  
This results in conservative models that do not represent epistemic uncertainty.  The 
engineering approach uses the large amount of experimental data available in order to 
develop mathematical models for the constituents of the risk model.  In addition, the 
uncertainty associated with these mathematical models is also accounted for, resulting 
in a model that avoids conservatism and characterizes uncertainty.   
 Finally, this research characterizes the validity of the various dose-response 
models.  Traditional QMRAs have been performed to determine the risk of 
pathogenic infection from various foods, but the dose-response models used in these 
risk assessments have yet to be fully validated.  Comparison of actual observations in 
outbreak data to the predicted observation lends credibility, ensures accuracy, and 
assesses uncertainty of the developed dose-response models.  Previous risk 
assessments have provided worst-case estimates of risk or been most useful as 
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relative assessments of risk.  By validating the dose-response models developed in 
this research, the results of the risk model can be used both as an absolute assessment 
of the risk and as a relative measurement of mitigation and control strategies.   
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2.  METHODOLOGY AND BACKGROUND  
 
 
2.1  Overview of Methodology and Background 
This research adapts probabilistic-based engineering tools and techniques to a 
food safety problem.  While this research uses E. coli O157:H7 contamination in 
cheese for the application of this approach, it should be noted that the methodology 
developed in this research can be applied to any food-pathogen combination of 
interest.  This chapter provides a general overview of the engineering risk assessment 
methodology developed in this research.  In addition, a statement of the problem is 
given, as applied to E. coli O157:H7 in cheese; this statement includes the purpose, 
structure, scope/assumptions, and goals of the application.  Finally, in order to better 
understand the application of the methodology, background information on cheese-
making is provided.   
 
2.2  Engineering-Based Probabilistic Risk Assessment Methodology 
The Dynamic Master Logic (DML) modeling concept is used to create the risk 
model which consists of the exposure assessment, dose-response assessment, and risk 
characterization.  The DML modeling concept is a knowledge management 
methodology, and relies on the fact that complex systems can generally be 
decomposed into hierarchies based on functions, structures, behaviors, goals, etc.  
This hierarchy model is primarily used to explain and simulate system behavior, by 
modeling system elements and the relationships between those elements.  The system 
is decomposed until the basic elements are discovered.  Once the system is broken 
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down into the basic elements, it is easier to understand how and why these basic 
elements exist and are interrelated.  Thus, the mathematical model developed in this 
research to describe the process by which contamination is propagated through the 
system is based upon the conceptual model created with the DML concept.  It should 
also be noted that the DML modeling concept is instrumental in developing the 
Probabilistic Risk Assessment of E. coli O157:H7 in Cheese (PRAEC) software 
interface that accompanies this project, as the PRAEC interface is based on the 
conceptual DML model as well.  The PRAEC tool is discussed in detail in Appendix 
I.   
In order to apply the DML concept to a food safety problem, a top-level 
model is established in order to model the system elements and their interactions in a 
systematic manner.  Although this methodology can be applied to any food safety 
problem, it is discussed in terms of E. coli O157:H7 contamination in cheese.  Figure 
2.1 shows this top-level conceptual DML model in which the relationship between 
the system elements of the exposure assessment (i.e., production, distribution, and 
consumption phases) are modeled, with each phase dependent on the previous phase.  
The initial input into this model is the distribution of E. coli O157:H7 contamination 
in milk.  This distribution of contamination enters the production phase, where 
contamination is increased or decreased.  The end result of the production phase is a 
distribution of E. coli O157:H7 contamination in the final cheese product.  This 
distribution is the input to the distribution phase where, again, the contamination of E. 
coli O157:H7 in cheese is increased or decreased.  The end result of the distribution 
phase is a distribution of E. coli O157:H7 contamination in cheese, and this 
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distribution becomes the input for the consumption phase.  Propagating the 
contamination through the model results in an estimate of the distribution of E. coli 
O157:H7 contamination in the cheese at the consumer level.  A number of risks can 
then be characterized by combining the result of the consumption phase with the 
dose-response assessment and the adverse health consequences.  Thus, the end 
societal risk is calculated by multiplication of the distribution of contamination per 
serving, the distribution of consumption, the distribution of tolerance level, and the 
distribution of the adverse health outcome of interest.  The dose-response relationship 
is represented by the area of overlap between the distribution of dose (i.e., resulting 
from the multiplication of the distribution of contamination per serving and the 
distribution of consumption) and the distribution of tolerance.   
 






















Next, the DML modeling concept is applied to each of the phases identified in 
the top-level model in order to further refine the phase.  If the production, 
distribution, and consumption phases are thought of as system elements, then each of 
these systems can be decomposed into sub-system elements.  The sub-system 
elements of each phase represent various steps that can increase or decrease the E. 
coli O157:H7 contamination, and the DML method models the dependencies and 
interrelationships between these sub-system elements.  Figure 2.2 demonstrates how 
this concept is abstractly applied to the system elements.  The system element, or 
phase, is broken down into its sub-system elements so that the model for this phase 
represents all the major process steps and events that affect contamination, as well as 
the dependencies and relationships between these steps (represented by the nodes).  
For example, step 3 directly depends on the contamination level of both steps 1 and 2; 
in addition, step 3 indirectly depends on step 1 through its direct dependence on step 
2.  In contrast, step 6 directly depends only on step 5.  The contamination at the start 
of the phase can be increased or decreased at each particular step.  Thus, the initial 
contamination is propagated through the various steps (i.e., sub-system elements) of 
the phase, and results in a distribution of contamination at the end of the phase.   
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Figure 2.2:  Example DML Modeling Approach to Sub-System Element 
 
 
 Finally, each sub-system element in a particular phase can be further 
decomposed depending on the practices and/or physical conditions (i.e., time, 
temperature, etc.) at that particular step.  Figure 2.3 demonstrates how the DML 
concept is abstractly applied to a step in order to identify the various basic elements at 
each step.  These basic elements represent the physical conditions, manufacturing 
practices, distribution practices, consumer practices, etc. that influence bacterial 
growth or inactivation during that particular step.  In addition, the DML concept is 
used to identify the sub-conditions, or options, for the physical conditions and various 















Figure 2.3:  Example DML Modeling Approach to Basic Elements 
 
 
 Figure 2.3 is representative of a production phase step and shows a particular 
step “N” with two physical conditions that influence the contamination level; physical 
condition 1 has three sub-conditions and physical condition 2 has two sub-conditions.  
The influence on contamination level is dependent on which sub-condition is selected 
for each physical condition.  A mathematical model called a Multiplicative Factor 
(MF) is developed to propagate the contamination through the production phase 
based on the selected sub-conditions at each step.  For step “N” represented in Figure 
2.3, there are six possible combinations of sub-conditions, and each combination has 
an associated MF.  Thus, if sub-condition 1-1 is selected for physical condition 1, and 
sub-condition 2-2 is selected for physical condition 2, then MF “N4” is the 
multiplicative factor used to propagate the contamination at this particular step.   
Each step in the production phase has a MF associated with it, based on the 
selected sub-conditions.  The contamination is propagated through the production 
phase by multiplying the selected MFs for each step; the following equation 
represents this concept: 
PHYSICAL 
CONDITION 1
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MF     (2.1) 
 
MFi represents the multiplicative factor at step i, and n represents the number of steps 
in the production phase.  Thus, the final contamination in the production phase is 
calculated by multiplying the initial contamination by the product of the MFs.  It 
should be noted that other mathematical models are used in the risk model, such as 
the Gompertz model in the distribution phase; however, regardless of the particular 
mathematical model used for a system element, the same decomposition approach is 
applied throughout the model.   
In terms of the exposure assessment, the DML concept reduces the system to a 
number of system elements, or phases.  The system elements are then reduced to sub-
system elements, or the steps of the phase that influence contamination.  The sub-
system elements are then reduced to the physical conditions or practices at that 
particular step that influence contamination.  Finally, the various sub-conditions for 
the physical conditions or practices are identified.  By accounting for the various 
options, or sub-conditions, of the basic elements at each step within the phase, the 
DML concept takes variability into account throughout the exposure assessment.  
More specifically, the DML concept takes the variability of industry practices into 
account during the production phase, the variability of physical conditions into 
account during the distribution phase, and the variability of the consequences into 
account during the consumption phase.  In this way, the DML methodology not only 
identifies the various steps throughout the phases of the exposure assessment and 
establishes the interdependencies, but also identifies the sub-conditions for each 
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physical condition or practice at each step in order to account for the variability 
within the entire process.   
The DML decomposition approach is not just applicable to the exposure 
assessment; this reductionist, approach is applied to the dose-response assessment and 
risk characterization portions of the risk model.  In addition, by using this concept to 
develop the PRAEC interface, any number of different scenarios can be analyzed.  
Thus, the DML methodology concept builds on the idea of the process risk model 
(PRM) introduced by Cassin et al. (1998) by integrating the quantitative microbial 
risk assessment methodology with scenario analysis.  However, while PRM 
investigates one specific scenario, the DML concept structures the PRAEC tool in 
such a way that multiple scenarios can be examined.   
 
2.3  Risk Assessment Problem Statement  
   2.3.1  Purpose 
Not only has E. coli O157:H7 been shown to survive the cheese 
manufacturing and ripening process, but it has also been linked to several outbreaks 
involving cheese, thereby establishing the need for a quantitative microbial risk 
assessment (QMRA) on this particular food-pathogen combination.  This research 
proposes the adaptation of probabilistic-based engineering risk assessment tools and 
techniques in order to study E. coli O157:H7 contamination in cheese.  The use of 
methods, such as Dynamic Master Logic (DML), Multiplicative Factors (MF), and 
Analytical Hierarchy Process (AHP), allow for consideration of data, parameter, and 
model uncertainty, as well as variability, generally not accounted for in traditional 
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QMRAs.  In addition, by accounting for the variability throughout the process with 
the DML modeling concept, this research builds on the idea of the PRM by allowing 
multiple scenarios to be examined.   
   2.3.2  Structure 
Although this research introduces engineering techniques to QMRA, the risk 
assessment to study E. coli O157:H7 in cheese still follows the traditional four-
component structure for quantitative microbial risk assessments:  hazard 
identification, exposure assessment, dose-response assessment, and risk 
characterization.  In this research, the hazard identification includes information about 
E. coli O157:H7, its presence in cheese, and the adverse health outcomes associated 
with the consumption of E. coli O157:H7.  The exposure assessment is the 
quantitative evaluation of the probability that E. coli O157:H7 will be present in the 
cheese and the level of E. coli O157:H7 consumed through cheese; the exposure 
assessment accounts for the impact of production, distribution, and storage on the 
overall potential exposure.  The dose-response assessment determines the relationship 
between the quantity of E. coli O157:H7 consumed and the magnitude and frequency 
of the adverse health effects.  Finally, risk characterization involves the integration of 
the results from the exposure and dose-response assessments to provide an overall 
estimate of the likelihood and magnitude of adverse health outcomes from exposure 
to E. coli O157:H7 in cheese; in addition, this step includes the scientific and 
statistical uncertainties associated with the assessment. 
The information and data collected for the risk assessment of E. coli O157:H7 
in cheese are obtained from the literature.  The database and user-interface are 
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developed within Microsoft Excel (Microsoft Corp., CA) and linked using Visual 
Basic for Applications (VBA).  The interface allows for the development of any 
number of different scenarios in terms of the distributions attributed to the various 
options throughout the process.  Developing the risk model in this way lends itself to 
Monte Carlo simulation, in which the simulation represents not only the variability 
throughout the cheese manufacturing process, but also the uncertainty in the 
mathematical model of the process.  The final outcome is the human health risk of the 
population represented as a probability density function.  The simulations are run on 
an Intel Pentium 1500 MHz based PC with the @RISK software package, version 
4.5.5 (Palisade, Newfield, NY), as an add-in for Microsoft Excel.  Due to computer 
limitations and time constraints, one thousand iterations are performed for 100 
simulations.   
   2.3.3  Scope/Assumptions 
The scope of this risk assessment is confined to rennet-coagulated cheeses 
made with cow’s milk, with the exception of Feta cheese.  In addition, the scope is 
restricted to the cheese production, distribution, and consumption phases, and does 
not consider the on-farm processes associated with milk production or consumer 
handling before consumption.  Finally, the model only considers contamination from 
the milk and does not account for contamination from sources such as the production 
facility and machinery.    
The model is based solely on information and data available in the open 
literature through 2005.  Therefore, the model developed for this research should be 
considered a baseline risk assessment, in that it reflects to the extent possible, a full 
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range of current practices, behaviors, and conditions of the cheese-making process.  
In addition, while each cheese variety is produced differently, there are basic steps 
involved in the production of most cheeses (Fox, 1993, Law, 1999).  An effort is 
made to identify all major process steps or events affecting contamination during 
cheese production, distribution, and consumption.   
   2.3.4  Goals 
The goals of the engineering QMRA approach remain the same as those of 
traditional QMRA:   
1) Quantitatively model and account for the uncertainty of E. coli O157:H7 
contamination in cheese 
2) Estimate the likelihood and magnitude of E. coli O157:H7 contamination 
occurring at various locations along the exposure pathway 
3) Estimate various adverse human health effects due to E. coli O157:H7 
exposure 
4) Determine risk-significant contributors/activities 
5) Identify possible control and/or mitigation strategies 
6) Identify data gaps and future research needs to reduce uncertainty 
Furthermore, this research has the additional goal of adapting non-traditional 
models and methods to a quantitative microbial risk assessment.  Probabilistic-based 
engineering tools and techniques are adapted and then applied to a microbial risk 
assessment studying E. coli O157:H7 contamination in cheese, with the expectation 
of the following advancements: 
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1) Development of a framework that identifies the variability throughout the 
process, organizes the data, and links these with a user-interface  
2) Development of methods within the framework to account for data 
deficiencies and data uncertainty, as well as parameter uncertainty 
3) Development of a process risk model in which multiple scenarios can be 
created, sensitivity analyses can be performed, and dose-response model 
uncertainty is addressed   
 
2.4  Cheese-Making Background Information 
   2.4.1  Cheese-Making Overview 
      2.4.1.1  Origins of Cheese-Making 
In the most generic sense, cheese is the name for a group of fermented milk-
based food products that are produced in a great range of flavors and forms 
throughout the world.  Cheese manufacture is one of the classic examples of food 
preservation, dating from 6000-8000 BC (Fox, 1993; Davis, 1965).  Early on, it was 
recognized that cheese possessed much better keeping qualities than milk and 
provided a suitable food for journeys.  Thus, cheese-making was a convenient method 
of converting a considerable part of the constituents of milk (i.e., fat and protein) into 
a product that kept well; in addition, cheese was more compact than milk because it 
contained much less water, was of high nutritive value, and was both palatable and 
readily digestible (Davis, 1965).  Although the origins of cheese-making will never be 
known with absolute certainty, cheese existed during ancient Egyptian, Greek, and 
Roman times.  Despite the uncertainty about the origins of cheese-making, it is 
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commonly believed that cheese evolved in the Fertile Crescent between the Tigris and 
Euphrates, in today’s Iraq, during the Agricultural Revolution with the domestication 
of plants and animals.  It is probable that the first fermented dairy products were 
made by accident, with an unexpected combination of events occurring in order to 
produce either isoelectic or enzymatic coagulation.   
While the nutritive value of milk was realized very early on, it was also 
discovered that these nutrients provided a rich food source for the bacteria that 
contaminate the milk.  Bacterial growth and acid production would have occurred 
during attempts at storage in the warm, dry climate.  These bacteria utilized the 
natural sugar of the milk, or lactose, as a source of energy, producing lactic acid as a 
by-product.  Once the level of acid passed a certain point, the milk protein (i.e., 
casein) would separate from the watery content of milk, yielding solid curds and 
liquid whey (Battistotti et al., 1983).  The acidity of the naturally curdled milk was 
refreshing, but another important advantage was also discovered.  Few dangerous 
germs could live in this high-acid environment, and thus acid-curd cheese was safer 
to consume than milk directly from an animal (Battistotti et al., 1983).  Thus, 
isoelectric coagulation involves the growth of bacteria (now known as lactic acid 
bacteria) in milk, producing just enough acid to reduce the pH of milk to the 
isoelectric point of the caseins, resulting in coagulation of these proteins (Fox, 1993).   
While this explains the evolution of the acid cheeses, which include cottage 
cheese, cream cheese, quarg, and quesco blanco, an alternative mechanism to lactic 
acid coagulation was also recognized from an early date.  It was soon discovered that 
milk could be solidified more quickly by the addition of an acid, rather than letting 
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the milk sit to form acid-curd.  Adding a citrus juice or vinegar, for example, would 
speed up the process; however, this resulted in a sharp-tasting product (Battistotti et 
al., 1993).  Many proteolytic enzymes can modify the milk protein system, causing it 
to coagulate under certain circumstances.  Enzymes capable of causing this 
transformation are widespread in nature and include bacteria, molds, plant and animal 
tissues.  However, the most obvious source would have been animal stomachs, with 
the best known medium being rennet, which is made from the fourth stomach of 
young, cud-chewing animals (Battistotti et al., 1983).  Before the development of 
pottery (c. 5000 BC), storage of milk in bags made from animal stomachs was a 
common practice, as stomachs provide ready-made, easily sealed containers.  Under 
these circumstances, milk would extract coagulating enzymes from the stomach 
tissue, leading to coagulation during storage (Fox, 1993).  Thus, enzymatic 
coagulation also evolved by accident through the carrying of milk in the stomachs of 
animals, with the milk-clotting enzymes of the stomach eventually converting the 
souring milk into a solid mass (Davis, 1965).   
Once cheese could be made with the choice of either acidic or sweet curd 
there was no limit to the possibilities.  Every year scientists and historians find new 
evidence of the extraordinarily long history and early importance of cheese 
(Battistotti et al., 1983).  Although cheese-making was discovered as a convenient 
method of preserving the most important constituents of milk, it has evolved into a 
booming industry.  Current technology has smoothed out many of the once variable 
steps of cheese-making; however, due to the complex chemical and physical 
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phenomenon involved in the process, cheese-making remains an “art” even today 
(Law, 1999).   
      2.4.1.2  Cheese Classification  
Today, there are thousands of named varieties of cheese, as cheese may differ 
in size, shape, color, hardness, texture, odor, and taste.  The literature suggests that 
there are somewhere between 400-1000 different varieties of cheese, depending on 
the classification system (Fox, 1993).  The wide assortment of cheese and the 
variability in manufacturing make the classification of cheese difficult.  A number of 
attempts have been made to develop a classification scheme for cheese, with Fox 
(1993) providing a summary of these schemes.  One classification system proposed is 
based primarily on moisture content.  This scheme consists of five groups:  dried 
(<40%), grated (40-49.9%), hard (50-59.9%), soft (60-69.9%), and fresh (70-82%).  
Four of these groups (i.e., fresh, soft, hard, and grated) are further sub-divided into 
two subgroups based on whether or not the cheese is pressed and/or cooked.  Another 
scheme proposes cheese be classified by moisture into very-hard, hard, semi-hard, 
and soft, and then subdivided on the basis of the principal characteristic microflora,  
for example, normal lactic starter, surface mold, interior mold, etc. (Fox, 1993).  
However, it should be noted that these schemes can only be applied to rennet cheese.  
To address this limitation, Fox (1993) proposes a classification of cheese by super-
families, based on the coagulation agent:  rennet, acid, heat/acid, and 
concentration/crystallization.  Fox et al. (2000) expand on the concept of super-
families by further classifying rennet cheese based on the principal ripening agents 
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and/or characteristic technology.  Figure 2.4 represents the classification scheme 
proposed by Fox et al. (2000).   
 
Figure 2.4:  Cheese Classification by Super-Family 
 
 
   2.4.2  Modern Cheese Technology  
There are two main goals of modern cheese-making technology.  First, the 
parameters such as flavor, body, texture, melt, and stretch properties that make a 
given cheese desirable must be established.  Second, a manufacturing and ripening 
protocol that will routinely reproduce these parameters every time cheese is made 
must be developed (Law, 1999).  Modern cheese technology has been credited to 
Joseph Harding, an English innovator of the nineteenth century, who perfected 
various stages of making Cheddar cheese.  Harding asserted that the crucial part of 
cheese-making depended on how the procedure was handled in the dairy and 
-
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promoted the strictest standards of hygiene.  Each process was considered to be of 
equal importance needing to be carried out correctly and under controlled conditions; 
this scientific approach to the production of cheese represented a great step forward 
(Battistotti et al., 1983). 
Today, the production of the vast majority of cheese varieties can be sub-
divided into two well-defined phases:  manufacturing and ripening.  Essentially, 
cheese-making is a concentration, or dehydration, process, beginning with the 
gelation of the casein via isoelectric (acid) or enzymatic (rennet) coagulation (Law, 
1999).  Depending on the variety, the fat and casein in milk are concentrated 6-12 
fold.  The degree of dehydration is regulated not only by the extent and combination 
of a number of steps but also the chemical composition of the milk (Fox, 1993).  In 
turn, the moisture level, salt level, pH, and microflora regulate and control the 
biochemical changes that occur during ripening, and therefore determine the flavor, 
aroma, and texture of the finished product.  Thus, the nature and quality of the 
finished cheese are determined to a very large extent by the manufacturing steps, with 
each step serving a clearly defined purpose.  However, it is during the ripening phase 
that the characteristic flavor and texture of the individual cheese varieties develop 
(Fox, 1993). 
The manufacturing phase can be defined as those operations performed during 
the first 24 hours, although some of these operations (i.e., salting and dehydration) 
may continue over a longer period (Fox, 1993).  The manufacturing protocols for 
individual varieties of cheese differ in detail; however, a review of the literature 
(Kosikowski, 1977; Davies and Law, 1984; Fox, 1993; Varnam and Sutherland, 
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1994; Law, 1999; Fox et al., 2000) reveals that there are basic steps necessary and 
common among most cheeses.  The transformation of milk into cheese generally 
involves the following series of separate steps:  Milk Selection and Pre-Treatment, 
Addition of Starter Bacteria, Addition of Coagulant, Cutting, Cooking, Separating 
and Draining, Milling, Salting, Hooping and Pressing, and Packaging and Ripening.  
Figure 2.5 depicts a flow diagram from Law (1999), representing the main steps in 
cheese-making.  This diagram also shows possible variations of the process which are 
used to make different varieties of cheese.   
 
Figure 2.5:  Flow Diagram of Cheese-making Process 
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While these steps are common to all cheese, the conditions of manufacture 
vary considerably.  The differences in the final cheese product are due to the 
following main factors:  the type of milk used, the degree of souring and the type of 
souring organisms added, the temperature of renneting and subsequent cooking or 
scalding of the curd in the whey (not applied to all varieties), the method and fineness 
of cutting or breaking up the curd, the treatment of the curd after separation from the 
whey, the milling and salting of the curd before placing in the hoop or mold (not 
applied to all varieties), the pressure applied to the green cheese (not applied to all 
varieties), the time, temperature and relatively humidity of ripening, and special 
treatments such as pricking or stabbing the cheese (not applied to all varieties), 
bathing in brine (not applied to all varieties), and surface treatment to produce a 
certain type coat (Law, 1999). 
All of these variables are under the control of the cheese-maker and influence 
the physical, chemical, and microbiological changes taking place in the milk, 
coagulum, curd, and cheese.  While scientists and microbiologists understand the 
important changes, there are still many mechanisms and interactions between factors 
that are not completely known (Davis, 1965).  Of all dairy products, cheese is the 
most diverse group due to its biological, biochemical, and chemical instability.  The 
manufacturing and ripening processes represent a series of consecutive and associated 
biochemical events.  This series of biochemical events results in a flavorful cheese 
when synchronized and balanced; however, when unbalanced, this series of steps can 
result in off-flavors, odors, and allows for the growth of undesirable bacteria (Fox, 
1993).   
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While it has traditionally been assumed that pathogenic microorganisms in 
raw milk die during the cheese manufacturing process, it is now understood that 
pathogens can survive and grow during both the manufacturing and ripening phases.  
The following sections provide a detailed description of the main steps in the cheese-
making process, the possible manufacturing conditions at each step, and the influence 
of these manufacturing conditions on the survival of pathogenic microorganisms in 
the final cheese product.   
      2.4.2.1  Milk Selection and Pre-Treatment 
Cheese manufacture begins with the selection of milk, which should be of 
high microbiological and chemical quality.  Depending on the type of cheese being 
made, cow, sheep, goat, or buffalo milk may be selected.  It is recommended that 
milk for cheese be cooled to 4˚C immediately after milking and it may be held at this 
temperature for several days at the farm or factory (Fox, 1993).  However, the 
USDA/CFSAN Grade “A” Pasteurized Milk Ordinance (PMO), 2001 Revision states 
that all raw milk and milk products shall be maintained at 7°C or less until processed 
(USDA, 2001).  The type of milk used for cheese-making can be raw, pasteurized, or 
heat treated (i.e., thermization or sub-pasteurization).  Although raw milk can still be 
used both in commercial and farmhouse cheese-making, most cheese-milk is now 
pasteurized.  
Milk used for cheese-making is usually pasteurized immediately before use.  
The pasteurization process alters the indigenous microflora of the milk and facilitates 
the manufacture of cheese of a uniform quality.  However, proponents of raw milk 
cheese argue that cheese made from pasteurized milk develops a less intense flavor 
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and ripens more slowly than raw milk cheese (Fox, 1993).  Raw milk proponents also 
argue that pathogens that are present will die during the ripening process, and that 
pathogens can be introduced during cheese production after the milk is pasteurized 
(Law, 1999).  Proponents of pasteurization contend that by starting with milk free of 
pathogens and producing cheese in an environment free of pathogens, the end product 
will remain free of pathogens.  In addition, proponents of pasteurization claim that 
any difference in flavor is inconsequential as compared to the public health issues 
caused by some pathogens (Law, 1999).   
In this case, pasteurization is the process of heating the milk to a specific 
temperature for a specific period of time in order to kill all the naturally occurring 
pathogens.  The process is based on the thermal destruction of Coxiella burnetti, the 
most heat resistant organism found in milk.  Table 2.1 table gives the minimum time-
temperature combinations that are recommended for the pasteurization process 
according to the PMO Revision 2001 (USDA, 2001).     
 
Table 2.1:  Time-Temperature Combinations Recommended for Milk Pasteurization 
Temperature Time 
63 °C  
(145°F)* 
30 minutes 
72 °C  
(161°F)* 
15 seconds 
89 °C  
(191°F) 
1.0 seconds 
90 °C  
(194°F) 
0.5 seconds 
94 °C  
(201°F) 
0.1 seconds 
96 °C  
(204°F) 
0.05 seconds 
100 °C  
(212°F) 
0.01 seconds 
*If the fat content of the milk product is ten percent (10%) or more, or if it contains added sweeteners, the specified temperature 




In the United States, most cheese production employs the pasteurization 
process.  Legislation in most countries requires that cheese be made from high-
temperature, short-time (HTST) pasteurized milk, that cheese be aged for 60 days 
which allows food-poisoning and pathogenic bacteria to die, or the cheese itself 
should be pasteurized (i.e., converted to processed cheese) (Fox et al., 2000).  
However, in many other countries a significant amount of cheese is made from milk 
that has received either a lesser heat treatment or no heat treatment at all.  
Sub-pasteurization heat treatments, also known as thermization, encompass a 
wide range of time-temperature combinations; however, one typical time-temperature 
combination used in thermization involves heating the milk to 63°C for 10-15 
seconds (Fox et al., 2000).  This treatment results in less inactivation of enzymes and 
nonstarter lactic acid bacteria (NSLAB) that are important in developing cheese 
flavor.  There is some controversy over using thermalized milk for cheese-making.  
Fox et al. (2000) state that depending on the time and temperature used, thermization 
may not kill all of the pathogenic and food-poisoning microorganisms.  However, 
cheese made from heat-treated raw milk can be microbiologically safe; Johnson et al. 
(1990) report that a heat treatment of 65-65.6ºC for 16-18 seconds will destroy almost 
all pathogenic microorganisms that pose a treat to a safe cheese product.  In addition, 
studies by D’Aoust et al. (1988) show heating of raw milk at 65ºC for a mean holding 
time of 17.6 seconds destroyed all strains of E. coli O157:H7.  Therefore, 
temperatures higher than 63ºC are generally recommended for thermization (D’Aoust 
et al., 1988; Blackburn et al., 1997); however, some studies have investigated 
temperatures as low as 50ºC (Read et al., 1960).   
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Cheese made with milk receiving no heat treatment (i.e., raw milk cheese) is 
still made in many countries, including the United States.  However, raw milk used 
for cheese-making should be of good bacteriological quality (Fox, 1993).  According 
to the PMO Revision 2001 it is illegal to sell raw milk cheese across state lines, and 
raw milk cheese must be ripened for at least 60 days (USDA, 2001).  In addition, raw 
milk cheese should be cooked to a high temperature (>50 °C) for up to one hour 
during the cheese-making process, thereby killing some of the bacteria originating 
from the raw milk (Fox et al., 2000).  The influence of the cooking step in the cheese-
making process is further explained in section 2.2.5.  
      2.4.2.2  Addition of Starter Bacteria 
Carefully selected strains of different species of lactic acid bacteria (LAB), or 
starter cultures, are added to the milk shortly before renneting.  The purpose of these 
bacteria is to produce lactic acid, with this acid production having three main 
functions: 1) promote rennet activity through the reduction of pH, 2) aid the expulsion 
of whey from the curd, which reduces the moisture content of the cheese, and 3) help 
prevent the growth of undesirable bacteria in the cheese (Fox et al., 2000).  Although 
starter cultures can influence the taste, aroma, and texture of the cheese, other bacteria 
are typically added to influence these properties (Law, 1999).  The selection of starter 
bacteria in cheese-making is based not only on tradition, but also the flavor, rate and 
extent of acid development desired in the finished cheese.  Starter cultures differ in 
their sensitivity to salt, temperature, and pH, and exploitation of these characteristics 
during the cheese-making process influences the end product (Law, 1999).  Thus, the 
starter culture plays a crucial role in both manufacturing and ripening.   
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Starter cultures are commonly divided into two main groups:  mesophilic and 
thermophilic cultures.  Mesophilic cultures are typically used with cheese requiring 
an optimal temperature of 30˚C during the cooking step, while thermophilic cultures 
have an optimal cooking temperature of 42˚C or above (Fox et al., 2000).  Examples 
of mesophilic cultures include Lactococcus lactis subspp. cremoris and Lactococcus 
lactis subspp. lactis.  Typically, mesophilic cultures are used in the production of 
Cheddar, Gouda, Edam, Blue, and Camembert cheeses.  Swiss and Italian varieties of 
cheese typically use thermophilic starter cultures.  Examples of thermophilic cultures 
include Streptococcus salivarius subspp. thermophilus and several species of 
Lactobacillus (i.e., Lactobacillus helveticus, Lactobacillus delbrueckii subspp. lactis, 
and Lactobacillus delbrueckii subspp. bulgaricus) (Fox et al., 2000). 
Each group of starters can be further subdivided into defined- and mixed-
strain cultures.  Mixed-strain cultures contain unknown numbers of strains of the 
same species and are typically used by small-scale producers.  Defined-strain cultures 
are pure cultures, with known and identifiable physical characteristics, and are 
typically used by large-scale producers.  However, it should be noted that defined 
cultures are rarely used as pure cultures or single strains, but rather as mixtures of 2 to 
6 known strains (Fox et al., 2000).  Table 2.2 provides a short list common 
mesophilic and thermophilic starter cultures used to manufacture various types of 







Table 2.2:  Starter Cultures Used in the Manufacture of Different Cheeses 
Culture Type Species Name Cheese Type 
Mesophilic Lactococcus lactis subspp. lactis Cheddar, Gouda 
 Lactococcus lactis subspp. cremoris Tilsiter, Camembert 
 Leuconosoc lactis Gouda 
Thermophilic Streptococcus thermophilus Mozzarella, Brie 
 Lactobaccilus helveticus Swiss, Gruyere, Emmental 
 Lactobaccilus delbrueckii subspp. lactis Emmental 
 
 
      2.4.2.3  Addition of Coagulant 
The purpose of a coagulant in cheese-making is to convert the liquid milk to a 
gel.  All cheese varieties have this essential manufacturing step in which the casein 
component of the milk protein coagulates to form a gel which entraps the fat.  
According to Fox (1993), coagulation may be achieved by:  1) limiting proteolysis 
through selected proteinases, 2) acidification to pH ~4.6, or 3) acidification to pH 
values >4.6, in combination with heating.  Cheeses produced either by acid or 
heat/acid are usually consumed fresh, and are not very interesting from a biochemical 
viewpoint (Fox, 1993).  The majority of cheeses are produced by enzymatic (i.e., 
rennet) coagulations, with aspartic proteinases being the active milk-clotting enzyme.  
Rennet cheeses are almost always ripened, or matured, before consumption through 
the action of a complex battery of enzymes and are consequently in a dynamic state 
(Fox, 1993).  The properties of rennet curds are very different from those produced by 
isoelectric precipitation.  Rennet curds have better syneresis properties making it 
possible to produce low-moisture cheese curd without hardening; therefore, rennet 
curd can be converted to a more stable product than acid curds.  Rennet coagulation 
has become predominant in cheese manufacture and is the starting material for the 
vast majority of modern cheese varieties.   
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Typically, rennet refers to enzyme preparations from the lining of the fourth 
stomach of calves, with chymosin being the most important enzyme in rennet.  
Chymosin is considered nature’s enzyme for coagulating milk; thus, calf rennet is 
regarded as the ideal enzyme for cheese-making because of its high chymosin content 
(Law, 1999).  However, the increasing trend to slaughter calves at an older age and 
the increase in cheese production, has led to a shortage of calf rennet.  Due to this 
shortage rennet substitutes (usually bovine or porcine pepsins) are widely used in 
cheese-making (Fox, 1993).  The International Dairy Federation (IDF) has stated that 
the term rennet should be reserved for enzyme preparations from ruminant stomachs, 
whereas other milk-clotting enzymes should be named coagulants (Law, 1999). 
      2.4.2.4  Cutting 
Cutting occurs after the milk has clotted, and the coagulum is cut into pieces 
called grains or curd.  Cutting facilitates the removal of whey from the coagulated 
casein by increasing the surface area (Battistotti et al., 1983).  It is during cutting that 
the differentiation of the individual cheese varieties really begins, with the firmness 
and size of the cut coagulum being the two main influencing factors (Law, 1999).   
The smaller the coagulum is cut, the greater the surface area exposed and the 
more fat lost (Law, 1999).  The increased surface area of a small curd also results in 
the curd particle shrinking rapidly and expelling a larger amount of whey.  Therefore, 
low-moisture cheeses are made from a coagulum in which the curd is cut small and 
soft, while high-moisture cheeses are made from a coagulum in which the curd is cut 
large and firm (Law, 1999).   
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      2.4.2.5  Cooking 
After the curd is cut, it is typically cooked, or heated, and stirred.  Cooking 
not only influences the curd texture, but also gains time for lactic acid development 
and suppresses spoilage and pathogenic microorganisms.  The combination of stirring 
and heating, in addition to continued acid production by the starter, affect the final 
level of moisture in the cheese (Law, 1999).  However, the main objective of cooking 
is to contract the curd particles and drive out the free whey (Kosikowski, 1977).  
Internally, casein molecules are rearranging and tightening, in a process called 
syneresis, resulting in the squeezing out of the whey from the casein network (Law, 
1999).  The rate and extent of syneresis are influenced by milk composition, pH of 
the whey, cooking temperature, rate of stirring of the curd-whey mixture, and time 
(Fox, 1993).  The composition of the finished cheese is largely influenced by the 
extent of syneresis, and is under the control of the cheese-maker (Fox, 1993).  
Cooking is a thermal application which takes on many forms, ranging from 
direct steam to jacketed water; the choice is usually dictated by cheese type. 
Depending on the cheese variety, the maximum cooking temperature varies widely.  
The cooking of the curds must be conducted slowly and gently in the early stages, 
otherwise shattering of the curd results.  In addition, rennet formed curds are never 
heated beyond the generally accepted maximum temperature because of the danger of 
curtailing the lactic acid fermentation (Kosikowski, 1977).  Curds are heated at such a 
rate that the temperature rises to 32ºC in about 15 minutes and then to the maximum 
scalding temperature (35-43ºC) at the rate of 1ºC every four minutes (Davis, 1965).  
Typically, the curds for harder cheeses with lower moisture contents are heated to 
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between 46-56ºC, allowing more whey to be expelled.  In contrast, low scalding 
temperatures leave more moisture in the curd resulting in a softer cheese (Battistotti 
et al., 1983).   
      2.4.2.6  Separating and Draining 
At a carefully chosen point in the manufacturing process, the curd grains are 
separated from the whey.  Whey is the separated watery portion of the milk left over 
from the coagulation process (Kosikowski, 1977).  The method by which the whey 
and curd are separated plays an important role in not only the texture of the cheese, 
but also the color and flavor (Law, 1999).   
There are several methods for draining the whey.  With soft cheese, whey is 
typically drained from the perforations in the cheese molds.  In hard and semi-hard 
cheese, whey is drained from the vat, with the curds being held back with a screen 
and a channel is made in the curd mat to allow the whey to flow out.  Finally, in 
large-scale productions, the whey and curd are pumped into a vat with a perforated 
screen at the bottom.  The whey is able to flow through the screen, while the curd is 
held back.  Regardless of the draining technique, the curd is allowed to mat together 
as the whey is drained and the mat is then cut into slabs (Law, 1999). 
      2.4.2.7  Milling 
After draining the curd from the whey, the curds are allowed to mat together 
and form a slab, and as the layer of curd compacts, more whey is released from the 
curd (Fox, 1993).  With certain cheeses, such as Cheddar, the compression is allowed 
to continue for a considerable amount of time, after which the curd mass is cut, or 
milled, into small pieces.  Milling is the mechanical shredding and reduction of the 
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curd blocks to a size suitable for salting.  Other varieties of cheese allow for a short 
compression period, after which the blocks of curds are cut from the slabs and then 
subject to molding and pressing (Fox, 1993).   
      2.4.2.8  Salting 
The salting step consists of spreading coarse salt over the curd surfaces in a 
variety of ways:  manually, mechanically, or by immersing the pressed curd under 
brine.  Dry salting may be applied either to the loose curds or to the compact wheels 
(Kosikowski, 1977).  In some varieties of cheese, salting is dependent on when the 
milling occurs  (Davis, 1965).  For example, the Cheddar cheese curd blocks are first 
milled to a suitable size and then salted (Kosikowski, 1977).  If salt is not added to 
the curd before pressing, it may be added by soaking the cheese in brine (i.e., a 
sodium chloride solution).  The brine is usually a saturated salt solution (ca. 23% salt; 
but some are only 15%), at or near the pH of the cheese and at 40-50ºC (Law, 1999).  
Examples of cheeses that use a brine solution include Edam, Gouda, and Provolone.  
Salting may also be accomplished through rubbing dry salt onto the surface of the 
molded curds as in Blue-type cheeses.   
The salting of cheese not only improves its flavor, texture, and appearance, 
but also serves a variety of other functions.  First, salting helps control bacterial 
activity and the rate of ripening by suppressing the growth of some types of 
microorganisms.  In addition, salting also results in the immediate release of further 
whey from the curd.  However, while salting contributes to syneresis, it should not be 
used as a means of controlling the moisture content.  Finally, salting also assists in the 
matting of the curd (Davis, 1965).  Although salting should be a very simple 
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operation, quite frequently it is not performed properly, with adverse effects on 
cheese quality (Fox, 1993).  Cheeses made without salt or improperly salted often 
ripen too quickly and develop unpleasant flavors (Davis, 1965).  In addition, salting 
of the curd should be uniform otherwise the cheese may take on a mottled appearance 
(Kosikowski, 1977).  The curd should be uniformly salted at the rate of about one 
ounce to three pounds of curd in order to obtain a quality cheese (Davis, 1965). 
      2.4.2.9  Hooping and Pressing 
The term hoop is typically used in America (while mold is used in Britain), to 
refer to the containers used to receive the milled curd and shape the cheese (Davis, 
1965).  After the curd is placed in the hoop, the curd mass is pressed with the aim of 
obtaining a coherent mass.  The act of pressing accomplishes three main objectives:  
1) the curd is formed into its characteristic shape and compact texture; 2) whey is 
forced out; and 3) the curds knit together more quickly (Law, 1999). There are 
various ways and means of pressing the curd, with Kosikowski (1977) stating that 
confining the wet, warm curds (salted or unsalted) in a constricted wooden or metal 
form or cloth bag, with or without external weights or allowing the piled up curd to 
rest on itself in a vat for fixed periods of time constitutes pressing.  Typically, the 
time, pressure, and efficiency of pressing depends on the condition of the curd at the 
time of pressing and the decrease in pH during pressing (Law, 1999). 
A substantial amount of whey is released during the time the curd is being 
consolidated to form cheese.  The higher the moisture content of the curd (i.e., softer 
curd), the greater the amount of whey and rate of release of the whey from the curd.  
In order to accommodate the release of whey, hoops and molds are designed for the 
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escape of whey.  This may be accomplished by using detachable bottoms or no 
bottom, with the mold simply resting on a draining table.  Other designs involve small 
holes, perforations, slits, or other openings in the molds (Davis, 1965). 
      2.4.2.10  Packaging and Ripening 
Some cheeses are consumed fresh; however, most cheese varieties, including 
rennet coagulated, are not ready for consumption at the end of manufacturing and 
undergo a period of ripening.  Before the cheese is ripened, it is packaged.  Typically, 
packaging occurs after the curd has been pressed.  The cheese may be surface dried, 
parafinned (i.e., wrapped in a plastic film), or it may be left untouched, except for 
oiling of its surfaces (Kosikowski, 1977).  The shaped and packaged cheese is then 
allowed to ripen by placing the cheese in a temperature and humidity controlled room 
for a specified period of time.  Times for ripening (i.e. curing, maturation, aging) may 
vary from a few weeks to more than two years, depending on the variety of cheese; 
typically, the duration of ripening is inversely related to the moisture content of the 
cheese (Fox, 1993).  The temperature for ripening varies from 2-16ºC (Kosikowski, 
1977).   
The ripening step is one of the most important in the cheese-making process 
because during this time both physical and chemical changes are taking place that 
define the flavor, aroma, texture, and appearance of the final cheese.  Cheese ripens 
into distinct varieties because, according to Law (1999), cheeses are made physically 
different by the technology in the cheese plant and the microbial cultures.  Curds for 
different cheese varieties are noticeably different at the end of manufacture; however, 
the unique characteristics of the individual cheeses develop during ripening.  
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Therefore, the biochemical changes resulting in characteristics such as flavor, aroma, 
and texture that typically occur during ripening, are largely predetermined by the 
manufacturing process (Fox, 1993).   
The development of these characteristics in cheese is due to various types of 
chemical breakdowns involving the microorganisms in the milk and starter and the 
enzymes in the rennet and milk (Davis, 1965).  In addition, there are secondary 
microflora that also influence these characteristics; these secondary microflora arise 
from several sources.  Sometimes secondary microflora survive pasteurization, but 
more often they are added purposely depending on the type of cheese being 
manufactured.  For example, some microorganisms are added as a secondary starter, 
such as a blue or while mold during ripening or a surface smear of bacteria.   
Cheese ripening gives these microorganisms and enzymes in the cheese curd 
an opportunity to hydrolyze fat, protein, lactose, and other compounds.  According to 
Kosikowski (1977), the breakdown produces a softer, pliable body, and a more 
aromatic flavor, as the rigid insoluble protein changes to soluble nitrogenous forms 
and the neutral fat splits partially into free fatty acids and glycerol.  Thus, ripening 
catalyzes the production of a great variety of water-soluble, flavorful components:  
peptides, amino acids, amines, fatty acids, and carbonyls.  Presumably, in properly 
balanced ratios, these form the typical flavor of a ripened cheese (Kosikowski, 1977). 
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3.1  Application Overview 
The engineering-based risk assessment methodology developed in this 
research differs from traditional quantitative microbial risk assessment (QMRA); 
however, the engineering approach still works within the traditional QMRA 
framework of hazard identification, exposure assessment, dose-response assessment, 
and risk characterization.  The application of this approach to a particular food-
pathogen combination, E. coli O157:H7 contamination in cheese, demonstrates the 
engineering risk assessment methodology within the traditional QMRA framework.  
In addition, the adaptation of other engineering tools and techniques, such as 
Multiplicative Factors (MF) and Analytical Hierarchy Process (AHP), are explained 
throughout the risk model.    
 
3.2  Hazard Identification 
     3.2.1  Foodborne Disease 
 Infectious diseases spread through food are a common, and sometimes life-
threatening, problem for millions of people in the United States and around the world.  
In the United States alone, foodborne diseases have been estimated to cause 76 
million illnesses, 325,000 hospitalizations, and 5,000 deaths each year (Mead et al., 
1999).  There are more than 250 known foodborne diseases that can be caused by 
bacteria, parasites, viruses, or fungi; however, over 90% of confirmed foodborne 
human illness reported to the Centers for Disease Control (CDC) are attributed to 
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bacteria (Buzby et al., 1996).  In addition to the societal impact, the economic burden 
of foodborne illness is estimated to be approximately $6.9 billion annually for the five 
most common bacterial pathogens (ERS, 2004).   
Most bacteria do not cause human illness, with over 400 species of bacteria 
living harmlessly in the gastrointestinal tracts and skin of humans.  However, bacteria 
causing foodborne illness may be found in soil, water, plants, and animals (including 
humans) and may cause illness by direct killing of cells or through the production of 
toxins.  Some bacteria infect both animals and humans, while others can be harmless 
to animals but cause infection in humans.  Further, only certain strains of a bacterium 
may cause illness (Buzby et al., 1996).  One such bacterium, and the focus of this 
research, is Escherichia coli O157:H7, as this particular pathogen lives innocuously 
in the intestinal tract of some cattle, but can cause severe illness if ingested by 
humans.   
   3.2.2  Escherichia coli 
At the very basic level, Escherichia coli is a species of gram-negative, 
facultatively anaerobic, rod-shaped bacteria.  Many E. coli strains are normal 
inhabitants of the gastrointestinal tract of humans and other warm-blooded animals, 
and do not cause disease in humans (Buzby et al., 1996).  Prior to identification of 
specific virulence factors in diarrheal E. coli strains, serotypic analysis was used to 
differentiate pathogenic strains.  E. coli are serotyped on the basis of three major 
surface antigens:  O (somatic), H (flagellar), and K (capsular).  Specific combinations 
of O and H antigens define the “serotype” of an isolate.  E. coli of specific serogroups 
can be associated with certain clinical syndromes, but it is not the serologic antigens 
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themselves that determine virulence.  Rather, the serotypes and serogroups serve as 
readily identifiable chromosomal markers that correlate with specific virulence 
factors (Nataro and Kaper, 1998). 
Although serotypic markers correlate with certain clinical syndromes, E. coli 
strains that cause diarrheal illness are categorized into specific groups based on 
several characteristics:  virulence properties, pathogenic mechanisms, clinical 
syndromes, and distinct O:H serogroups (Nataro and Kaper, 1998).  The categories of 
diarrheal E. coli strains include:  enteropathogenic E. coli (EPEC), enterotoxigenic E. 
coli (ETEC), enteroinvasive E. coli (EIEC), diffuse-adhering E. coli (DAEC), 
enteroaggregative E. coli (EaggEC), and enterohemorrhagic E. coli (EHEC) 
(LeBlanc, 2003).   
   3.2.3  E. coli O157:H7 
E. coli O157:H7 belongs to the EHEC group; however, for an organism to be 
considered EHEC it must have two virulence factors that are necessary to cause 
disease.  E. coli that produce Shiga-like toxins are referred to as Shiga-toxin 
producing E. coli (STEC); however, production of Shiga-like toxins does not 
necessarily cause disease.  In addition to these toxins, some strains of E. coli have 
adherence factors (i.e., eaeA gene) that attach and damage intestinal tract cells 
causing attaching and effacing lesions (Nataro and Kaper, 1998).  Thus, EHEC is a 
distinct subgroup of STEC strains that appear to cause serious disease by both 
adherence to intestinal cells and the release of Shiga-toxins.   
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      3.2.3.1  Emergence of E. coli O157:H7 
Although E. coli O157:H7 was first isolated by the CDC in 1975, it was not 
identified as a cause of human illness until 1982, after it was associated with two 
outbreaks of hemorrhagic colitis in Oregon and Michigan.  Investigation of these two 
outbreaks linked the illness to the consumption of contaminated hamburgers (Riley et 
al., 1983).  The widespread occurrence of outbreaks and the increased incidence of 
reported cases resulted in designation of E. coli O157:H7 as an emerging pathogen.  
In 1994, E. coli O157:H7 was officially designated as a nationally notifiable disease 
by the Council of State and Territorial Epidemiologists.  And, in 1996, the Foodborne 
Diseases Active Surveillance Network (FoodNet), as a part of the CDC’s Emerging 
Infections Program (EIP), began a program of active surveillance of clinical 
laboratories for E. coli O157:H7 infections (Mead et al., 1999).  Based this 
surveillance data, Mead et al. (1999) estimate 62,000 annual cases of symptomatic E. 
coli O157:H7 infections in the United States related to foodborne exposure.  These 
infections result in approximately 1,800 hospitalizations and 52 deaths (Mead et al., 
1999).   
      3.2.3.2  Adverse Health Outcomes Associated with E. coli O157:H7 
Ingestion of food contaminated with E. coli O157:H7 results in a wide range 
of possible outcomes from asymptomatic infection to death.  In order to cause 
disease, E. coli O157:H7 must survive the acidic conditions of the stomach and move 
to the gastrointestinal tract.  The incubation period, or time from ingestion to the 
onset of symptoms, ranges from 1 to 8 days (Mead and Griffin, 1998).  The most 
common symptoms of illness include non-bloody diarrhea, hemorrhagic colitis (i.e., 
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bloody diarrhea), hemolytic uremic syndrome (HUS), and thrombotic 
thrombocytopenic purpura (TTP).   
Typically, illness due to E. coli O157:H7 infection begins with abdominal 
cramping and non-bloody diarrhea, with as many as 70% of patients developing 
hemorrhagic colitis after 1-2 days (Mead and Griffin, 1998).  The symptoms of 
hemorrhagic colitis include severe abdominal cramping, bloody diarrhea, and 
swelling, erosion and hemorrhage of the mucosal lining of the colon (Su and Brandt, 
1995).  While severe cases of hemorrhagic colitis can result in hospitalization (30 – 
45%), most patients with hemorrhagic colitis recover within 7 days (Mead and 
Griffin, 1998; Slutsker et al., 1998; Bell et al., 1994).   
Hemorrhagic colitis may be the only clinical manifestation of E. coli O157:H7 
infection, or it may precede other life-threatening complications such as HUS and 
TTP.  The onset of HUS is approximately a week after the onset of hemorrhagic 
colitis and is a severe form of kidney disease.  HUS is characterized by red blood cell 
destruction, lack of urine formation, kidney failure, and neurological complications, 
such as seizures and strokes (Buzby et al., 1996).  HUS occurs most often in children 
under the age of ten years and is the leading cause of acute renal failure in children 
(Duncan and Hackney, 1994).  Estimates of the number of hemorrhagic colitis cases 
progressing to HUS vary, with Mead and Griffin (1998) estimating 3-7% of sporadic 
cases and 20% or more of outbreak-related cases progress to HUS.  Bleem (1994) 
estimates up to 10% of hemorrhagic colitis cases progress to HUS while Duncan and 
Hackney (1994) estimate 15% of hemorrhagic colitis cases develop into HUS.  In 
addition, many patients with HUS die, with Mead and Griffin (1998) estimating the 
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mortality rate between 3-5% and Su and Brandt (1995) estimating the mortality rate 
to be as high as 10%.  
TTP is another condition which may follow hemorrhagic colitis, and typically 
affects the elderly (Buzby et al., 1996).  TTP is a condition that is similar to HUS, but 
with more prominent neurological symptoms and fewer renal symptoms; essentially, 
TTP is thought to represent a more extensive form of the clinical spectrum of vascular 
diseases that produces HUS (Su and Brandt, 1995).  It should be noted that there is 
some debate as to whether TTP and HUS are distinct syndromes.  In fact, Mead and 
Griffin (1998) believe when associated with E. coli O157:H7, TTP is probably the 
same disorder as HUS.  TTP related data is sparse, but Su and Brandt (1995) estimate 
as many as 8% of patients with E. coli O157:H7 associated hemorrhagic colitis 
progress to TTP.  The mortality rate for TTP varies widely among outbreaks.  Griffin 
and Tauxe (1991) give the combined case-fatality rate of four nursing home outbreaks 
as 18%, while Duncan and Hackney (1994) report that the incidence of death in the 
elderly from TTP is reported to be as high as 50%.  
The case-fatality rate of those suffering hemorrhagic colitis, without 
progression to HUS or TTP, is thought to be less than 1% (Ryan et al., 1986; Boyce et 
al., 1995).  However, Su and Brandt (1995) estimate the case-fatality rate for E. coli 
O157:H7 infection from 3% to 36% among the elderly and Gerba et al. (1996) 
speculate that case-fatality rate can be 10-100 times greater in the elderly than in the 
general population.  Therefore, age and immune system status appear to be the 
greatest risk factors for the development of E. coli O157:H7 related illness.  Persons 
at extremes of age are at an increased risk for E. coli O157:H7 associated diarrhea as 
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well as for HUS, TTP, and death (Su and Brandt, 1995).  According to Gerba et al. 
(1996) infectious diseases are a major problem in the elderly because the immune 
function declines with age, antibiotic treatment is less effective because of a decrease 
in physiological function, and malnutrition is more common.  Consequently, 
outbreaks of gastroenteritis in nursing homes can be devastating and result in a 
significantly higher mortality rate than the general population.   
Table 3.1, from Su and Brandt (1995), gives a summary of statistics relating to 
E. coli O157:H7 associated diarrhea, hemorrhagic colitis, and HUS.  However, it 
should be noted that these statistics vary greatly from source to source and that the 
actual incidence rates are impossible to determine.  Information on the incidence of 
foodborne disease is obtained through surveillance systems, which collects outbreak 
data from state and local health departments.  The reporting of outbreaks is dependent 
on patient and physician recognition, motivation to contact local health officials, and 
resources of laboratories to identify the pathogen.  For these reasons, it is thought that 
only a small fraction of foodborne disease outbreaks are actually reported to the CDC 
and outbreak data seriously under-represents the prevalence of foodborne illness in 
the United States (Steahr, 1994). 
 
Table 3.1:  Statistics on the Association of E. coli O157:H7 Infection with Diarrhea, Hemorrhagic 
Colitis, and HUS 
Variable Percentage 
Incidence of E. coli O157:H7 in all cases of diarrhea 0.6-2.4 
Incidence of E. coli O157:H7 in bloody diarrhea of hemorrhagic colitis 15-36 
Development of hemorrhagic colitis in E. coli O157:H7 infection 38-61 
Incidence of E. coli O157:H7 in HUS 46-58 




      3.2.3.3  Sources of E. coli O157:H7 
While E. coli O157:H7 may be transmitted through water or person-to-person 
contact, foodborne transmission is the most important means of infection and the 
focus of this research; Mead et al. (1999) estimate that 85% of E. coli O157:H7 
illnesses are foodborne.  E. coli O157:H7 have been isolated from a variety of 
animals including pigs, horses, dogs, cats, birds, and rodents (Duffy et al., 2001); 
however, healthy cattle are the primary reservoir for human infection with E. coli 
O157:H7 (Mead and Griffin, 1998).  E. coli O157:H7 lives innocuously in the 
intestinal tracts of some cattle and is excreted through the feces (Buzby et al., 1996), 
with most foodborne outbreaks being traced to foods derived from cattle, especially 
ground beef and raw milk (Mead and Griffin, 1998).  Contamination of foods 
generally occurs in one of three ways:  1) through fecal contamination of food crops 
when untreated or poorly treated manure is used for fertilizer, 2) fecal contamination 
of carcasses through poor hygienic practices during slaughter and evisceration 
processes, and 3) consumption of fecally contaminated raw milk or products made 
from such milk (Bell and Kyriakides, 1998).   
The principle food vehicle implicated in many E. coli O157:H7 outbreaks has 
been ground beef (Riley et al., 1993; Ryan et al., 1986; Ostroff et al., 1990; Bell et al., 
1994; CDC, 1993); however, E. coli O157:H7 outbreaks have also been associated 
with raw milk, apple cider, mayonnaise, and vegetables (Olsen et al., 2000).  Fresh-
pressed, unpreserved apple cider has been implicated in two outbreaks of E. coli 
O157:H7 infection, with the transmission possibly occurring through the pressing of 
apples contaminated on the ground (Besser et al., 1993; CDC, 1997).   Multiple 
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outbreaks of E. coli O157:H7 linked to the ingestion of milk have been reported 
(Keene et al., 1997; Martin et al., 1986; Upton and Coia, 1994).  In addition, an 
outbreak of E. coli O157:H7 infection associated with eating fresh cheese curds has 
also been documented (CDC, 2000).  E. coli O157:H7 has been associated with 
numerous outbreaks involving ground beef and milk, and the pathogen has been 
isolated from milk and the feces of healthy cattle (Martin et al., 1986; Wells et al., 
1991).  Thus, it appears that cattle are an important reservoir for E. coli O157:H7.  
      3.2.3.4  Survival and Growth Factors of E. coli O157:H7 
E. coli O157:H7 presents a serious food safety issue not only in terms of the 
severe health outcomes it causes, but also because it is an extremely virulent 
organism.  A number of studies have investigated the effects of temperature, pH, salt, 
and water activity on the survival and growth of E. coli O157:H7 (Buchanan and 
Bagi, 1997; Sutherland et al., 1995; Buchanan et al., 1993; Buchanan and Klawitter, 
1992).   First, E. coli O157:H7 is capable of surviving at low temperatures and resists 
freezing.  The organism will not typically grow below 8°C - 10°C or above 45°C, 
with optimal growth occurring at 37°C (Doyle and Schoeni, 1984; Buchanan and 
Doyle, 1997).  E. coli O157:H7 has no unusual resistance to heat, and thorough 
cooking of foods or pasteurization will kill the organism (Doyle et al., 1997).  
Second, unlike many foodborne disease-causing organisms, E. coli O157:H7 is 
tolerant of acidic environments, and it can survive the high acidity of the stomach 
(Buzby et al., 1996); Duncan and Hackney (1994) state that E. coli O157:H7 can 
survive pH as low as 3.7.  Third, E. coli O157:H7 is a facultative anaerobe, meaning 
it can grow in environments where oxygen is present, low, or absent.  Therefore, 
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modified-atmosphere packaging, which is commonly used to prevent bacterial growth 
in packaging fresh foods, has little effect on the growth and survival of the organism 
(Hao and Brackett, 1993; Duffy et al., 2001).  Finally, while E. coli O157:H7 does 
not tolerate high salt conditions, the organism is able to survive for extended periods 
under conditions of reduced water activity (Buchanan and Doyle, 1997).   
      3.2.3.5  Low Infectious Dose 
Although the precise infectious dose for E. coli O157:H7 is unknown, it is 
thought to be extremely low.  The literature reveals an infectious dose of between 10-
1000 cells.  CAST (1994) estimates between 10-1000 cells are required to cause 
infection, while the Institute of Food Science & Technology (2004) estimate between 
10-100 cells can cause infection.  Dennis (2000) estimates that fewer than 100 cells 
are required to cause infection, while Duncan and Hackney (1994) estimate as few as 
10 cells could cause infection.  Regardless of the true infectious dose, E. coli 
O157:H7 presents a serious food safety concern due to the low infectious dose and 
ability to survive the acidic conditions of the stomach.   
   3.2.4  E. coli O157:H7 Relevance to Cheese  
Multiple outbreaks of E. coli O157:H7 have been linked to the ingestion of 
both raw and pasteurized milk (Keene et al., 1997; Martin et al., 1986; Upton and 
Coia, 1994).  Contamination with cattle fecal material has been implicated in the 
infections of E. coli O157:H7 associated with raw milk.  Outbreaks related to 
pasteurized milk have occurred due to inadequate pasteurization or post-process 
contamination (Duffy et al., 2001).  Wang et al. (1997) showed that E. coli O157:H7 
was able to grow in both pasteurized and unpasteurized milk stored at 8ºC, 15ºC, and 
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22ºC; however, while E. coli O157:H7 failed to grow at 5ºC, it did survive with only 
a small population decrease after 28 days of storage.  Studies performed by Mamani 
et al. (2003), Massa et al. (1999), Palumbo et al. (1997), and Altieri et al. (1997) were 
consistent with the results of Wang et al. (1997).   
The association of milk with E. coli O157:H7 outbreaks and the previous 
studies on the growth of E. coli O157:H7 in milk raises the possibility of E. coli 
O157:H7 survival in other dairy products such as cheese.  Traditionally, it has been 
assumed that pathogenic microorganisms in raw milk die during the cheese 
manufacturing process due to the production of high acidity (i.e., low pH value) and 
competition from starter cultures (Fox, 1993).  However, studies on the survival of E. 
coli O157:H7 in hard cheese indicate that the pathogen can grow during the cheese 
manufacturing process and survive for up to 70 days post-manufacturing (Hudson et 
al., 1997; Maher et al., 2001; Reitsma et al., 1996; Teo et al., 2000).  Therefore, the 
indications are that the additional hurdles imposed during cheese manufacturing are 
insufficient to prevent the growth and survival of the pathogen in cheese produced 
from milk contaminated with the pathogen.   
Not only has E. coli O157:H7 been shown to survive the cheese 
manufacturing process, but it has also been linked to several outbreaks involving 
cheese, thereby establishing cheese as a viable route of transmission for E. coli 
O157:H7.  Table 3.2 presents a summary of these cheese related E. coli O157:H7 
outbreaks.  Although cheese related E. coli O157:H7 outbreaks do not represent a 
large proportion of all E. coli O157:H7 outbreaks, on some occasions the health 
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consequences have been particularly severe, resulting in serious infections, long-term 
sequelae, and even death (IFST, 1998).    
 
Table 3.2:  Summary of Reported Cheese Related E. coli O157:H7 Outbreaks  
Reference Outbreak Cheese 
Type 



















Brie Unpasteurized >3000 NR1 NR 
Anon., 
1994a 
1992, France Fromage 
frais 
Unpasteurized NR NR 1 
Anon, 1994b 1994, Scotland Farm cheese Unpasteurized 20 1 0 
Anon, 1997 1997, Wyre, 
England 
Lancashire Unpasteurized 2 0 0 














In the majority of these outbreaks, the cheese was made with unpasteurized 
milk.  In the outbreak associated with cheese made from pasteurized milk, post-
pasteurization contamination occurred.  While it is recognized that post-pasteurization 
contamination can occur whether or not the milk is pasteurized, the data in Table 3.2 
indicate that outbreaks are more likely to arise from cheese made from unpasteurized 
milk even if the starting material is of exceptionally high microbiological quality and 
the manufacturing conditions are the most hygienic possible (IFST, 1998).   
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3.3  Exposure Assessment 
 
   3.3.1  Production 
 
      3.3.1.1  Production Overview 
 
In order to estimate the extent to which cheese may become contaminated 
with E. coli O157:H7 during the production phase, the steps (i.e., sub-system 
elements) in the cheese-making process where E. coli O157:H7 contamination may 
be increased or decreased are identified; in addition, the mechanisms affecting the 
growth or inactivation of E. coli O157:H7 contamination at each step (i.e., the basic 
elements) are identified as well; the basic elements are further reduced into options in 
order to account for the variability of the process.  The significant steps in the 
production of cheese have been identified as:  milk storage, milk heat treatment, 
addition of coagulant, cutting the curd, cooking the curd, separation of whey and 
curd, salting, hooping and pressing, and ripening.  These steps and their relationships 




Figure 3.1:  DML Model of Cheese Production Phase 
 
 
The input to the production model is the initial contamination of E. coli 
O157:H7; this contamination may come from various sources such as fecal 
contamination of the teats and udder, udder infections (i.e., mastitis), or contaminated 
equipment.  The contamination is propagated through the production phase, with the 
contamination level at each step dependent on the contamination at the previous step.  
In addition, the milk heat treatment step influences the contamination at all of the 
subsequent steps.  The end result of the production phase is the level of E. coli 
O157:H7 contamination in 1 kilogram of cheese which serves as the input to the 
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      3.3.1.2  Multiplicative Factor Approach 
  As previously stated, the DML model represents the conceptual model upon 
which the mathematical model is based.  The mathematical predictive model used to 
propagate the contamination through the production phase is the Multiplicative Factor 
(MF).  The MF is essentially a “multiplier” that allows the contamination to be 
propagated through the model.  If a selection increases the contamination, the 
multiplier will be greater than 1; if a selection decreases the contamination, the 
multiplier will be between 0 and 1.  These multipliers can be calculated by obtaining 
the contamination level at the input and output of the step from the experimental data 
in the literature.  Figure 3.2 demonstrates how the MF is used to propagate the 
contamination at a particular step.  The distribution of contamination before step “N” 
is multiplied by the MF in order to obtain the distribution of contamination after step 
“N”. 
Figure 3.2:  Multiplicative Factors Approach 
 
    
In order to consider the uncertainty associated with the MFs, the MFs are also 
shown in the form of a distribution.  The distribution of the MFs is assumed to be 
lognormal for several reasons.  First, the lognormal distribution is often used to model 
bacterial survival and the MFs represent the survival of E. coli O157:H7 from one 
step to the next.  In addition, the range of the multipliers can be from more than 0 to 
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infinity, depending on whether a particular option increases or decreases the 
contamination, and are positively skewed.  Since the MF can vary by orders of 
magnitude, the lognormal distribution is a natural choice.  Finally, the contamination 
at the end of the production phase is calculated by multiplying the initial 
contamination by the various MFs for each step.  The Central Limit theorem shows 
that the product of a large number of probability distributions is lognormally 
distributed, therefore, it seems reasonable to assume the MFs are lognormally 
distributed (Vose, 2000). 
Although the MFs are assumed to be lognormally distributed in the Bayesian 
analysis for describing the distribution of the MF, no prior knowledge of the 
parameters of the distribution is assumed.  For each MF distribution, non-informative 
uniform prior distributions are assumed for both the mean and standard deviation.  
Using data from the literature, multipliers are calculated for each option from the 
level of contamination at the input and output of a step.  These multipliers are the 
“observed” data and used as evidence for developing the likelihood function in the 
Bayesian updating process.  The Bayesian updating results in posterior distributions 
of the mean and standard deviation of the MF distribution.  Figure 3.3 illustrates this 
approach; the MF parameter distributions, and the data used to develop these 







Figure 3.3:  Bayesian Approach for Developing Multiplicative Factor Distribution 
 
  
The Bayesian updating process illustrated in Figure 3.3 is accomplished using 
the WinBUGS (Bayesian Inference Using Gibbs Sampling) software, version 1.4.1.  
This software allows for the Bayesian analysis of complex statistical models using 
Markov Chain Monte Carlo (MCMC) methods.  WinBUGS allows a model to be 
specified, and then updated with the observed data using MCMC methods.  The final 
output is posterior distributions for the parameters of interest.   
      3.3.1.3  Production Phase Decomposition 
Again, the production phase is reduced to a series of sub-system elements 
(i.e., steps), basic elements (i.e., physical conditions and/or manufacturing practices), 
and options (i.e., variations within the physical conditions and/or manufacturing 
practices) using the DML concept.  MF distributions exist for the various 
combinations of options for the basic elements of a step.  However, only one MF 
distribution is applied to each step, based on the options selected for that particular 
step.  Thus, the DML decomposition aids in the identification of the selected MF 
distribution.  The following sections discuss the basic elements and options for each 
step of the production phase.  In addition, the MF distributions available for each step 
are identified.   
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         3.3.1.3.1  Production Step A0:  Initial Contamination 
The input to the production model is the initial contamination of E. coli 
O157:H7, which may come from a variety of sources.  The initial contamination is a 
variable in the form of the lognormal distribution, as the bacterial concentration is 
positively skewed in the range from 0 to infinity.  Any mean and standard deviation 
of contamination may be used and is in the form of colony-forming units per milliliter 
(CFU/ml).  This analyst-defined contamination level is assumed for a 1,000 L vat of 
milk, an amount representative of smaller scale cheese production (Bemrah et al., 
1998).  Thus, the remaining steps in the production phase influence the E. coli 
O157:H7 contamination in the entire vat of milk used to produce the cheese.  Figure 
3.4 illustrates the calculation for the initial E. coli O157:H7 contamination in a 1,000 
L vat of milk using the basic elements for step A0.   
 
 
Figure 3.4:  DML Representation of Step A0 (Initial Contamination) Calculation  
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         3.3.1.3.2  Production Step A1:  Milk Storage 
Step A1 determines the level of E. coli O157:H7 contamination after milk 
storage.  Time and temperature are identified as the two factors contributing to the 
growth or inactivation of the pathogen.  Although the literature reveals that milk 
should be stored at less than 5ºC (Law, 1999), the PMO Revision 2001 states that 
milk should be maintained at 7ºC or less (USDA, 2001).  Four temperature options 
are available for milk storage temperature:  T ≤ 5ºC, 5ºC < T < 8ºC, T = 8ºC, or T > 
8ºC.  Milk may be stored for several days prior to cheese-making (Law, 1999); Fox et 
al. (2000) state that raw milk may be stored on the farm for 3-4 days and stored an 
additional 1-2 days at the factory prior to use in cheese-making.  In this analysis, five 
options are available for milk storage time:  1, 2, 3, 4, or 5 days.  The various 
combinations of both milk storage time and temperature result in the development of 
20 MF distributions.  Figure 3.5 shows how the DML concept is applied to step A1 in 
order to model the variability.  
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Figure 3.5:  DML Decomposition of Production Step A1 (Milk Storage) 
 
 
         3.3.1.3.3  Production Step A2:  Milk Heat Treatment 
Step A2 determines the level of E. coli O157:H7 contamination after milk 
heat treatment.  It should also be noted that the milk treatment step is an influencing 
factor in all the subsequent production steps, as shown in Figure 3.4.  While a study 
by Wang et al. (1997) showed no significant difference in the survival and growth of 
E. coli O157:H7 in pasteurized milk, Marek et al. (2004) found that E. coli O157:H7 
persisted longer in pasteurized whey versus unpasteurized whey, indicating that there 
might be a difference in E. coli O157:H7 survival in cheese made from pasteurized 
milk versus unpasteurized milk.   
Three categories of heat treatment for cheese-milk are identified for step A2:  
1) cheese made from raw milk (i.e., no heat treatment), 2) cheese made from 
thermalized, or sub-pasteurized milk, and 3) cheese made from pasteurized milk.  For 
cheese made from raw milk, the milk heat treatment step has no influence on the level 

























and temperature are taken into account, so increasing the time at a particular 
temperature will decrease the multiplicative factor.  The time used for thermalization 
is defined by the analyst, and temperature options range from 50-100ºC.  In addition, 
the thermalized milk option may be used to account for an inadequate pasteurization 
process.  Finally, the pasteurization of milk will have the most significant impact on 
the reduction of bacterial contamination.  According to Fox et al. (2000), 
pasteurization is the single most important step in cheese-making in terms of reducing 
bacterial contamination, as it kills the majority of pathogens found in raw milk.  
Figure 3.6 illustrates the DML decomposition for step A2.   
 
 
Figure 3.6:  DML Decomposition of Production Step A2 (Milk Heat Treatment) 
 
 
         3.3.1.3.4  Production Step A3:  Addition of Coagulant 
Step A3 determines the level of E. coli O157:H7 contamination after the 
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development of acidity, the more rapid the death of E. coli O157:H7; starter cultures 
that are able to obtain a higher level of acidity appear to have more influence on the 
survival of E. coli O157:H7.  Dennis (2000) identifies several mesophilic cultures as 
being more effective in controlling E. coli O157:H7 contamination.  Therefore, step 
A3 considers the influence of mesophilic and thermophilic starter cultures.  As stated 
previously, the influence of the milk heat treatment is also considered.  Figure 3.7 
shows the DML decomposition of these influencing factors for step A3.    
Figure 3.7:  DML Decomposition of Production Step A3 (Addition of Coagulant) 
 
 
         3.3.1.3.5  Production Step A4:  Cutting of Curd 
Step A4 determines the level of E. coli O157:H7 contamination after the curd 
has been cut.  No manufacturing variations have been identified at this step that 
would influence the level of contamination; therefore, the only influencing factor 
considered is the heat treatment of the milk.  Figure 3.8 shows the DML 
decomposition for step A4.    
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Figure 3.8:  DML Decomposition of Production Step A4 (Cutting of Curd) 
 
 
         3.3.1.3.6  Production Step A5:  Cooking of Curd 
Step A5 determines the level of E. coli O157:H7 contamination after the curd 
has been cooked.  The cooking temperature is dependent on the type of cheese being 
manufactured.  Typically, softer cheeses are cooked at a lower temperature and harder 
cheeses are cooked at a higher temperature.  Law (1999) identifies four cooking 
temperature ranges:  30˚C ≤ T ≤ 32˚C, 33˚C ≤ T ≤ 35˚C, 36˚C ≤ T ≤ 40˚C, or T > 
40˚C.  Therefore, step A5 considers the influence of cooking temperature, with higher 
temperatures being more likely to thermally inactivate E. coli O157:H7.  Again, the 
influence of the milk heat treatment is also considered.  Figure 3.9 shows the DML 
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Figure 3.9:  DML Decomposition of Production Step A5 (Cooking of Curd) 
 
 
         3.3.1.3.7  Production Step A6:  Separation of Curd and Whey 
Step A6 determines the level of E. coli O157:H7 contamination after the curd 
has been separated from the whey.  No manufacturing variations have been identified 
at this step that would influence the contamination level; therefore, the only 
influencing factor considered is the heat treatment of the milk.  While E. coli 
O157:H7 growth can occur during this step, it is also important to account for the 
percentage of bacteria remaining in the curd versus the bacteria transferred to the 
whey.  Based on Bemrah et al. (1998), it is assumed that 90% of the bacteria resides 
in the curd and continues through the rest of the production phase; the remaining 10% 
of the bacteria is transferred to the whey.  Figure 3.10 shows the DML decomposition 
for step A6, and accounts for 90% of the bacteria continuing through to the next step 
in production.    
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Figure 3.10:  DML Decomposition of Production Step A6 (Separation of Curd and Whey) 
 
 
         3.3.1.3.8  Production Step A7:  Salting 
Step A7 determines the level of E. coli O157:H7 contamination after salting.  
The salting step can help control bacterial activity and the rate of ripening by 
suppressing the growth of some types of microorganisms (Davis, 1965).  The type of 
salting varies depending on the type of cheese being manufactured.  Two types of 
salting are considered in step A7:  dry and brine.  Therefore, step A7 considers the 
influence of salting on E. coli O157:H7 contamination in combination with milk heat 
treatment.  Figure 3.11 shows the DML decomposition of these influencing factors 
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Figure 3.11:  DML Decomposition of Production Step A7 (Salting) 
 
         3.3.1.3.9  Production Step A8:  Hooping and Pressing 
Step A8 determines the level of E. coli O157:H7 contamination after hooping 
and pressing.  No manufacturing variations have been identified at this step that 
would influence the E. coli O157:H7 contamination level; therefore, the only 
influencing factor considered is the heat treatment of the milk.  Figure 3.12 shows the 
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Figure 3.12:  DML Decomposition of Production Step A8 (Hooping and Pressing) 
 
         3.3.1.3.10  Production Step A9:  Packaging and Ripening 
Step A9 determines the level of E. coli O157:H7 contamination after 
packaging and ripening.  The previous steps have determined the level of E. coli 
O157:H7 contamination in the entire cheese vat; step A9 assumes that the vat is 
packaged into 1 kg portions of cheese.  Several calculations are needed in order to 
determine the amount of cheese per 1,000 L vat of milk.  The amount of cheese 
produced from a given amount of milk varies depending on the type of cheese, 
typically, it takes 8-15 units of milk to produce 1 unit of cheese (Battistotti et al., 
1983).  The 1,000 L vat of milk assumed at the start of the production phase should 
yield 67-125 kg of cheese; a uniform distribution is used to represent this variability.  
Thus, in order to determine the amount of contamination per kilogram cheese, the 
amount of contamination in the entire cheese vat is divided by the uniform 
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Once the cheese is packaged into 1 kg portions, step A9 determines the level of 
contamination after ripening.  Previously, it was assumed that any pathogenic 
microorganisms surviving the cheese-making process would die during cheese 
ripening, resulting in the PMO Revision 2001 stipulation that raw milk cheese must 
be ripened for at least 60 days.  However, numerous studies have shown that E. coli 
O157:H7 can survive the ripening period (Hudson et al., 1997; Maher et al., 2001; 
Reitsma et al., 1996; Teo et al., 2000).  Time has been identified as the main 
influencing factor on the survival of E. coli O157:H7 during the ripening period.  The 
ripening time is dependent on the type of cheese being manufactured, and may vary 
from a few weeks to more than two years; typically, the duration of ripening is 
inversely related to the moisture content of the cheese (Fox, 1993).  From the 
literature, a number of different ripening times have been identified for step A9:  14, 
27, 45, 75, 90, 104, and 150 days.  Therefore, step A9 considers the influence of 
ripening time, in combination with milk treatment, with longer ripening times 
resulting in a more significant decrease in E. coli O157:H7 contamination.  Figure 




Figure 3.13:  DML Decomposition of Production Step A9 (Packaging and Ripening) 
 
 
      3.3.1.4  Production Calculation Summary  
After entering the initial E. coli O157:H7 contamination, this contamination is 
propagated through the production phase.  The contamination is increased or 
decreased by the multiplicative factor for each step; the multiplicative factor varies 
based on the options selected for the basic elements of that step.  The end result of the 
production phase is an estimation of E. coli O157:H7 contamination in 1 kg of 
cheese; this level of contamination is also used as the initial contamination in the 
distribution phase.  A summary of the production phase calculations is given in Table 
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Table 3.3:  Production Phase Calculations 
Step Description Distribution/Model Calculation Unit 
A0 Initial E. coli O157:H7 
Contamination (CFU/ml) 
Lognormala  Lognormal(μ,σ)*(1000ml/1L)*1000L CFU/vat 
A1 Contamination after Milk 
Storage 
MF A1ib (i = 1-20) A0*(A1i) CFU/vat 
A2 Contamination after Milk Heat 
Treatment 
MF A2i (i = 1-16) A1*(A2i) CFU/vat 
A3 Contamination after Addition 
of Coagulant 
MF A3i (i = 1-4) A2*(A3i) CFU/vat 
A4 Contamination after Cutting of 
Curd 
MF A4i (i = 1-2) A3*(A4i) CFU/vat 
A5 Contamination after Cooking 
of Curd 
MF A5i (i = 1-8) A4*(A5i) CFU/vat 
A6 Contamination after 
Separation of Curd and Whey 
MF A6i (i = 1-2) 0.9c*A5*(A6i) CFU/vat 
A7 Contamination after Salting MF A7i (i = 1-4) A6*(A7i) CFU/vat 
A8 Contamination after Hooping 
and Pressing 
MF A8i (i = 1-2) A7*(A8i) CFU/vat 
A9 Contamination after 
Packaging and Ripening 
MF A9i (i = 1-14) Uniform(67,125)d*A8*(A9i) CFU/kg 
aAnalyst-defined mean and standard deviation 
bMultiplicative Factor model for step A1; the MF used is based on user selections, with 20 options available for step A1 
cMultiplication by 0.9 accounts for 90% of bacteria being transferred to curd 




   3.3.2  Distribution 
      3.3.2.1  Distribution Overview 
 The distribution phase begins after cheese ripening and uses the distribution of 
E. coli O157:H7 contamination after cheese ripening as the input (i.e., step A9).  The 
distribution phase identifies the steps (i.e., sub-system elements) along the path from 
cheese production to the end consumer.   In addition, the mechanisms (i.e., the basic 
elements) affecting growth of E. coli O157:H7 contamination at each step are 
identified as well, with these basic elements being further reduced into options.  The 
significant steps that affect the growth of E. coli O157:H7 in the distribution phase 
are identified as:  storage before transportation, transportation to retail, retail storage, 
transportation to consumers, and consumer storage.  Figure 3.14 shows the sub-




Figure 3.14:  DML Model of Cheese Distribution Phase 
 
 
Using the distribution of E. coli O157:H7 contamination from the production 
phase as the input, the distribution phase accounts for the growth of microorganisms 
between the time of production and the time of consumption.  Loss of temperature 
control as the cheese is being transported and stored may result in microbial growth.  
The amount of bacterial growth is dependent on the nature of the cheese, with pH, 
sodium chloride concentration, and water activity being the most influential.  In 
addition, the behavior of the organism is also influenced by conditions such as the 
temperature and length of storage time.  The end result of the distribution phase is the 
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in contamination along the distribution pathway.  This distribution is then used as the 
input to the consumption phase.  
      3.3.2.2  Gompertz Model Approach 
Several mathematical models have been proposed in the literature to represent 
the dynamic growth behavior of microorganisms in food, including the Gompertz, 
Baranyi, logistic, and exponential (Buchanan et al., 1997).  The literature search 
reveals a number of experiments in which growth curves of E. coli O157:H7 are 
successfully fit to the Gompertz equation.  These experiments use the Gompertz 
equation to describe the effect of a number of different variables, such as temperature, 
pH, sodium chloride concentration, and water activity on the growth of E. coli 
O157:H7 (Buchanan et al., 1993; Duffy et al., 1999; Sutherland et al., 1995).  Due to 
its wide acceptance in the literature and the availability of data to define the 
Gompertz equation parameters, the Gompertz model is selected to describe the 
growth of E. coli O157:H7 during the distribution phase.   
  The Gompertz equation is a commonly used mathematical model that 
predicts the log increase in microorganism concentration at a constant temperature.  
The growth curve is sigmoidal with two shoulders and a period of exponential 
growth, with the shape of the curve controlled by three parameters:  B, M, and C.  
Table 3.4 gives the Gompertz equation, defines the Gompertz parameters, and derives 
the growth kinetics (Rajkowski and Marmer, 1995).   
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Table 3.4:  Gompertz Equation and Parameters 




= A  +  C * exp[-exp(-B (t – M))] 
 
 
L(t) = log count of bacteria (log CFU/ml) at time (t) (in hours); 
A = asymptotic log count of initial bacteria as time decreases indefinitely, (log CFU/ml); 
C = asymptotic amount of bacteria growth that occurs as T increases (number of log cycles of growth (log CFU/ml)); 
B = relative growth rate at M, [log (CFU/ml)/h], where 
M = the time at which the absolute growth rate is maximal (h) 
Derived growth kinetic values: 
Name Definition Value Unit 
Exponential Growth Rate (EGR) The time cells divide at a constant rate BC/2.71818 [log (CFU/ml)]/h 
Generation Time (GT) The time cells take to double in number [(log 2)*2.71818]/BC hours 
Lag Phase Duration (LPD) The time before cells start to grow at a 
constant rate 
(M - 1)/B hours 
Maximum Population Density 
(MPD) 
The final count at the end of growth study A + C [log (CFU/ml)]/h 
Time one-thousand (T1000) The time to obtain a 3-log increase in cell 
numbers 
10.1155GT + LPD hours 
 
 
Based on the data obtained from the literature, distributions for the Gompertz 
equation parameters B, M, and C are estimated using a Bayesian approach similar to 
the one described for the multiplicative factors.  Again, a lognormal distribution is 
assumed for each of the Gompertz parameters (i.e., B, M, and C), as these parameters 
describe bacterial survival.  However, no prior knowledge of the parameters (i.e., 
mean and standard deviation) of the lognormal distribution describing the Gompertz 
parameters is assumed; therefore, uniform prior distributions are assumed for both the 
mean and the standard deviation.  Data for B, M, and C are obtained from the 
literature, and this data serves as the likelihood in the Bayesian updating process.  The 
Bayesian updating results in posterior distributions of the mean and standard 
deviation of the Gompertz parameters, thereby addressing the parameter uncertainty 
of the distributions describing B, M, and C.  The parameter distributions for B, M, 
and C, and the data used to develop these distributions, are given in Appendix III.  
For each of the steps in the distribution phase, the DML concept is used to 
identify the physical conditions (i.e., basic elements) that affect the growth or 
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inactivation of E. coli O157:H7.  In this research, temperature and pH are presumed 
to be the determining factors in the magnitude of microbial growth, and the 
distributions of the Gompertz parameters are developed for the various combinations 
of temperature and pH.  Sodium chloride concentration has also been identified as a 
factor that affects E. coli O157:H7 growth (Buchanan and Klawitter, 1992; 
Sutherland et al., 1995); however, this factor is not considered in this research as 
there is insufficient data to develop distributions for the Gompertz parameters based 
combinations of temperature, pH, and sodium chloride concentration.   
In addition, the DML concept is used to identify the various temperature and 
pH options that might be observed during distribution.  A number of different 
temperatures options are available at each of the steps in the distribution phase; these 
temperature options allow both proper cheese storage and severe temperature abuse to 
be considered.  The temperature options available for the steps in the distribution 
phase are:  5, 8, 10, 12, 19, 28, 37, and 42ºC.  A number of different pH options are 
available as well in order to account for the variation in pH among cheeses (USDA, 
2003).  The pH options available in the distribution phase are:  4.5, 5.0, 5.5, 6.0, 6.5, 
7.0, 7.5, 8.0, and 8.5.  Although the pH of cheese is dynamic during the ripening 
phase, it is assumed that once the cheese enters the distribution phase, the pH remains 
constant.  Therefore, the pH selection is made only in the first step of the distribution 
phase (i.e., storage before transportation step).  Figure 3.15 illustrates how each of the 
Gompertz parameters are represented by a distribution based on a specified pH and 
temperature; the initial bacterial count is also represented by a distribution.  The end 
result is a distribution of the final bacterial count at the end of the step. 
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Figure 3.15:  Dynamic Growth Represented by Gompertz Equation 
 
       
      3.3.2.3  Distribution Phase Decomposition 
The distribution phase resembles the production phase in that the phase is 
reduced to a series of sub-system elements (i.e., steps), basic elements (i.e., physical 
conditions), and options (i.e., variations within the physical conditions) using the 
DML concept.  In the distribution phase, temperature and pH have been identified as 
the basic elements for each step.  Based on the pH and temperature selection for a 
step, a distribution exists for each of the Gompertz equation parameters.  Therefore, 
based on the distribution of the E. coli O157:H7 contamination from the previous 
step, the distributions for the Gompertz parameters (determined by the pH and 
temperature selections), and a uniform distribution for time, the final distribution of 
E. coli O157:H7 contamination for a particular step is calculated.  The following 
sections discuss each of the distribution steps in detail and demonstrate how the DML 
concept is applied to the Gompertz equation.   
L(t)  =  A  +  C * exp[-exp(-B (t – M))]
Initial Bacterial 
Count
Growth at t ∞ Growth rate at M Time at maximum growth
A = f(initial contamination from previous step)
C = g(pH, Temp)
B = h(pH, Temp)




         3.3.2.3.1  Distribution Step B1:  Storage Before Transportation   
Step B1 describes the level of E. coli O157:H7 contamination after storage, 
before transportation to retail.  The level of contamination after step A9 (i.e., the 
contamination after cheese ripening in the production phase) is the initial distribution 
of E. coli O157:H7 contamination for step B1.  In this step, the pH of the cheese is 
selected, as is the storage temperature of the cheese.  Based on the options for pH and 
temperature, there are 72 pH/temperature combinations.  Figure 3.16 shows a 
simplified example of the pH/temperature combinations identified with the DML 
concept for parameter B for step B1; a distribution exists for each of these 
pH/temperature combinations.  In addition, distributions exist for these 
pH/temperature combinations for parameters M and C.   
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 Figure 3.17 shows how the DML concept is applied to step B1 using the 
Gompertz equation.  The contamination after the production phase represents the 
initial bacterial count, A, in the Gompertz equation.  This is added to the remainder of 
the equation which includes the parameters B, M, and C, as well as the time.  A 
selection is made for pH and temperature, and the distributions for B, M, and C are all 
based on these selections, with 72 available pH/temperature combinations for each 
parameter; the time is represented by a uniform distribution. The end result is the 
distribution of E. coli O157:H7 contamination after storage, before transportation to 
retail.  It should be noted that the pH value selected in step B1 is used as the pH value 
for all the remaining steps in the distribution phase.  
 
 
Figure 3.17:  DML Decomposition of Distribution Step B1 (Storage Before Transportation) 
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         3.3.2.3.2  Distribution Step B2:  Transportation to Retail 
Step B2 describes the level of E. coli O157:H7 contamination after 
transportation to retail.  The level of E. coli O157:H7 contamination after step B1 
represents the initial distribution of E. coli O157:H7 contamination for step B2 (i.e., 
parameter A in the Gompertz equation).  In this step, only the temperature of the 
cheese during transportation to retail is selected; the pH value for step B2 remains the 
same as the value used in step B1.  The time is represented as a uniform distribution.  
The DML representation of the basic elements (i.e., options) for step B2 is shown in 
Figure 3.18.   
 
Figure 3.18:  DML Decomposition of Distribution Step B2 (Transportation to Retail) 
 
 
         3.3.2.3.3  Distribution Step B3:  Retail Storage 
Step B3 describes the level of E. coli O157:H7 contamination after retail 
storage.  The level of E. coli O157:H7 contamination after step B2 represents the 
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initial distribution of E. coli O157:H7 contamination for step B3.  In this step, only 
the temperature of the cheese during retail storage is selected; the pH value for step 
B3 remains the same as the value used in step B1.  The time is represented by a 
uniform distribution.  The DML representation of the basic elements for step B3 is 
shown in Figure 3.19.   
 
Figure 3.19:  DML Decomposition of Distribution Step B3 (Retail Storage) 
 
 
         3.3.2.3.4  Distribution Step B4:  Transportation to Consumers  
Step B4 describes the level of E. coli O157:H7 contamination after 
transportation to consumers.  The level of E. coli O157:H7 contamination after step 
B3 represents the initial distribution of E. coli O157:H7 contamination for step B4.  
Again, only the temperature of the cheese during transportation to consumers is 
selected, the pH value for step B4 remains the same as the value used in step B1.  The 
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time is represented by a uniform distribution.  The DML representation of the basic 
elements for step B4 is shown in Figure 3.20.   
 
Figure 3.20:  DML Decomposition of Distribution Step B4 (Transportation to Consumers) 
 
 
         3.3.2.3.5  Distribution Step B5:  Consumer Storage 
Finally, step B5 describes the level of E. coli O157:H7 contamination after 
consumer storage.  The level of E. coli O157:H7 contamination after step B4 
represents the initial distribution of E. coli O157:H7 contamination for step B5.  The 
temperature of the cheese during consumer storage is selected, with the pH value for 
step B5 being the same as the value used in step B1.  The time is represented by a 
uniform distribution.  The DML representation of the basic elements for step B5 is 
shown in Figure 3.21.   
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Figure 3.21:  DML Decomposition of Distribution Step B5 (Consumer Storage) 
 
 
      3.3.2.4  Distribution Calculation Summary 
The distribution phase uses the distribution of E. coli O157:H7 contamination 
after cheese ripening (i.e., step A9) as the initial contamination for the phase.  The 
level of contamination is calculated at each step of the distribution phase using the 
Gompertz equation.  The distributions for the Gompertz parameters are determined by 
the pH/temperature selection for the step, with pH remaining constant after the initial 
selection is made in step B1, the initial contamination for each step is the distribution 
of contamination from the previous step, and time is entered as a user-defined 
uniform distribution.  The end result of the distribution phase is an estimation of E. 
coli O157:H7 contamination in 1 kg of cheese.  A summary of the distribution phase 
calculations is given in Table 3.5.   
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Table 3.5:  Distribution Phase Calculations 
Step Description Distribution/Model Calculation Unit 
B1 Contamination after Storage, 
before Transportation 
Gompertz  A9 +CB1· exp[-exp(-BB1(tB1-MB1))] a CFU/kg 
B2 Contamination after 
Transportation to Retail 
Gompertz B1 +CB2· exp[-exp(-BB2(tB2-MB2))] b CFU/kg 
B3 Contamination after Retail 
Storage 
Gompertz B2 +CB3· exp[-exp(-BB3(tB3-MB3))] CFU/kg 
B4 Contamination after 
Transportation to Consumer 
Gompertz B3 +CB4· exp[-exp(-BB4(tB4-MB4))] CFU/kg 
B5 Contamination after Consumer 
Storage 
Gompertz B4 +CB5· exp[-exp(-BB5(tB5-MB5))] CFU/kg 
a CB1, BB1, and MB1 are lognormal distributions based on pH and temperature selections for Step B1; tB1 is a user-defined uniform 
distribution for Step B1 
b Parameters for remaining steps are lognormal distributions based on pH selected in Step B1 and temperature based on selection 
for given step;  time is a user-defined uniform distribution for given step 
 
 
   3.3.3  Consumption 
 
      3.3.3.1  Consumption Overview 
In order to estimate the amount of E. coli O157:H7 ingested by the consumer, 
a number of steps (i.e., sub-system elements) are identified in the consumption phase.  
The distribution of E. coli O157:H7 in cheese after the distribution phase is used as an 
input to the consumption phase.  The dose ingested by the consumer is calculated as a 
function of the amount of E. coli O157:H7 in a serving of cheese and the number of 
servings of cheese ingested.  The distribution of dose then becomes an input to the 
dose-response assessment in the risk characterization portion of the model.  The DML 





















Figure 3.22:  DML Model of Cheese Consumption Phase  
 
 
      3.3.3.2  Consumption Phase Decomposition 
The consumption phase is further refined into sub-system elements, basic 
elements, and options using the DML concept.  A number of calculations are made 
during the consumption phase in order to determine the amount of E. coli O157:H7 
ingested by the consumer.  The following sections provide a detailed discussion of 
each of the steps identified in the consumption phase, as well as the DML 
decomposition of the step.   
         3.3.3.2.1  Consumption Step C1:  Contamination in One Serving 
 The input to the consumption model is the distribution of E. coli O157:H7 
contamination after the distribution phase (i.e., step B5); the contamination is given 
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per serving of cheese, assuming that a serving size is 1 ounce.  Thus, the 
contamination per serving is determined by dividing the contamination in 1 kilogram 
of cheese by the number of ounces in a kilogram (35.274 ounces/kg).  Figure 3.23 
illustrates this calculation using the DML concept.   
 
 
Figure 3.23:  DML Decomposition of Consumption Step C1 (Contamination in One Serving) 
 
 
         3.3.3.2.2  Consumption Step C2:  Number of Servings Consumed 
 Step C2 represents the number of 1 ounce servings consumed.  The number of 
servings is entered as a user-defined variable; the number of servings consumed is 
represented by a uniform distribution in which the user enters the minimum and 
maximum values.  Figure 3.24 illustrates the calculation for the number of servings 
consumed.   
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Figure 3.24:  DML Decomposition of Consumption Step C2 (Number of Servings Consumed) 
 
 
         3.3.3.2.3  Consumption Step C3:  Ingested Dose 
Step C3 determines the distribution of E. coli O157:H7 contamination 
ingested by the consumer.  The ingested dose is a function of the contamination per 
serving and the number of servings consumed, as depicted in Figure 3.25.  Figure 
3.28 illustrates the calculation of the ingested dose using the DML concept.   
 
Figure 3.25:  DML Decomposition of Consumption Step C3 (Ingested Dose) 
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      3.3.3.3  Consumption Calculation Summary 
 The consumption phase uses the distribution of E. coli O157:H7 
contamination after consumer storage (i.e., step B5) as the contamination level for 
several calculations.  Using the end result from step B5, the distribution of E. coli 
O157:H7 in one serving is calculated.  In addition, based on the number of servings 
consumed, the ingested dose is calculated.  A summary of the consumption phase 
calculations is given in Table 3.6.   
 
Table 3.6:  Consumption Phase Calculations 
Step Description Distribution/Model Calculation Unit 
C1 Contamination in One Serving --- B5/35.274 CFU/ounce 
C2 Number of Servings 
Consumed 
Uniforma Uniform(min, max) Ounce 
C3 Ingested Dose --- C1*C2 CFU/serving 





3.4  Dose-Response Assessment 
 
   3.4.1  Dose-Response Assessment Overview 
An important part of the quantitative risk assessment is the dose-response 
assessment, as it provides the connection between the amount of E. coli O157:H7 
ingested in the consumption phase and the adverse health outcomes associated with 
E. coli O157:H7, which are estimated in the risk characterization component of the 
quantitative microbial risk assessment.  Thus, the dose-response model predicts the 
relationship between the level of microbial exposure and the likelihood of occurrence 
of an adverse health outcome (i.e., illness).  
Developing the dose-response assessment for E. coli O157:H7 is a difficult 
task and presents a number of challenges due to model uncertainty, data uncertainty, 
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and lack of model validation.  First, the literature review demonstrates that there is no 
consensus on which specific model is most applicable to microbial dose-response, as 
a number of dose-response models have been proposed in quantitative microbiology 
to describe the relationship between the level of microbial exposure and the 
likelihood of illness.  Second, there is a lack of E. coli O157:H7 dose-response data; 
due to ethical considerations, adequate human dose-response data is not available for 
highly infectious agents, like E. coli O157:H7.  Third, the E. coli O157:H7 dose-
response assessments that have been performed have not been validated.   
      3.4.1.1  Dose-Response Assessment Challenges 
         3.4.1.1.1  Model Uncertainty 
In terms of the model used for microbial dose-response, Holcomb et al. (1999) 
suggest that model applicability should include properties such as:  1) adequacy in 
how well the model fits available data, 2) simplicity in model formulation including 
parsimony in the number of parameters in the model without sacrificing the quality of 
adequacy, and 3) the range of conditions over which the model gives good 
predictions.  The models that have been used to describe microbial dose-response 
data include:  log-logistic, lognormal, exponential, beta-Poisson, and Weibull-
Gamma.  The log-logistic and lognormal models have commonly been used to 
describe quantal bioassay data, though not necessarily microbial dose-response data.   
The exponential model is considered to be the simplest form of the single-hit 
model in which only one ingested organism is required to cause infection even though 
the probability of this occurring may be very small (Haas et al., 1999).  Thus, this 
model assumes that the host-pathogen interaction probability is constant for a 
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population, although this is unlikely because there is variability in microorganism 
infectivity and host susceptibility (Holcomb et al., 1999).  The exponential model has 
been successfully used for microbial dose-response by Sanaa et al. (2004) to describe 
the dose-response of Listeria monocytogenes.   
The beta-Poisson model is derived from the single-hit exponential model.  
However, while the exponential model assumes a discrete value for the host-pathogen 
interaction probability, the beta-Poisson model assumes a beta distribution for the 
host-pathogen interaction.  In most cases, the beta-Poisson provides a statistically 
significant improvement in fit over the exponential model (Strachan et al., 2005).  
The beta-Poisson model is most widely associated with microbial dose-response and 
has been used to model data from several foodborne pathogens including Shigella 
spp., Campylobacter jejuni, and E. coli O157:H7 (Crockett et al., 1996; Haas et al., 
2000; Holcomb et al., 1999; Powell et al., 2000).   
Finally, the Weibull-Gamma model is an example of an empirical model.  
Although empirical models lack biological plausibility, this type of model can be 
especially useful when there is no direct dose-response data available (Haas et al., 
1999).  As with the beta-Poisson model, the host-pathogen heterogeneity in the 
Weibull-Gamma model is described with a distribution rather than a constant.  
Parameter estimation with the Weibull-Gamma model can be more difficult, but 
research has shown that it is a more flexible and powerful model (Powell et al., 2000).  
Farber et al. (1996) have successfully estimated infectious doses for Listeria 
monocytogenes with this model.   
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         3.4.1.1.2  Data Uncertainty 
The lack of dose-response data for E. coli O157:H7 makes parameter 
estimation for the dose-response model challenging as well.  One obvious alternative 
to human data is the use of animal models; however, animal models must be carefully 
reviewed for applicability to humans, because of the inherent variability in host-
pathogen interaction (Strachan et al., 2005).  Another alternative has been to use 
human dose-response relationships of surrogate pathogens, such as Shigella 
dysenteriae, Shigella flexneri, infant diarrheal E. coli strains, and enteropathogenic E. 
coli (EPEC) strains, to estimate the dose-response of E. coli O157:H7 (Marks et al., 
1998; Powell et al, 2000; Crockett et al., 1996; Haas et al., 1999).  Studies have 
shown that E. coli O157:H7 produces shiga-like toxins similar to S. dysenteriae and it 
has been suggested that Shigella can be used as a surrogate for E. coli O157:H7, since 
their mechanisms of infection are quite similar (Hass et al., 2000).  EPEC stains share 
the attaching and effacing gene with E. coli O157:H7 and have also been proposed as 
a surrogate pathogen (Powell et al., 2000).  
Previous E. coli O157:H7 dose-response models include several beta-Poisson 
models based on feeding studies in humans and animal data.  Marks et al. (1998) 
proposed pooling strains of S. dysenteriae and S. flexneri as possible surrogates for E. 
coli O157:H7.  Strachan et al. (2001) demonstrated that the surrogate Shigella model 
gave the closest fit to data obtained from an environmental outbreak.  A model by 
Crockett et al. (1996) pooled experimental data from both S. flexneri and S. 
dysenteriae strains as well, and was shown to be statistically indistinguishable from 
separate dose response models of each species, suggesting its potential to represent 
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the Shigella species.  Powell et al. (2000) proposed a dose-response envelope for E. 
coli O157:H7 with bounding values of the dose-response defined by two separate 
beta-Poisson dose-response curves fitted to human clinical trial data for two surrogate 
pathogens (i.e., S. dysenteriae and EPEC).  Marks et al. (1998) also proposed infant 
diarrheal E. coli as a possible surrogate as these strains are part of the STEC group.  
Finally, Haas et al. (2000) proposed a dose-response model for E. coli O157:H7 based 
on data from rabbits inoculated with E. coli O157:H7.   
         3.4.1.1.3  Model Validation 
Lastly, quantitative microbiological risk assessments have been performed to 
determine the risk of E. coli O157:H7 infection from various foods, but the dose-
response models used in these risk assessments have yet to be fully validated.  
Quantitative microbial risk assessments are extremely useful in proposing mitigation 
strategies for reducing risk of infection; however, to ensure accuracy and assess 
uncertainty, a risk assessment requires a validated dose-response model (Strachan et 
al., 2005).  Dose-response models should be validated with outbreak data using both 
the attack rate and likely dose.  However, this information is often difficult to obtain, 
making model validation another difficult task in dose-response assessment.   
      3.4.1.2  Dose-Response Assessment Approach 
This research uses the DML concept to decompose the dose-response 
assessment into its basic elements.  In order to address the model uncertainty, the 
DML method identifies several dose-response models, previously used in other 
QMRAs, as possibilities for describing the dose-response relationship for E. coli 
O157:H7.  In addition, the DML method also addresses the data uncertainty by 
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identifying several data sets from which the various dose-response model parameters 
can be estimated.  Finally, this research also proposes a new method for developing a 
“weighted-average” dose-response for the various models investigated.  These 
weights are developed using the Analytical Hierarchy Process (AHP) method in 
which alternative data sets are compared on several criteria defined in this research as 
data relevance, data quality, data quantity, and data extrapolation/fit.  The weighted 
average dose-response models developed in this research offer an alternative way to 
account for the data uncertainty associated with the dose-response relationship for E. 
coli O157:H7.  A detailed explanation of the dose-response models, data and 
methodology used for parameter estimation, development of the weighted-average 
model, and validation follows.   
   3.4.2  Development of Dose-Response Models 
      3.4.2.1  Traditional Dose-Response Model Approach 
         3.4.2.1.1  Dose-Response Models 
A number of different microbial dose-response models have been derived in 
order to describe the relationship between the level of exposure (i.e., dose or number 
of organisms ingested) and the likelihood of occurrence of an adverse consequence 
(i.e., illness).  Prior work has shown that the exponential, beta-Poisson, and Weibull-
Gamma provide good fits for microbial dose-response data (Haas et al., 2000).  Table 
3.7 provides a summary of these models, followed by a discussion of the derivation.   
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Table 3.7:  Dose-Response Models and Parameter Definition 
Model Name Function Where 
Exponential ( ) ( )rddPI −−= exp1   r = constant host-pathogen interaction probability,  Denotes the fraction of microorganisms ingested 













ddPI 11   
α, β = shape parameters, 
Beta-Poisson derived from exponential, assumes 
beta distribution for host-pathogen interaction 





















ddP 11  
α, β, x = shape parameters,  
Weibull-Gamma reduces to beta-Poisson if x = 1 




Haas et al. (1999) state that the process of infection requires two sequential, 
but independent, subprocesses to occur:  1) the human host must ingest one or more 
organisms that are capable of causing disease and 2) the organisms undergo decay or 
are impaired from multiplying to cause infection by host responses, and only a 
fraction of the ingested organisms reach a site where infection can begin.  Infection 
occurs when at least some critical number of organisms survive to initiate infection.  
This minimum number, kmin, is the probability of infection, or the fraction of 
individuals who are exposed to an average dose d and become infected, and may be 
written as: 







I jkPdjPdP ||)( 21
min
    (3.1) 
 
Here, the probability of ingesting j organisms from an exposure to a dose, d, is 
written as P1(j|d).  The function P1 includes the individual-to-individual variation in 
the actual number of organisms ingested or exposed.  The probability of k organisms 
(≤ j) surviving to initiate an infection is written as P2(k|j).  The function P2 addresses 
the host-pathogen interaction that allows some organisms to survive to initiate 
infection.  Thus, by specifying functional forms for P1 and P2, as well as numerical 
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value of kmin, a number of dose-response relationships can be derived (Haas et al., 
1999).   
The exponential dose-response model is the simplest model that can be 
formulated.  This model assumes that the distribution of organisms is random 
(modeled by a Poisson distribution), each organism has an independent and identical 
survival probability, r, and kmin equals 1.  Thus, by substituting the Poisson 
distribution for P1(j|d) and the binomial distribution for P2(k|j) in equation (3.1), Haas 
et al. (1999) derive the exact exponential dose-response relationship.  However, the 
following approximation is generally used for the exponential dose-response model:   
( ) ( )rddPI −−= exp1      (3.2) 
 
Thus, the exponential dose-response model defines the probability of infection given 
a dose, d, in terms of one parameter, r, which characterizes the process.   
While the exponential model assumes a constant value for the host-pathogen 
survival probability, r, there may be variation in this success rate.  This variation may 
be attributed to diversity in human responses, diversity in pathogen competence, or 
both.  The beta-Poisson model is derived from the exponential model and addresses 
this variation by allowing r to be governed by a probability distribution (Haas et al., 
1999).  The beta-Poisson model still assumes that P1(j|d) is a Poisson distribution; 
however, the beta-Poisson model characterizes the probability of an ingested 
organism surviving to infect the host as following a beta distribution (i.e., P2(k|j)) 
(Powell et al., 2000).  Haas et al. (1999) derive the exact solution of the beta-Poisson; 













ddPI 11     (3.3)  
 
Thus, in the beta-Poisson model, the average probability of infection, ( )dPI , when 
exposed to a dose, d, is described by two parameters, α and β.  It should be noted that 
α is nonnegative, resulting in a slope which is less than the respective exponential 
model; however, when α approaches infinity, the beta-Poisson model approaches the 
exponential model.  The parameter β describes the shape of the dose-response curve 
(Haas et al., 1999) 
In contrast to the exponential and beta-Poisson models which are developed 
from mechanistic assumptions, the Weibull-Gamma is an empirical model in that it 
lacks biological plausibility (Haas et al., 1999); however, empirical models can be 
especially useful when there is no direct dose-response data available.  These models 
are flexible enough to accommodate all qualitative information and adaptable to both 
healthy and high risk groups (Farber et al., 1996).  The Weibull model is one such 
model that has been proposed as a flexible dose-response model (Haas et al., 1999; 
Farber et al., 1996), and defined by Farber et al. (1996) as: 
( ) ( )xI addP −−= exp1     (3.4) 
 
Where ( )dPI  denotes the probability of illness for an individual exposed to a dose, d, 
of a pathogen.  The properties of this relationship are determined by the parameters a 
and x.  The parameter x determines the shape of the individual dose-response curve.  
The parameter a is related to the probability of illness given exposure to a single 
pathogen.  The host-pathogen heterogeneity can be described by specifying a 
probability distribution for the Weibull parameter a; in this case, a Gamma 
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distribution with parameters α and β is specified.  As a result, the Weibull-Gamma 
dose-response model for the average probability of illness for a given dose, d, can be 




















ddP 11     (3.5) 
 
Hence, the Weibull-Gamma dose-response model defines the probability of 
infection, ( )dPI , when exposed to a dose, d, in terms of three parameters, α, β, and x.  
It should be noted that the Weibull-Gamma dose-response model reduces to the beta-
Poisson dose-response relationship when x = 1.  In addition, the Weibull-Gamma 
dose-response model reduces to the log-logistic model when α = 1 (Farber et al., 
1996). 
         3.4.2.1.2  Parameter Estimation 
After selecting the three dose-response models for study, a method for 
estimating the parameters of the models must be established.  In this work, the 
parameters of the three models described above are estimated by the method of 
maximum likelihood.  Prior work (Crockett et al., 1996; Haas et al., 2000; Powell et 
al., 2000) has shown that the fit of the dose-response model can be determined using 
a binomial likelihood function, as derived by Strachan et al. (2005).  This prior work 
has also shown that by minimizing the deviance of the binomial likelihood function, 
the maximum likelihood estimates (MLE) of the dose-response parameters can be 
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Where pi = ( )θ;dPI  is the predicted response, with PI representing the dose-response 
relationship and θ representing the set of dose-response parameters.  The observed 
response is represented by oip = Pi /Ti  where Pi is the observed number of positive 
responses at the ith dose group and Ti is the total number of subjects in the ith dose 
group.  Thus, the maximum likelihood estimates are obtained by finding the values of 
θ that through their influence on pi, minimize Y (Haas et al., 1999).  No model should 
be accepted for use without examination of goodness of fit.  In order to test the 
goodness of fit, Y is compared to the χ2 value at j – q degrees of freedom, where j is 
the number of doses and q is the number of parameters in the dose-response model of 
interest (Haas et al., 2000).  For example, the null hypothesis of fit acceptability may 
be rejected (i.e., the dose-response model is rejected) if Y exceeds the 5th percentile of 
the χ2 distribution.   
The parameter estimates and goodness of fit calculations are obtained using a 
spreadsheet procedure described by Haas (1994).  An advantage of this spreadsheet 
routine is that it facilitates analysis of the effect of differing the starting values (i.e., 
initial estimates) for the parameters to confirm that the maximum likelihood estimates 
of the parameters obtained are unique and stable (Powell et al., 2000).  Optimizations 
are performed using Microsoft Excel (2000) loaded with the Solver add-in tool.  
Thus, the parameters of the three dose-response models are calculated using this 
method for each of the data sets examined and then tested for goodness of fit.  
         3.4.2.1.3  Clinical Trial Data for Parameter Estimation 
Table 3.8 presents the data used to develop the parameters of the exponential, 
beta-Poisson, and Weibull-Gamma dose-response models.  This data includes feeding 
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study data for Shigella spp. in healthy male human adults, E. coli O157:H7 in infant 
New Zealand white rabbits, and EPEC and infant diarrheal E. coli strains fed at 
different doses to adult male human volunteers.   
 
Table 3.8:  Dose-Response Data from Human and Animal Feeding Studies  
S.  flexneri S.  dysenteriae E. coli O157:H7 
Rabbita 
EPEC Infant Diarrheal 
E. coli 
Doseb +/Totalc Dose +/Total Dose +/Total Dose +/Total Dose +/Total 
d10 1/10 e104 1/4 Control 0/7 g106 0/4 j5x108 3/5 
d200 2/4 e105 3/4 105 1/3 g1010 3/5 j2.5x109 6/6 
d2000 7/10 e106 7/8 106 2/5 h108 0/5 j2x1010 2/2 
d104 5/6 e107 13/19 107 5/5 i106 1/5 k7x106 7/11 
d200 1/4 e108 7/8 108 12/13 i108 1/5 k5.3x108 8/12 
d104 2/6 f180 6/36 109 5/5 i1010 5/5 k6.5x109 11/11 
  f5000 33/49 3x109 2/2   k9x109 12/12 
  f104 66/87 1010 6/6   k1.4x108 6/8 
  f105 15/24     k1.7x109 5/7 
        k5.3x109 6/8 
        k1.6x1010 7/8 
a E. coli O157:H7 rabbit data (Pai et al., 1986) 
b Dose is the number of colony forming units ingested 
c +/Total is the number of subjects infected with symptoms of disease divided by the total number exposed 
d S. dysneteriae data (Levine et al., 1973) 
e S. flexneri data (Dupont et al., 1969) 
f S. flexneri data (Dupont et al., 1972) 
g E. coli O127 data (Levine et al., 1978) 
h E. coli O128 data (Levine et al., 1978) 
i E. coli O142 data (Levine et al., 1978) 
j E. coli B-171-8 data (Levine et al., 1978) 
k E. coli 55, B5 and 111, B4 data (June et al., 1953) 
 
The data in Table 3.8 is analyzed in a number of different ways; in addition to 
analyzing the data individually (i.e., S. dysenteriae, S. flexneri, E. coli O157:H7 
rabbit, EPEC, and infant diarrheal E. coli), the data sets are also combined and 
analyzed (i.e., all data, all human data, all E. coli data, all human E. coli data, all 
Shigella data).  In all, ten data sets are considered in this study:  all data, all human 
data, all E. coli data, all human E. coli data, EPEC data, infant diarrheal E. coli data, 
E. coli O157:H7 rabbit data, all Shigella spp. data, S. dysenteriae data, and S. flexneri 
data.  These data sets are referred to as data sets 1-10, respectively.  The data included 
in each of the ten data sets evaluated in this research is documented in Table 3.9.      
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Table 3.9:  Data Sets for Evaluation with the Exponential, Beta-Poisson, and Weibull-Gamma 
Dose-Response Models 
Data Set Name Data Set 
Number 
Data Included (reference) 
All Data 1 E. coli O157:H7 rabbit (Pai et al., 1986)  
S. dysneteriae (Levine et al., 1973) 
S. flexneri (Dupont et al., 1969) 
S. flexneri (Dupont et al., 1972) 
E. coli O127 (Levine et al., 1978) 
E. coli O128 (Levine et al., 1978) 
E. coli O142  (Levine et al., 1978) 
E. coli B-171-8 (Levine et al., 1978) 
E. coli 55, B5 and 111, B4 (June et al., 1953) 
All Human Data 2 S. dysneteriae (Levine et al., 1973) 
S. flexneri (Dupont et al., 1969) 
S. flexneri (Dupont et al., 1972) 
E. coli O127 (Levine et al., 1978) 
E. coli O128 (Levine et al., 1978) 
E. coli O142 (Levine et al., 1978) 
E. coli B-171-8 (Levine et al., 1978) 
E. coli 55, B5 and 111, B4 (June et al., 1953) 
All E. coli Data 3 E. coli O157:H7 rabbit (Pai et al., 1986)  
E. coli O127 (Levine et al., 1978) 
E. coli O128 (Levine et al., 1978) 
E. coli O142 (Levine et al., 1978) 
E. coli B-171-8 (Levine et al., 1978) 
E. coli 55, B5 and 111, B4 (June et al., 1953) 
All Human E. coli Data 4 E. coli O127 (Levine et al., 1978) 
E. coli O128 (Levine et al., 1978) 
E. coli O142 (Levine et al., 1978) 
E. coli B-171-8 (Levine et al., 1978) 
E. coli 55, B5 and 111, B4 (June et al., 1953) 
EPEC Data 5 E. coli O127 (Levine et al., 1978) 
E. coli O128 (Levine et al., 1978) 
E. coli O142 (Levine et al., 1978) 
Infant diarrheal E. coli Data 6 E. coli B-171-8 (Levine et al., 1978) 
E. coli 55, B5 and 111, B4 (June et al., 1953) 
E. coli O157:H7 rabbit Data 7 E. coli O157:H7 rabbit (Pai et al., 1986)  
Shigella spp. Data 8 S. dysneteriae (Levine et al., 1973) 
S. flexneri (Dupont et al., 1969) 
S. flexneri (Dupont et al., 1972) 
S.  dysenteriae Data 9 S. dysneteriae (Levine et al., 1973) 
S.  flexneri Data 10 S. flexneri (Dupont et al., 1969) 
S. flexneri (Dupont et al., 1972) 
 
 
         3.4.2.1.4  Dose-Response Model Parameter Estimation Results 
The parameter estimates for the exponential, beta-Poisson, and Weibull-
Gamma dose-response models are obtained for each of the data sets evaluated.  The 
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parameters, along with the residual deviance and goodness of fit are summarized in 
Table 3.10.   
 
Table 3.10:  Results of Exponential, Beta-Poisson, Weibull-Gamma Dose-Response Analysis 
based on Data Sets 1-10  
Data Seta Model Parameters Residual 
Deviance (Y) 
P  
(goodness of fit) 
1 Exponential r = 2.08E-09 3366.10 ~0 
 Beta-Poisson α = 0.094 
β = 1.24 
94.82 5.67E-07 
 Weibull-Gamma α = 0.020 
β = 4.09 




2 Exponential r = 2.10E-09 3272.96 ~0 
 Beta-Poisson α = 0.087 
β = 0.61 
78.69 1.81E-06 
 Weibull-Gamma α = 0.013 
β = 0.078 
x = 6.52 
78.61 1.07E-06 
3 Exponential r = 9.11E-10 278.38 1.04E-45 
 Beta-Poisson α = 0.23 
β = 279603.34 
39.12 0.01 
 Weibull-Gamma α = 0.028 
β = 1.38E+42 
x = 7.87 
38.40 0.01 
4 Exponential r = 5.91E-10 143.95 3.83E-23 
 Beta-Poisson α = 0.22 
β = 643283.44 
23.75 0.049 
 Weibull-Gamma α = 100.67 
β = 6627.039 
x = 0.22 
23.19 0.057 
5 Exponential r = 4.07E-10 31.83 4.37E-05 
 Beta-Poisson α = 0.22 
β = 3112329.52 
11.24 0.081 
 Weibull-Gamma α = 1.94 
β = 7408.83 
x = 0.42 
9.57 0.088 
6 Exponential r = 7.10E-10 109.19 1.35E-20 
 Beta-Poisson α = 0.17 
β = 48284.30 
8.95 0.18 
 Weibull-Gamma α = 1064.55 
β = 11847.74 
x = 0.14 
8.17 0.15 
7 Exponential r = 5.70 17.98 0.012 
 Beta-Poisson α = 0.49 
β = 189343.32 
3.12 0.79 
 Weibull-Gamma α = 0.090 
β = 9.611E+36 





8 Exponential r = 3.74-07 1487.57 ~0 
 115
 Beta-Poisson α = 0.16 
β = 16.86 
26.54 0.014 
 Weibull-Gamma α = 0.14 
β = 21.89 
x = 1.12 
26.51 0.01 
9 Exponential r = 0.00021 30.45 1.21E-05 
 Beta-Poisson α = 0.16 
β = 9.17 
4.88 0.30 
 Weibull-Gamma α = 0.022 
β = 19456.03 
x = 6.40 
4.82 0.19 
10 Exponential r = 3.74-07 1268.25 ~0 
 Beta-Poisson α = 0.17 
β = 29.16 
21.02 0.0037 
 Weibull-Gamma α = 0.029 
β = 6.77E+09 
x =  6.31 
20.24 0.0025 
a Data sets 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 refer to all data, all human data, all E. coli data, all human E. coli data, E. coli EPEC data, 
infant diarrheal E. coli data, E. coli O157:H7 rabbit data, all Shigella spp. data, S.  dysenteriae data, and S.  flexneri data  
 
 
From the data in Table 3.10, it is clear that the beta-Poisson and Weibull-
Gamma models provide good fits for data sets 4, 5, 6, 7, and 9 (all human E. coli, 
EPEC, infant diarrheal E. coli, E. coli O157:H7 rabbit data, and S. dysenteriae data); 
however, these models do not provide good fits to data sets 1, 2, 3, 8, and 10 (all data, 
all human data, and all E. coli, Shigella spp., and S. flexneri data).  This suggests that 
there is too much variance among the data sets from multiple sources.  In addition, 
Table 3.10 shows that the exponential dose-response model fails the goodness of fit 
test (P<0.05) for all of the data sets investigated.  Therefore, the exponential model 
does not provide a good estimate for the dose-response of E. coli O157:H7 and is 
excluded as a potential dose-response model for E. coli O157:H7.   
A graphical comparison of the dose-response models for the various data sets 
is given in the Figures 3.26-3.28.  Although the fits are undesirable, Figure 3.26 











Figure 3.26:  Exponential Dose-Response Curves for Data Sets 1-10 
 
 
Figures 3.27 and 3.28 show the beta-Poisson and Weibull-Gamma dose-
response models for the ten data sets investigated, respectively.  The bold lines 
represent the data sets that have a significant fit (P>0.05); those data sets include all 
human E. coli, EPEC, infant diarrheal E. coli, E. coli O157:H7 rabbit data, and S. 
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Figure 3.28:  Weibull-Gamma Dose-Response Curves for Data Sets 1-10 
 
 
      3.4.2.2  AHP Dose-Response Model Approach 
         3.4.2.2.1  AHP Methodology 
Within the literature, there is some disagreement as to which of the data listed 
in Table 3.8 is most appropriate for estimating the dose-response of E. coli O157:H7.  
To address this data uncertainty issue, this research proposes a method for weighting 
the dose-response results on a number of criteria in order to obtain a “weighted-
average” for the most common dose-response models (i.e., exponential, beta-Poisson, 
and Weibull-Gamma).  These weighted-average models are developed using the 
Analytical Hierarchy Process (AHP) method.  The AHP method is a powerful and 
flexible decision making process that helps set priorities and compare alternative 
concepts when both qualitative and quantitative aspects of a decision need to be 
considered.  It is a comprehensive, logical, and structured framework that helps to 
improve the understanding of complex decisions by decomposing the problem in a 
hierarchical structure.  The incorporation of all relevant decision criteria, and their 
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objectives.  Thus, by reducing complex decisions to a series of one-on-one 
comparisons, then synthesizing the results, the AHP method not only helps decision 
makers arrive at the best decision, but also provides a clear rationale that it is the best 
(Measurement Methods, 2005).   
The AHP method is based on three principles:  decomposition of the decision 
problem, comparative judgment of the elements, and synthesis of the priorities.  The 
first step is to decompose the problem by determining the goal of the analysis, 
identifying the criteria relevant for this goal, and identifying the alternatives to be 
evaluated.  The second step is the comparison of the alternatives and the criteria.  A 
pair-wise comparison of the various criteria is completed for each alternative; the 
scale in Table 3.11 is used for this relative comparison.  This allows the comparisons 
to be expressed in verbal terms which are then translated into the corresponding 
numbers.  The last step synthesizes the comparisons to get the priorities of the 
alternatives with respect to each criterion and the weights of each criterion with 
respect to the goal.  The local priorities are then multiplied by the weights of the 
respective criterion.  The results are summed up to get the overall priority of each 
alternative (Measurement Methods, 2005).   
 
Table 3.11:  Fundamental Scale for Pair-Wise Comparisons for the AHP Method 
Verbal Scale Numerical Values 
Equally important, likely or preferred 1 
Moderately more important, likely or preferred 3 
Strongly more important, likely or preferred 5 
Very strongly more important, likely or preferred 7 
Extremely more important, likely or preferred 9 




The AHP method is used to compare the data sets resulting in significant fits 
for the dose-response models examined.  The data sets are compared using four 
criteria:  relevance, quality, quantity, and extrapolation/fit.  These four characteristics 
are selected as the criteria because they provide ways to judge and measure the 
uncertainty of the data.  Data relevance is important due to the disagreement within 
the literature as to which pathogens should be used to describe the dose-response of 
E. coli O157:H7.  The quality criterion is used to judge how much information is 
available about the experiment and how tightly that experiment is controlled.  The 
quantity characteristic is used to judge the number and size of the administered doses, 
as it is problematic to make realistic estimates based on only a few doses.  Finally, 
most experiments and clinical trials administer dose levels that are much higher than 
what would be expected to be ingested; therefore, the extrapolation/fit criteria judges 
how well the data could be extrapolated from high to low doses.  After establishing 
the alternatives and criteria of the problem, the pair-wise comparisons of the various 
criteria are completed for each alternative.   
         3.4.2.2.2  AHP Weighted-Average Model Results 
The AHP method compares the data sets on the relevance, quality, quantity, 
and extrapolation/fit criteria and is used to develop weights for the data sets 
considered.  Only the data sets resulting in a significant fit with the beta-Poisson and 
Weibull-Gamma models are considered in the AHP method; the AHP method is not 
applied to the exponential dose-response model, as this model did not result in a 
significant fit for any of the data sets investigated.  Since the all human E. coli data 
set includes the data in the EPEC and infant diarrheal E. coli data sets, only the all 
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human E. coli, E. coli O157:H7 rabbit, and S. dysenteriae data sets are used in the 
development of the weighted-average dose-response models for the beta-Poisson and 
Weibull-Gamma models.  The pair-wise comparison of each criterion is completed 
for the three significant data set alternatives using expert judgment.  The comparisons 
are then synthesized to get the absolute weights of the alternatives with respect to 
each criterion.  Table 3.12 shows this pair-wise comparison of the alternatives for 
each of the criterion; in addition, the absolute weight, with respect to the criterion, is 
also given for each alternative.  Table 3.13 gives the pair-wise and absolute weights 
of the criteria with respect to the goal.   
 
Table 3.12:  AHP Pair-Wise and Absolute Weights of Alternatives for each Criterion 
Pair-wise Weights with Respect to Relevance  
E. coli Human O157:H7 Rabbit S. dysenteriae 
E. coli Human 1.000 0.500 0.250 
O157:H7 Rabbit 2.000 1.000 0.500 
S. dysenteriae 4.000 2.000 1.000 
Absolute Weights with 
Respect to Relevance 0.143 0.286 0.571 
Pair-wise Weights with Respect to Quality  
E. coli Human O157:H7 Rabbit S. dysenteriae 
E. coli Human 1.000 0.500 1.000 
O157:H7 Rabbit 2.000 1.000 3.000 
S. dysenteriae 1.000 0.333 1.000 
Absolute Weights with 
Respect to Quality 0.240 0.550 0.210 
Pair-wise Weights with Respect to Quantity  
E. coli Human O157:H7 Rabbit E. coli Human 
E. coli Human 1.000 2.000 1.000 
O157:H7 Rabbit 0.500 1.000 0.333 
S. dysenteriae 1.000 3.000 1.000 
Absolute Weights with 
Respect to Quantity 0.387 0.169 0.444 
Pair-wise Weights with Respect to Fit/Extrapolation  
E. coli Human O157:H7 Rabbit S. dysenteriae 
E. coli Human 1.000 2.000 0.250 
O157:H7 Rabbit 0.500 1.000 0.333 
S. dysenteriae 4.000 3.000 1.000 











Table 3.13:  AHP Pair-Wise and Absolute Weights of the Criteria 
Pair-wise Weights of the Criteria  
Relevance Quality Quantity Fit/Extrapolation 
Relevance 1.000 6.000 4.000 1.000 
Quality 0.167 1.000 3.000 0.167 
Quantity 0.250 0.333 1.000 0.143 
Fit/Extrapolation 1.000 6.000 7.000 1.000 
Absolute Weights 
of the Criteria 0.393 0.095 0.059 0.453 
 
 
Finally, the overall priority of each alternative is obtained from a matrix 
operation involving the absolute weights of the alternatives with respect to the criteria 
and the absolute weights of the criteria with respect to the goal.  Equation (3.7) shows 
this matrix operation and the resulting priority of each alternative.  The S. dysenteriae 
data has the highest weight of the alternatives examined, followed by the E. coli 
































      (3.7) 
 
Using these weights, a weighted-average dose-response model can be 
developed.  For the beta-Poisson model, the form of the AHP weighted-average dose-























































The AHP weighted-average Weibull-Gamma dose-response model, therefore, has the 






















































































Figures 3.29 and 3.30 show the AHP weighted-average dose-response curves 
for the beta-Poisson and Weibull-Gamma models, respectively.  The three data sets 
used to develop the AHP weighted-average model are shown for comparison 





















































































   3.4.3  Validation of Dose-Response Models 
            3.4.3.1  Validation Method Overview 
It is desirable to validate dose-response models with human epidemiological 
information; this is especially important in the case of E. coli O157:H7 since the 
underlying data here are based on animal studies and surrogate pathogens.  Especially 
in the case of the animal data, there is little experience with interspecies dose-
response extrapolation from animals to humans (Haas et al., 2000).  Furthermore, 
dose-response experiments are frequently, and of necessity, conducted at higher doses 
and levels of risk than may be encountered in an actual exposure situation.   
Comparing actual observations in outbreak data to the predicted observation 
lends credence to the developed dose-response models.  Thus, this research attempts 
to characterize the validity of the various dose-response models developed using the 
clinical trial data as well as validate the AHP weighted-average dose-response 
relationships by comparing the model estimates with actual human outbreak 
information.  This characterization is achieved by obtaining E. coli O157:H7 outbreak 
data from Strachan et al. (2005), in which the attack rate and duration of exposure are 
used to determine the likely dose of the pathogen in the incriminated source.   Using 
the attack rate and likely dose, the predicted response for each model is calculated 
and then compared with the levels observed during the outbreak (Haas et al., 2000).  
In addition, a comparison of the clinical trial data to the dose-response curves is also 
performed.  Each model is developed from a subset of all of the relevant clinical trial 
data, by comparing the each model to all of the clinical trial data it can be determined 
if one model provides an overall best fit.  
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The maximum likelihood method is used to quantitatively assess which model 
best fits the observed data.  Using the dose and attack rates in Table 3.14, equation 
3.6 is solved for each of the dose-response models developed.  The dose-response 
model producing the minimum deviance provides the best fit to the outbreak data.  
Next equation 3.6 is solved using the dose and attack rate information in Table 3.8 for 
the clinical trial data.  The dose-response model producing the minimum deviance 
provides the best fit to the clinical trial data.   
      3.4.3.2  E. coli O157:H7 Outbreak Data for Model Validation  
In order to validate a dose-response model, it is necessary to obtain outbreak 
information with the following well-documented characteristics:  (1) vehicles of 
infection, (2) attack rates, and (3) measurements of bacteria levels in the incriminated 
sources.  While it is difficult to obtain outbreak data that has these characteristics 
accurately determined, Strachan et al. (2005) have identified eight E. coli O157:H7 
outbreaks in which enough information is known to estimate the dose and the attack 
rate (i.e., response).  Table 3.14, taken from Strachan et al. (2005), summarizes these 
outbreaks.   
 125
























14 228 20 8.77% 
2 (Nauta et al., 2001; 







31 871 215 24.68% 




Deer jerky 10000 12 10 83.33% 




Melon 1100 71 32 45.07% 
5 (Bell et al., 1994; 
Tuttle et al., 1999) 
USA, 
Washington 
Hamburger 23 5634 398 15.11% 





Salami 23 2778 17 0.61% 




Water 75 2350 12 0.51% 
8 (Anon., 1997) UK, Wyre Cheese 380 360 2 0.56% 
 
 
      3.4.3.3  Validation Results:  Traditional vs. AHP Weighted-Average 
To validate the AHP weighted-average dose-response models, the data from 
the outbreaks documented in Table 3.14 is superimposed on the graphs for each of the 
dose-response models investigated.  Figures 3.31 and 3.32 display the beta-Poisson 
and Weibull-Gamma dose-response curves and AHP weighted-average models, 
respectively, with the data points from the eight outbreaks.  Both of the AHP 


















Figure 3.31:  Beta-Poisson Dose-Response Curves (for data sets 4, 7, & 9) with AHP Weighted-





















Figure 3.32:  Weibull-Gamma Dose-Response Curves (for data sets 4, 7, & 9) with AHP 
Weighted Average Superimposed with Outbreak Data 
 
Visual inspection of the beta-Poisson models in Figure 3.31, show that the S. 
dysenteriae model provides a good fit to data points 1, 2, 3, 4, and 5; however, this 







































































O157:H7 rabbit models appear to fit data points 6, 7, and 8, but not 1, 2, 3, 4, or 5.  
Although each of these models appears to fit a few of the outbreak data points, none 
of these models provide a good fit to all of the outbreak data points.  While the AHP 
model does not fit all of the data points either, it does appear to provide a good fit to 
data points 1, 2, 4, 5, 6, and 7.  Again, visual inspection of the various Weibull-
Gamma models in Figure 3.32 show that neither the all human E. coli nor E. coli 
O157:H7 rabbit Weibull-Gamma model appear to be a good approximation for E. coli 
O157:H7 as these models appear to only fit data points 6, 7, and 8, but not 1, 2, 3, 4, 
or 5.  However, the S. dysenteriae Weibull-Gamma model does provide a good fit to 
data points 1, 2, 3, 4, and 5.  The AHP Weibull-Gamma model provides a good fit to 
data points 1, 2, 4, 5, and 6.  These results suggest that either the S. dysenteriae 
Weibull-Gamma model or the AHP Weibull-Gamma model may provide a good 
approximation for the dose-response of E. coli O157:H7.    
Figures 3.33 and 3.34 show the AHP weighted-average dose-response curves 
for the beta-Poisson and Weibull-Gamma models, respectively.  The three data sets 
used to develop the AHP weighted-average model are shown for comparison 
purposes along with the actual clinical trial data from which the dose-response curves 
are generated.  While the all human E. coli, E. coli O157:H7 rabbit, and S. 
dysenteriae dose-response models fit their respective data points well, both the AHP 
weighted-average beta-Poisson and Weibull-Gamma models visually provide the best 














Figure 3.33:  Beta-Poisson Dose-Response Curves and Clinical Trial Data Points (for data sets 


















Figure 3.34:  Weibull-Gamma Dose-Response Curves and Clinical Trial Data Points (for data 
sets 4, 7, & 9) with AHP Weighted-Average 
 
 
As seen in Figures 3.31-3.34, there is wide dispersion amongst the clinical 
trial and outbreak data, and graphically, none of the beta-Poisson or Weibull-Gamma 
models alone appear to provide a good estimate to all of the available data.  However, 
by comparing these data points to the AHP weighted-average dose-response curves 
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method provides a reasonable fit to all of the available data.  The results in Figures 
3.31-3.34 are quantitatively verified by examining the deviance calculations for the 
various models; the model that minimizes the deviance statistic (i.e., Equation 6) best 
fits the outbreak data.  The deviance statistic is calculated for the outbreak data, the 
clinical trial data, and the outbreak and clinical trial data combined.  As seen in Table 
3.15, the S. dysenteriae beta-Poisson model results in the minimum deviance for the 
outbreak data.  However, the AHP model results in the minimum deviance for the 
clinical trial data and the outbreak and clinical trial data combined.  While these 
results are not significant when the deviance is compared to the critical values of the 
χ2 distribution, the AHP weighted-average model considerably reduces the deviance 
compared to the other models for both the clinical trial data and the clinical trial and 
outbreak data combined.  In the case of the outbreak data, both the S. dysenteriae and 
AHP weighted-average model reduce the deviance as compared to the all human E. 
coli and E. coli O157:H7 rabbit models.   
The results for the Weibull-Gamma model show slightly different results in 
that the all human E. coli model results in the minimum deviance for the outbreak 
data and the outbreak and clinical trial data combined.  However, the AHP model 
results in the minimum deviance for the clinical trial data.  Again, these results are 
not significant when the deviance is compared to the critical values of the χ2 
distribution; however, the AHP weighted-average model considerably reduces the 
deviance compared to the other models in the case of the clinical trial data.  Although 
the all human E. coli model produces the minimum deviance for the outbreak and the 
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outbreak and clinical data combined, the AHP weighted-average model still 
noticeably reduces the deviance as compared to the S. dysenteriae model.   
 
Table 3.15:  Deviance Calculation for Dose-Response Models 










E. coli O157 
rabbit 
S. dysenteriae AHP 
beta-Poisson Outbreak Data  11622.11 26547.97 8753.08 9023.10 
 Clinical Trial Data 269.05 255.70 90.66 73.22 
 Outbreak & Clinical 
Trial Data 
11891.16 9008.77 4468.70 2303.95 
Weibull-Gamma Outbreak Data  1356.00 No solution 6432.20 3085.91 
 Clinical Trial Data 98.60 No solution 85.14 66.12 
 Outbreak & Clinical 
Trial Data 




3.5  Risk Characterization 
 
   3.5.1  Overview of Risk Characterization 
The final component in the quantitative microbial risk assessment framework 
is the risk characterization.  The risk characterization involves the integration of the 
results from the consumption phase of the exposure assessment with the dose-
response assessment in order to provide an overall estimate of the likelihood and 
magnitude of the adverse health outcomes from exposure to E. coli O157:H7 in 
cheese; in addition, this step includes aleatory and epistemic uncertainties associated 
with the assessment.  Another important aspect of the risk characterization includes 
sensitivity analysis which identifies the steps and the physical conditions and/or 
practices at those steps (i.e., sub-system elements and basic elements) that influence 
the occurrence and magnitude of E. coli O157:H7 contamination in cheese, and 
therefore, the risk to consumers.   
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Risk may be estimated in a variety of ways.  The estimated risk of an adverse 
health outcome may vary depending on the level at which the risk is focused and the 
duration of the exposure.  First, the risk of an adverse health outcome may be focused 
on an individual consuming a single serving of cheese, the risk adverse health 
outcomes for a group of individuals consuming cheese from the same production lot, 
or the risk of an adverse health outcome across the entire United States population.  
Second, the risk of an adverse health outcome may be calculated per serving, per 
annum, or per lifetime.  The decomposition of the cheese manufacturing and 
distribution process using the DML concept results in a model that lends itself to 
scenario development, thereby making the model helpful in calculating the adverse 
health outcomes associated with cheese-related outbreaks of E. coli O157:H7.  Thus, 
this research focuses on calculating the risk of adverse health outcomes associated 
with exposure to E. coli O157:H7 in cheese for a group of individuals consuming 
cheese made from the same vat of milk, and is calculated on a per serving basis.   
While the output of the dose-response assessment is a probability of illness 
(i.e., response) given exposure to E. coli O157:H7 (i.e., dose), several other adverse 
health outcomes may be assessed with a QMRA.  As indicated in the hazard 
identification, E. coli O157:H7 infection can lead to many other severe health risks 
including:  hospitalization, HUS/TTP, and death.  In order to identify the adverse 
health outcomes to be assessed, the DML concept is applied to the risk 
characterization.  Figure 3.35 decomposes the risk characterization into a number of 





Figure 3.35:  DML Model of Risk Characterization 
 
For a particular scenario, the dose-response assessment results in a probability 
of illness given the ingested dose from the consumption phase.  The probability of 
illness given the ingested dose, in combination with the number of people exposed, 
results in an estimated distribution of the number of illnesses for a specific outbreak 
scenario.  As shown in Figure 3.35, the remaining risk calculations are based on the 
number of people exposed, the probability of a specific consequence, and the 
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Since population type influences the proportion of illnesses progressing to 
adverse health outcomes, it is an important step in the risk characterization.  
According to Gerba et al. (1996), approximately 20% of the population in the United 
States is more susceptible to serious illness and mortality from foodborne pathogens.  
The susceptible population is comprised of the very young, the elderly, pregnant 
women, and the immunocompromised.  Thus, the type of population affected 
determines the severity of the adverse health outcomes, with the susceptible 
population facing the most severe outcomes.  However, as illustrated in Figure 3.35, 
the dose-response models for the normal and susceptible population are the same, 
with the distinction between population type accounted for in the consequence 
distributions.  This is a similar approach to that used by Cassin et al. (1998) in which 
the normal and susceptible populations are assumed to have a similar vulnerability to 
illness following the ingestion of E. coli O157:H7, but the susceptible population has 
an increase propensity for severe health outcomes progressing from illness. 
The end result of the risk characterization is an estimated distribution of the 
number of people affected by an adverse health outcome based on the number of 
people exposed, the probability of a specific consequence, and the influence of 
population type on consequence of interest.  The risk calculations considered include:  
the number of hospitalizations given illness, the number of HUS/TTP cases given 
hospitalization, the number of deaths given HUS/TTP, the number of HUS/TTP cases 
given illness, and the number of deaths given illness.  It should be noted that the all of 
the risks characterized are in the form of a distribution, as all the inputs (i.e., 
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contamination/serving, consumption, tolerance, and consequences) to the risk 
calculation are distributions.   
   3.5.2  Methodology for Consequence Distributions 
Although the dose-response assessment is used to calculate the probability of 
illness given E. coli O157:H7 exposure, the probability of E. coli O157:H7-related 
illnesses progressing to other severe health outcomes needs to be determined for both 
the normal and susceptible populations.  Surveillance data provides the best estimate 
of the incidence of various adverse health outcomes due to E. coli O157:H7 infection.  
Typically, surveillance data for foodborne outbreaks is given in terms of the number 
of illnesses, hospitalizations, HUS/TTP, and deaths.  This data is utilized to determine 
the proportion of E. coli O157:H7 illnesses that progress to more severe outcomes 
such as hospitalization, HUS/TPP, and death.  Probability distributions are used to 
describe the outbreak data and updated using Bayesian inference to account for the 
uncertainty about the proportion of illnesses progressing to severe adverse health 
outcomes.  
Previous research has also accounted for the uncertainty associated with the 
underreporting of outbreaks (Powell et al., 2000; Powell et al., 2001); however, these 
previous analyses focused on estimating the annual risk due to E. coli O157:H7 
exposure for the entire United States population.  Since this research focuses on 
calculating the adverse health outcomes of a specific E. coli O157:H7 outbreak 
scenario, it is assumed that all cases associated with the outbreak are reported.  
Therefore, the risk characterization does not account for the underreporting of cases.   
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      3.5.2.1  E. coli O157:H7 Surveillance Data 
         3.5.2.1.1  Normal Population 
Epidemiological data for E. coli O157:H7 foodborne outbreaks is collected 
from several sources for the normal population in order to determine the proportion of 
E. coli O157:H7 illnesses that progress to more severe adverse health outcomes.  
First, FoodNet (Foodborne Diseases Active Surveillance Network), publishes annual 
reports containing a summary of E. coli O157:H7 outbreaks collected through active 
surveillance.  FoodNet obtains this surveillance data from laboratories in several 
states including Connecticut, Georgia, Maryland, Minnesota, Oregon, and Tennessee 
and select counties in California, Colorado, and New York.  Second, the CDC’s 
Foodborne Outbreak Response and Surveillance Unit collects data on E. coli 
O157:H7 outbreaks and clusters due to foodborne, waterborne, and person-to-person 
transmission reported to CDC by the states or regulatory agencies; the Foodborne 
Outbreak Response and Surveillance Unit also provides annual summaries of these E. 
coli O157:H7 outbreaks.  Finally, unpublished E. coli O157:H7 foodborne outbreak 
data from the CDC is obtained from Powell et al. (2001).  The outbreak data collected 
includes information on the number of illnesses and the number of hospitalizations, 
HUS/TTP cases, and deaths resulting from E. coli O157:H7 illness.  Based on the E. 
coli O157:H7 foodborne outbreak data collected between 1982-2003 there are 8,894 
cases of illness.  Of these 8,894 illnesses, 2,430 cases resulted in hospitalization, 488 
cases progressed to HUS/TTP, and 58 cases resulted in death.  Table 3.16 provides a 
summary of this data in terms of the adverse health outcomes for the normal 
population.   
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Table 3.16:  Summary of Surveillance Data used for Consequence Determination of Normal 
Population 
Reference Year Ill Hospitalized HUS/TTP Deaths 
Powell et al., 
2001 




















2003 444 173 --- 4 
CDC, 1999 1998 377 73 8 1 
CDC, 2000 1999 659 96 15 2 
CDC, 2001 2000 206 70 10 1 
CDC, 2002 2001 131 53 8 0 
CDC, 2003 2002 267 63 10 1 
TOTAL  8894 2420 488 58 
 
 
It should be noted that for the normal population, an effort has been made so 
as not to duplicate any of the outbreak data, include non-foodborne related E. coli 
O157:H7 outbreak data, or include data specifically related to the susceptible 
population.  First, the unpublished foodborne E. coli O157:H7 outbreak data from 
Powell et al. (2001) encompasses data from 1982-1998.  For this reason, data from 
the FoodNet Annual Reports from 1996, 1997, and 1998 is omitted.  The Foodborne 
Outbreak Response and Surveillance Unit annual reports provide information on the 
vehicle of transmission, the setting, and the state in which the outbreak occurred.  
Data relating to non-foodborne E. coli O157:H7 outbreaks, settings which include the 
susceptible population, and outbreaks occurring in any of the states (i.e., CT, GA, 
MD, MN, OR, TN, CA, CO, and NY) monitored by FoodNet are eliminated.   
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         3.5.2.1.2  Susceptible Population 
The epidemiological data for determining the proportion of E. coli O157:H7 
illnesses progressing to more severe adverse health outcomes for the susceptible 
population is collected from reported cases in the literature and the Foodborne 
Outbreak Response and Surveillance Unit annual summaries.  In addition to 
providing information on the various health outcomes and the vehicle of infection for 
a particular E. coli O157:H7 outbreak, the Foodborne Outbreak Response and 
Surveillance Unit annual summaries also provide information on the setting in which 
the outbreak occurred.  Settings involving day care, schools, and retirement 
communities are utilized in order to determine the proportion of E. coli O157:H7 
illnesses progressing to severe outcomes for the susceptible population.  For each E. 
coli O157:H7 outbreak, the data collected for the susceptible population includes not 
only the number of illnesses, but also the number of hospitalizations, HUS/TTP cases, 
and deaths resulting from those illnesses.  Based on the E. coli O157:H7 outbreak 
data collected from various sources between 1980-2002 there are 495 cases of illness.  
Of these 495 E. coli O157:H7 illnesses among the susceptible population, 126 
resulted in hospitalization, 34 progressed to HUS/TTP, and 30 resulted in death.  
Table 3.17 provides a summary of this data in terms of the adverse health outcomes 
for the susceptible population.   
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Table 3.17:  Summary of Surveillance Data used for Consequence Determination of Susceptible 
Population 
Reference Year Ill Hospitalized HUS/TTP Deaths 
Griffin et al., 
1988 
1980-1986 178 69 20 30 
Griffin et al., 
1991 
1988-1990 125 8 1 0 
CDC, 1999 1998 21 7 2 0 
CDC, 2000 1999 45 9 2 0 
CDC, 2001 2000 43 10 4 0 
CDC, 2002 2001 40 18 5 0 
CDC, 2003 2002 43 5 1 0 
TOTAL  495 126 34 30 
 
 
      3.5.2.2  Characterization of Consequence Uncertainty 
Although proportions of E. coli O157:H7 illnesses progressing to severe 
adverse health outcomes can be developed from the surveillance data collected, there 
is uncertainty about these proportions.  This research accounts for the uncertainty 
regarding the number of illnesses that progress to more severe health outcomes (i.e., 
hospitalization, HUS/TTP, and death) through Bayesian inference.  By selecting a 
distribution to represent the prior state of knowledge about a particular adverse health 
consequence, and updating the prior with the observed surveillance data (i.e., the 
likelihood), a posterior distribution which accounts for the uncertainty about the 
surveillance data can be obtained.  Thus, knowledge of Bayes’ theorem is needed in 
order to understand the selection of the prior distribution and likelihood function for 
developing the posterior distribution to characterize the uncertainty.  Bayes’ theorem 
may be written as: 
( ) ( ) ( )







||     (3.10) 
 
Where the prior distribution is represented by ( )θπ , the likelihood function is 
represented by ( )θ|Xl , and the posterior distribution is represented by ( )Xf |θ .  The 
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prior distribution is the density function of the prior belief about the parameter θ 
before the observed data, X, is obtained.  In other words, the prior distribution is not a 
probability distribution of θ but rather an uncertainty distribution, as it represents the 
state of knowledge about θ before the data X is observed.  The likelihood function is 
the calculated probability of randomly observing the data X for a given value of θ, 
with the shape of the likelihood function embodying the amount of information 
contained in the data.  Finally, the posterior distribution is the description of the state 
of knowledge of θ after the observed data X is obtained, given the prior belief of the 
value of θ before X is observed (Vose, 2000).   
In terms of Bayesian inference, the E. coli O157:H7 outbreak surveillance 
data represents the likelihood, or observed data, and a probability distribution is 
needed to describe this data.  The surveillance data collected represents a binomial 
process, where the probability of the consequence of interest, p, can be estimated 
from the number of observations, n, resulting in s consequences of interest.  Selection 
of the conjugate prior for the binomial likelihood results in a posterior distribution 
belonging to the same distribution family as the prior, thus avoiding complicated 
mathematics (Vose, 2000).   
By selecting the Beta-binomial conjugate pair, the resulting posterior 
distribution will be in the form of a Beta distribution.  This posterior Beta distribution 
represents the uncertainty about the binomial distribution representing the 
surveillance data and can be derived as follows.  The prior distribution is represented 
by Beta (α1, α2) and has a probability density function ( )θf given by: 
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αα θθθ    (3.11) 
 
The likelihood function represents the surveillance data and is in the form of a 
binomial distribution.  Thus, the likelihood function ( )θ;, nsl is given by:   









= θθθ 1;,    (3.12) 









is constant for the given data set.   Thus, the Beta distribution and the 
binomial likelihood function have the same functional form in θ, that is ( )ba θθ −1 ,  
where a and b are constants (Vose, 2000). 
Since the posterior distribution is a product of the prior and likelihood 
functions, it will have the same functional form; the resulting posterior distribution is:   


















αα θθθ    (3.13) 
Where f(θ | s, n) is the Beta(α1 + s, α2 + n – s) distribution.  
 
      3.5.2.3  Consequence Distribution Results  
 No prior information about the proportion of illnesses progressing to adverse 
health outcomes is known for either population; therefore, an uninformed distribution 
should be used for the prior distribution as it adds no information to the Bayesian 
inference.  A Uniform(0,1) distribution is considered an uninformed prior for 
estimating a binomial probability because it states that prior to collection of any data, 
every possible value for the true probability is equally likely.  According to Vose 
(2000), the Beta(1,1) distribution is equivalent to the Uniform(0,1) distribution. 
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Therefore, using the uninformed Beta(1,1) distribution as the prior distribution 
for the binomial likelihood function, the posterior distribution, Beta(α1 + s, α2 + n – 
s), becomes Beta(s + 1, n – s + 1).  Using the surveillance data from Table 3.16 for 
the normal population, the proportion of illnesses progressing to adverse health 
consequences, with uncertainty, can be derived.  These distributions are given in 
Table 3.18.   
 
Table 3.18:  Uncertainty Characterization about Proportion of Severe Outcomes for Normal 
Population 
Description of Adverse 
Health Consequence 
Likelihood Function Prior 
Distribution 
Posterior Distribution 
Proportion of illnesses 
progressing to hospitalization  








θθ  Beta(1,1) Beta(2420+1, 8894-2420+1) 
Proportion of hospitalizations 
progressing to HUS/TTP 








θθ  Beta(1,1) Beta(448+1, 2420–448+1) 
Proportion of HUS/TTP 
progressing to death 








θθ  Beta(1,1) Beta(58+1, 448–58+1) 
Proportion illnesses 
progressing to HUS/TTP 








θθ  Beta(1,1) Beta(448+1 8894–448+1) 
Proportion illnesses 
progressing to death 








θθ  Beta(1,1) Beta(58+1, 8894–58+1) 
 
Using the surveillance data from Table 3.17 for the susceptible population, the 
proportion of illnesses progressing to adverse health consequences, with uncertainty, 
can be derived.  These distributions are given in Table 3.19.   
 
Table 3.19:  Uncertainty Characterization about Proportion of Severe Outcomes for Susceptible 
Population 
Description of Adverse 
Health Consequence 
Likelihood Function Prior 
Distribution 
Posterior Distribution 
Proportion of illnesses 
progressing to hospitalization  








θθ  Beta(1,1) Beta(126+1, 495-126+1) 
Proportion of hospitalizations 
progressing to HUS/TTP 








θθ  Beta(1,1) Beta(34+1, 126–34+1) 
Proportion of HUS/TTP 
progressing to death 








θθ  Beta(1,1) Beta(30+1, 34–30+1) 
Proportion illnesses 
progressing to HUS/TTP 








θθ  Beta(1,1) Beta(34+1 495–34+1) 
Proportion illnesses 
progressing to death 








θθ  Beta(1,1) Beta(30+1, 495–30+1) 
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   3.5.3  Risk Characterization Decomposition 
In terms of the DML method, the risk characterization may be thought of as a 
system element of the quantitative microbial risk assessment.  As such, the risk 
characterization can be decomposed into sub-system elements as well.  The end result 
of the consumption phase (i.e., the distribution of the ingested dose of E. coli 
O157:H7) is an input to the dose-response model, and based on the population type 
and number of people exposed, a number of different risk distributions can be 
estimated.  Section 3.5.2 explained the methodology for determining the probability 
distributions that describe the various adverse health consequences resulting from 
illness.  The following sections provide a detailed discussion of how these 
consequence distributions are used in the various risk calculations. 
      3.5.3.1  Risk Characterization Step D1:  Dose-Response Model 
Step D1 in the DML decomposition of the risk characterization of E. coli 
O157:H7 represents the dose-response assessment, as discussed in section 3.4.  Step 
D1 determines the dose-response model used to calculate the probability of illness 
given the ingested dose, and thereby influences the remaining adverse health 
outcomes in the risk characterization.  Developing a dose-response model for E. coli 
O157:H7 is a difficult task due to both model and data uncertainty.  Although there 
are a number of different dose-response models that describe the relationship between 
the level of microbial exposure and the likelihood of occurrence of an adverse health 
consequence, there is no consensus on which specific model is most applicable to E. 
coli O157:H7.  In addition, due to the severe nature of E. coli O157:H7, volunteer 
human dose-response studies are not possible, resulting in much uncertainty about the 
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data used for parameter estimation of the dose-response model.  The DML concept is 
used in step D1 to identify various dose-response models, as well as various data sets 
from which the model parameters can be calculated.  Figure 3.36 gives the DML 
decomposition for step D1.   
 
 
Figure 3.36:  DML Decomposition of Consumption Step D1 (Dose-Response Model) 
 
 
      3.5.3.2  Risk Characterization Step D2:  Number of Illnesses Given Dose 
Step D2 estimates the distribution of the number of illnesses in the exposed 
population given the ingested dose.  The inputs to this calculation are the probability 
of illness given the ingested dose, calculated from the dose-response model in step 
D1, and the number of people in the exposed population.  The number of people in 
the exposed population is a user-defined input.  Again, for this calculation, the 
population type is not an input, as the normal and susceptible populations are 
assumed to have a similar vulnerability to illness following the ingestion of E. coli 
O157:H7.  The susceptible population’s increased propensity for severe health 
outcomes progressing from illness is accounted for in the remaining risk calculations.  
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Figure 3.37:  DML Decomposition of Consumption Step D2 (Number of Illnesses Given Dose) 
 
 
3.5.3.3  Risk Characterization Step D3:  Number of Hospitalizations Given 
Illness 
 
Step D3 estimates the distribution of the number of hospitalizations in the 
exposed population given the illness.  The inputs to this calculation are the probability 
of illness given the ingested dose, calculated from the dose-response model in step 
D1, the number of people in the exposed population, and the population specific 
probability of hospitalization given illness.  Figure 3.38 represents the DML 
decomposition for step D3.   
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3.5.3.4  Risk Characterization Step D4:  Number of HUS/TTP Cases Given 
Hospitalization 
 
Step D4 estimates the distribution of the number of HUS/TTP cases in the 
exposed population given hospitalization.  The inputs to this calculation are the 
probability of illness given the ingested dose, calculated from the dose-response 
model in step D1, the number of people in the exposed population, and the population 
specific adverse health consequences of the probability of hospitalization given 
illness and the probability of HUS/TTP given hospitalization.  Figure 3.39 represents 




























      3.5.3.5  Risk Characterization Step D5:  Number of Deaths Given HUS/TTP 
Step D5 estimates the distribution of the number of deaths in the exposed 
population given HUS/TTP.  The inputs to this calculation are the probability of 
illness given the ingested dose, calculated from the dose-response model in step D1, 
the number of people in the exposed population, and the population specific adverse 
health consequences of the probability of hospitalization given illness, the probability 
of HUS/TTP given hospitalization, and the probability of death given HUS/TTP.  
Figure 3.40 represents the DML decomposition for Step D5.   
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Figure 3.40:  DML Decomposition of Consumption Step D5 (Number of Deaths Given HUS/TTP) 
 
 
3.5.3.6  Risk Characterization Step D6:  Number of HUS/TTP Cases Given 
Illness 
 
Step D6 estimates the distribution of the number of HUS/TTP cases in the 
exposed population given illness.  The inputs to this calculation are the probability of 
illness given the ingested dose, calculated from the dose-response model in step D1, 
the number of people in the exposed population, and the population specific 
probability of HUS/TTP given illness.  Figure 3.41 represents the DML 
decomposition for Step D6.   
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      3.5.3.7  Risk Characterization Step D7:  Number of Deaths Given Illness 
 
Step D7 estimates the distribution of the number of deaths in the exposed 
population given illness.  The inputs to this calculation are the probability of illness 
given the ingested dose, calculated from the dose-response model in step D1, the 
number of people in the exposed population, and the population specific probability 
of death given illness.  Figure 3.42 represents the DML decomposition for Step D7.   
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Figure 3.42:  DML Decomposition of Consumption Step D7 (Number of Deaths Given Illness) 
 
 
   3.5.4  Risk Characterization Calculation Summary 
 
The risk characterization element of the QMRA integrates the exposure and 
dose-response assessments with the consequence analysis in order to calculate the 
human health risk.  The end result of the consumption phase (i.e., step C3) is the input 
for the dose-response assessment, and based on the probability of illness given the 
ingested dose, the number of exposed people, and the population specific probability 
of an adverse health outcome, any number of risks can be estimated.  A summary of 
the risk characterization calculations is given in Table 3.20.   
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Table 3.20:  Risk Characterization Calculations 




and Data Sets 
f(C3) probability 




D1*(# exposed) people 
D3 Number of Hospitalizations 
Given Illness 
Beta D3ia (i = 1–3) D2*D3i people 
D4 Number of HUS/TTP Cases 
Given Hospitalization 
Beta D4i (i = 1–3) D3*D4i people 
D5 Number of Deaths Given 
HUS/TTP 
Beta D5i (i = 1–3) D4*D5i people 
D6 Number of HUS/TTP Cases 
Given Illness 
Beta D6i (i = 1–3) D2*D6i people 
D7 Number of Death Given 
Illness 
Beta D7i (i = 1–3) D2*D7i people 
aBeta distribution for specific risk characterization step, based on population type(i.e., normal, susceptible, or mixed)   
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4.  ENGINEERING-BASED PROBABILISTIC RISK ASSESSMENT 
APPLICATION RESULTS 
 
4.1  Results Overview 
The model described in the exposure assessment is integrated with the dose-
response assessment in order to estimate a number of different risks for a particular 
outbreak.  The exposure assessment estimates not only the level of E. coli O157:H7 
contamination along the various steps of the cheese manufacturing and distribution 
processes, but also provides an estimate of the dose.  The dose-response model is then 
used to describe the probability of illness given the estimated dose.  Finally, the 
adverse health consequences resulting from illness can be characterized.  The result is 
an estimate of the overall likelihood and magnitude of the adverse health outcomes 
from the exposure to the ingested dose of E. coli O157:H7, with the associated 
uncertainty.   
One of the key advancements of this research is the development of a model 
that can assess any number of scenarios for the cheese manufacturing and distribution 
process and provide various risk estimates for these scenarios.  The Dynamic Master 
Logic (DML) decomposition of the process into basic elements with various options 
allows this model to represent the cheese-making process for a wide variety of cheese 
types and also account for mistreatment of the cheese during production and 
distribution.  While previous research focused on a process risk model (PRM) in 
order to assess one particular scenario, the DML concept results in the ability to 
construct and analyze multiple scenarios.  Furthermore, by changing the selections 
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within a scenario, various sensitivity analyses can be performed and possible 
mitigation strategies assessed.   
 The results discussed in this chapter are based on a particular scenario 
developed with the model, with the purpose of demonstrating how the model can be 
used as both a risk assessment and risk management tool.  A case study is performed 
in order to demonstrate how the model can be used as a risk assessment tool by 
estimating the E. coli O157:H7 contamination at various points along the exposure 
path and then characterizing the adverse health consequences.  In addition, critical 
points in the cheese exposure path that most significantly influence risk are identified 
in the case study and used to identify possible risk mitigations.  These various 
mitigation strategies are then imposed on the case study; by comparing the results 
from the control strategies to the baseline case study, the model demonstrates its 
value as a risk management and decision making tool as well.  Finally, a worst-case 
analysis is performed on the case study in order to determine the sensitivity of the 
model to a variety of factors.   
 
4.2  Methodology 
The results of this risk assessment consider both aleatory and epistemic 
uncertainty.  As discussed in Chapter 1, an important part of a probabilistic 
quantitative microbial risk assessment (QMRA) is the inclusion of both types of 
uncertainty.  Again, aleatory uncertainty, or variability, refers to the real and 
identifiable differences in nature and represents the diversity in a well-characterized 
population or parameter.  In contrast, epistemic uncertainty arises from a lack of 
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knowledge, and may be related to the model used to characterize the risk, the 
parameters used to provide values for the model, or both (Thompson, 2002).  Thus, 
recognizing and characterizing both the aleatory and epistemic uncertainty in a risk 
assessment is important, as these have different implications in the risk assessment 
results, and therefore, the risk management decisions (Thompson, 2002).  If aleatory 
and epistemic uncertainties are not separated within a risk assessment, the simulation 
on such a model randomly selects from all the distributions (i.e., aleatory uncertainty 
distributions and epistemic uncertainty distributions).  The resultant output 
distribution is a composite distribution of both uncertainty components.  The output 
distribution becomes difficult to interpret in this case, as the vertical scale represents 
neither aleatory nor epistemic uncertainty.  To this end, information is lost regarding 
what part of the resultant distribution is due to the inherent variability and what part is 
due to a lack of knowledge.  In other words, mixing the aleatory and epistemic 
uncertainty eliminates the ability to determine how much of the total uncertainty 
comes from variability and from epistemic uncertainty (Vose, 2000).  For this reason, 
it is crucial that aleatory and epistemic uncertainty be separated within the risk 
assessment. 
Separating the aleatory and epistemic uncertainty within a risk assessment 
results in the ability to identify which part of the total uncertainty is due to epistemic 
uncertainty and/or aleatory uncertainty.  This is important when making risk 
management decisions because if the total uncertainty is due mostly to aleatory 
uncertainty then additional data collection is not warranted; the only way to reduce 
the total uncertainty is to change the physical system.  In contrast, if the total 
 154
uncertainty is due mostly to epistemic uncertainty then collecting additional 
information reduces the uncertainty and improves future estimates.  Thus, the 
separation of aleatory and epistemic uncertainty underscores the steps that can be 
taken to reduce the total uncertainty of the model, and measures the value of more 
information versus potential changes to the system (Vose, 2000).   
Clearly, it is important to develop a second-order model (i.e., a model that 
separates uncertainty and variability), and there are several Monte Carlo simulation 
approaches that can be used to accomplish this task.  A two-dimensional Monte Carlo 
simulation methodology is used in this model to properly disaggregate and evaluate 
the consequences of aleatory and epistemic uncertainty.  This methodology employs a 
two-loop approach in which the aleatory and epistemic uncertainties are simulated 
separately.  The resultant outputs illustrate the aleatory uncertainty about the x-axis 
and the epistemic uncertainty about the y-axis.   
 
4.3  Case Study 
   4.3.1  Baseline Case Study Assumptions 
The results generated for the baseline case study are based on one particular 
scenario entered into the model.  The following tables list the sub-system elements, 
basic elements, and options for the basic elements, as well as the selections made for 
the baseline case study for each of the system elements (i.e., production, distribution, 
consumption, and risk characterization).  Table 4.1 documents the selections made for 
the production phase, with these selections emulating cheddar cheese production.  An 
initial distribution of 10±10 CFU/ml is entered as the concentration of E. coli 
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O157:H7 in the raw milk.  The milk is held in storage for 2 days at a temperature 
between 5-8ºC, and receives no heat treatment.  Consistent with cheddar cheese 
production, a mesophilic starter culture is then added to the milk.  The curd is cut and 
then cooked at a temperature of 36-40ºC, also consistent with cheddar cheese.  The 
whey is removed, a dry salt is applied to the cheddar cheese curds, and the salted 
curds are then placed in hoops and pressed.  Typically, cheddar cheese is ripened for 
at least 60 days; in addition, the PMO Revision 2001 states that raw milk cheese must 
be ripened for at least 60 days.  Thus, a ripening time of 75 days is selected.   
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Table 4.1:  Production Phase Case Study Selections 
Step Sub-System Element 
Description 
Basic Elements Options Case Study 
Selection 
A0 Initial E. coli O157:H7 
Contamination (CFU/ml) 
--- Analyst-defined  10 ± 10 CFU/ml 





2 days A1 Contamination after Milk 
Storage 
Temperature Temp ≤5˚C 
5˚C < Temp < 8˚C 
Temp = 8˚C 
Temp > 8˚C 
5˚C < Temp < 8˚C 
 
A2 Contamination after Milk 
Heat Treatment 
Milk Treatment Pasteurized Milk 
Unpasteurized Milk 
Heat Treated Milk 
Unpasteurized Milk 
 
Type of Starter Culture Mesophilic 
Thermophilic 
Mesophilic A3 Contamination after Addition 
of Coagulant 
Milk Treatment Determined by A2 
selection 
--- 
A4 Contamination after Cutting 
of Curd 
Milk Treatment Determined by A2 
selection 
--- 
Temperature 30˚C ≤ Temp < 32˚C 
33˚C ≤ Temp ≤ 35˚C 
36˚C ≤ Temp ≤ 40˚C 
Temp > 40˚C 
36˚C ≤ Temp ≤ 40˚C 
 
A5 Contamination after Cooking 
of Curd 
Milk Treatment Determined by A2 
selection 
--- 
A6 Contamination after 
Separation of Curd and Whey 
Milk Treatment Determined by A2 
selection 
--- 
Type of Salt Dry 
Brine 
Dry A7 Contamination after Salting 
Milk Treatment Determined by A2 
selection 
--- 
A8 Contamination after Hooping 
and Pressing 
Milk Treatment Determined by A2 
selection 
--- 







75 days A9 Contamination after 
Packaging and Ripening 





Table 4.2 documents the selections made for the distribution phase.  The pH 
of cheddar cheese is 6.0, and this selection is held constant through the various steps 
in the distribution phase.  Next, minimum and maximum times are entered for each 
step.  Finally, the temperature is selected for each step.  The temperatures selected for 
the baseline case study are meant to reflect moderate temperature abuse.   
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Table 4.2:  Distribution Phase Case Study Selections 
Step Sub-System Element 
Description 














Time Analyst-defined  1 - 24 hours 











Time Analyst-defined 1 - 12 hours B2 Contamination after 










Time  Analyst-defined 1 - 120 hours B3 Contamination after Retail 










Time  Analyst-defined 1- 2 hours B4 Contamination after 










Time Analyst-defined 1 - 336 hours B5 Contamination after 









1pH held constant for remaining distribution steps 
 
 
Table 4.3 documents the selections made for the consumption phase.  The 
only input for the consumption phase is the number of servings of cheese consumed.  
The serving size is entered as a minimum and maximum.  For the baseline case study, 
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it is assumed that the average person consumes between 1-3 servings of contaminated 
cheese.    
 
Table 4.3:  Consumption Phase Case Study Selections 
Step Sub-System Element 
Description 
Basic Elements Options Case Study 
Selection 
C1 Contamination in One 
Serving 
--- --- --- 
C2 Number of Servings 
Consumed 
Serving Size Analyst-defined  1 – 3 servings 
C3 Ingested Dose --- --- --- 
 
 
Finally, Table 4.4 documents the selections made for the risk characterization 
portion of the model.  For the risk characterization element, several selections are 
made for the dose-response model and the data set for parameter estimation basic 
elements.  By generating results for various dose-response models, the model 
uncertainty can be assessed; furthermore, by generating results for a particular dose-
response model using various data sets for the parameter estimation, the parameter 
uncertainty of the dose-response model can be evaluated.  Thus, for the baseline case 
study, both the beta-Poisson and Weibull-Gamma dose-response models are selected 
for comparison purposes.  The data sets selected for parameter estimation of the dose-
response models are:  all human E. coli, E. coli O157:H7 rabbit, and S. dysenteriae.  
It should be noted that the data sets selected for the parameter estimates of the beta-
Poisson and Weibull-Gamma models are those that resulted in significant fits.  Lastly, 
the AHP weighted-average models for the beta-Poisson and Weibull-Gamma 
relationships are also examined, as the AHP weighted-average models provide an 
alternative way to assess the data uncertainty associated with the dose-response 
models. 
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The adverse health outcomes characterized in this model are based on a 
particular outbreak scenario in which a group of individuals consume cheese from the 
same production and distribution scenarios.  A population of 1,500 people is exposed 
to the E. coli O157:H7 contaminated cheese.  The number of illnesses given the 
ingested dose is estimated for the population.  In addition, for both the normal and 
susceptible populations, the number of hospitalizations given illness, the number of 
HUS/TTP cases given hospitalization, the number of deaths given HUS/TTP, the 
number of HUS/TTP cases given illness, and the number of deaths given illness are 
estimated in the risk characterization element of the model.  
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Table 4.4:  Risk Characterization Case Study Selections 
Step Sub-System Element 
Description 













  Data Set for Parameter 
Estimation 
All Data 
All Human Data 
All E. coli Data 
All Human E. coli Data 
EPEC 
Infant Diarrheal E. coli 





All Human E. coli Data 
E. coli O157:H7 Rabbit 
Data 
S. dysenteriae 
D2 Number of Illnesses Given 
Dose 
Number of People 
Exposed 
Analyst-defined 1,500 people 
  P(Illness|Dose) Determined by D1 
selection 
--- 
D3 Number of Hospitalizations 
Given Illness 
Number of People 
Exposed 
Determined by D2 
selection  
--- 
  P(Illness|Dose) Determined by D1 
selection 
--- 





D4 Number of HUS/TTP Cases 
Given Hospitalization 
Number of People 
Exposed 
Determined by D2 
selection  
--- 
  P(Illness|Dose) Determined by D1 
selection 
--- 










D5 Number of Deaths Given 
HUS/TTP 
Number of People 
Exposed 
Determined by D2 
selection  
--- 
  P(Illness|Dose) Determined by D1 
selection 
--- 















D6 Number of HUS/TTP Cases 
Given Illness 
Number of People 
Exposed 
Determined by D2 
selection  
--- 
  P(Illness|Dose) Determined by D1 
selection 
--- 





D7 Number of Death Given 
Illness 
Number of People 
Exposed 
Determined by D2 
selection  
--- 
  P(Illness|Dose) Determined by D1 
selection 
--- 







 Based on these selections, results are generated for the scenario entered in the 
model.  The end result is an estimate of the distribution of E. coli O157:H7 
contamination at various points along the exposure path, and the adverse health 
consequences resulting from illness.  The results are presented in the form of 
complementary cumulative distributions and show both the uncertainty and the 
variability; the graphs depict the 90% confidence level, the 25th, 50th, and 75th 
percentiles, and the mean for the probability of exceedance.    
   4.3.2  Baseline Case Study Results 
      4.3.2.1  Contamination after Production 
Based on the initial contamination level and the selections made in the 
production phase of the model, the number of E. coli O157:H7 in 1 kg of cheese after 
production is estimated.  Figure 4.1 shows both the variability and uncertainty of the 
predicted distribution of E. coli O157:H7 after production and depicts the probability 
of exceeding a given amount of contamination in 1 kg of cheese. 
Figure 4.1:  Variability and uncertainty for probability of exceeding contamination level per 1 kg 































Figure 4.1 shows a 0.79 probability of exceeding an E. coli O157:H7 
contamination level of 6.5 CFU/kg, with the 90% confidence interval for the 
probability of exceeding this contamination level ranging from 0.65-0.94.  There is 
approximately a 0.26 probability of exceeding a contamination level of 8.0 CFU/kg, 
with a 90% confidence interval of 0.11-0.53.  These results demonstrate that a 
moderate level of initial contamination in combination with moderate abuse during 
the production phase can lead to high levels of E. coli O157:H7 contamination in the 
final cheese product.  
      4.3.2.2  Contamination after Distribution 
Based on the contamination level at the end of the production phase and the 
selections made in the distribution phase of the model, the number of E. coli O157:H7 
in 1 kg of cheese after distribution is estimated.  Figure 4.2 shows the predicted 
distribution of E. coli O157:H7 after the distribution phase.  In addition, the mean 
contamination after production is superimposed for the purpose of comparing of the 
contamination levels between the two phases.  A numerical comparison of the 
contamination levels after production and distribution for the 5th percentile, mean, and 
95th percentile of the 0.50 probability of exceedance is also shown.  
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 Production Distribution 
5th percentile 6.67 9.25 
Mean 7.25 9.75 
95th percentile 8.05 10.50 
 
Figure 4.2:  Variability and uncertainty for probability of exceeding contamination level per 1 kg 
cheese after distribution, superimposed with contamination after production results  
 
There is a 0.97 probability of exceeding an E. coli O157:H7 contamination 
level of 6.5 CFU/kg after distribution, with a 90% confidence interval of 0.95-1.0.  
For a contamination level of 8.0 CFU/kg, there is a 0.86 probability of exceedance, 
with a 90% confidence interval of 0.77-0.94.  Figure 4.2 also illustrates the increase 
in the level of contamination after distribution as compared to the contamination after 
production.  Thus, given the contamination level after production, the mild 
temperature abuse in the distribution phase results in an increase in contamination.  It 
should be noted that the increase is significant, as the uncertainty ranges for the 































      4.3.2.3  Contamination per Gram 
Based on the contamination level at the end of the distribution phase, the 
number of E. coli O157:H7 per gram of cheese is estimated.  Figure 4.3 shows the 
predicted distribution of E. coli O157:H7 per gram of cheese.   
 
Figure 4.3:  Variability and uncertainty for probability of exceeding contamination level per 
gram of cheese 
 
 
 Figure 4.3 shows that there is a 0.57 probability of exceeding a contamination 
level of 6.5 CFU/g, with a 90% confidence interval for the probability of exceedance 
ranging from 0.46-0.71.  In addition, there is a 0.27 probability of exceeding 8.0 
CFU/g, with a 90% uncertainty range from 0.19-0.41.     
      4.3.2.4  Contamination per Serving 
The E. coli O157:H7 contamination in 1 kg of cheese after the distribution 
phase is also used to estimate the contamination per serving, with a serving being one 
ounce, or 28 grams, of cheese.  Figure 4.4 shows both the variability and uncertainty 































Figure 4.4:  Variability and uncertainty for probability of exceeding contamination level per one 
ounce serving of cheese 
 
 
Figure 4.4 shows approximately a 0.85 probability of exceeding an E. coli 
O157:H7 contamination level of 6.5 CFU/serving, with a 90% confidence interval of 
0.76-0.93.  For a contamination level of 8.0 CFU/serving there is a 0.56 probability of 
exceedance, with a 90% confidence interval of 0.45-0.71. 
      4.3.2.5  Contamination per Dose 
 The ingested dose varies depending on the number of servings consumed.  For 
the baseline case study, it is assumed that the average person consumes between 1-3 
servings of contaminated cheese.  Using the E. coli O157:H7 contamination per 
serving and the number of servings consumed the dose is estimated.  Figure 4.5 






























Figure 4.5:  Variability and uncertainty for probability of exceeding contamination level per dose 
 
 
There is a 0.89 probability of exceeding an E. coli O157:H7 contamination 
level of 6.5 CFU/dose, with the 90% confidence interval for the probability of 
exceedance at this contamination level ranging from 0.81-0.94.  For a contamination 
level of 8.0 CFU/dose, there is a 0.62 probability of exceedance with a 90% 
confidence interval of 0.49-0.73.   
      4.3.2.6  Probability of Illness 
         4.3.2.6.1  Beta-Poisson Dose-Response Model 
The dose-response assessment uses the ingested dose as an input in the dose-
response model in order to estimate the probability of illness.  For the baseline case 
study, both the beta-Poisson and Weibull-Gamma models are examined, using three 
different data sets for the parameter estimates.  The data sets for parameter estimation 
are:  all human E. coli, E. coli O157:H7 rabbit, and S. dysenteriae.  In addition, the 
AHP weighted-average models for the beta-Poisson and Weibull-Gamma 
relationships are also examined.  Figure 4.6 compares the estimates of the probability 





























AHP weighted-average model as well.  A numerical comparison of the probability of 
illness for the various beta-Poisson dose-response models for the 5th percentile, mean, 
and 95th percentile of the 0.50 probability of exceedance is also shown.  
 
 All human 
E. coli 
E. coli O157:H7 
rabbit 
S. dysenteriae AHP 
5th percentile 0.64 0.95 0.92 0.87 
Mean 0.74 1.00 0.93 0.90 
95th percentile 0.80 1.00 0.94 0.93 
 
Figure 4.6: Variability and uncertainty for probability of illness given ingested dose using beta-




By generating results for a particular dose-response model using various data 
sets for the parameter estimation, the parameter uncertainty of the dose-response 
model can be evaluated.  Figure 4.6a shows the results for the beta-Poisson model 
using parameters estimated from the all human E. coli data.  There is a 0.90 
probability of exceeding a probability of illness of 0.25, with a 90% confidence 
interval for the probability of exceedance of 0.83-0.96; in contrast, there is a 0.49 
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from 0.36-0.60.  Figure 4.6b shows the results for the beta-Poisson model using 
parameters estimated from the E. coli O157:H7 rabbit data.  This results in a 0.98 
probability of exceeding a probability of illness of 0.25, with a 90% confidence 
interval of 0.96-1.00; there is a 0.87 probability of exceeding a probability of illness 
of 0.75, with a 90% confidence range from 0.78-0.94.  Figure 4.6c shows the results 
for the beta-Poisson model using parameters estimated from the S. dysenteriae data.  
There is approximately a 1.00 probability of exceeding a probability of illness of 
0.25; there is a 0.99 probability of exceeding a probability of illness of 0.75, with a 
90% confidence interval of 0.98-1.00.  Obviously, there is wide dispersion among the 
results of the beta-Poisson model using these three data sets for the parameter 
estimates, indicating much parameter uncertainty.  The S. dysenteriae data set 
provides the most conservative estimate of the probability of illness, followed by the 
E. coli O157:H7 rabbit and all human E. coli data sets.  The AHP weighted-average 
model is derived from these three data sets and provides an alternative method to 
account for the data and parameter uncertainty associated with the dose-response 
relationship for E. coli O157:H7.  Figure 4.6d shows the results for the AHP 
weighted-average beta-Poisson model.  This model results in a 1.00 probability of 
exceeding a probability of illness of 0.25; there is a 0.85 probability of exceeding a 
probability of illness of 0.75, with a 90% confidence interval of 0.75-0.92.   
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         4.3.2.6.2  Weibull-Gamma Dose-Response Model 
In order to examine the model uncertainty, the probability of illness given the 
ingested dose is also estimated with the Weibull-Gamma model.  For the baseline 
case study, the same data sets are used for the parameter estimates of the Weibull-
Gamma model and the AHP weighted-average Weibull-Gamma model is investigated 
as well.  Figure 4.7 compares the estimates of the probability of illness for the 
Weibull-Gamma model for the three data sets and the AHP weighted-average model; 
the mean beta-Poisson probability of illness is superimposed for the purpose of model 
comparison.  A numerical comparison of the probability of illness for the various 
Weibull-Gamma dose-response models is shown for the 5th percentile, mean, and 95th 
percentile of the 0.50 probability of exceedance.  
 
 All human 
E. coli 
E. coli O157:H7 
rabbit 
S. dysenteriae AHP 
5th percentile 0.55 0.95 0.90 0.85 
Mean 0.66 1.00 0.92 0.88 
95th percentile 0.75 1.00 0.93 0.91 
 
Figure 4.7: Variability and uncertainty for probability of illness given ingested dose using 
Weibull-Gamma model for (a) all human E. coli, (b) E. coli O157:H7 rabbit, (c) S. dysenteriae, 
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 Figure 4.7 illustrates the parameter uncertainty for the Weibull-Gamma 
model.  Similar to the beta-Poisson model, comparison of the three data sets for the 
Weibull-Gamma model shows a wide dispersion among the results.  Again, the S. 
dysenteriae data set provides the most conservative estimate of the probability of 
illness followed by the E. coli O157:H7 rabbit and all human E. coli data sets.  In 
addition, Figure 4.7 also illustrates the model uncertainty through comparison of the 
results for the beta-Poisson and Weibull-Gamma models.   
Figure 4.7a shows the results for the Weibull-Gamma model using parameters 
estimated from the all human E. coli data.  There is a 0.95 probability of exceeding a 
probability of illness of 0.25, with a 90% confidence interval of 0.91-0.98; in contrast, 
there is a 0.41 probability of exceeding a probability of illness of 0.75, with a 90% 
uncertainty range for the probability of exceedance of 0.27-0.51.  Comparison with 
the beta-Poisson model shows a slight difference in the shape of the curve, with the 
results of the beta-Poisson model generally being less severe for lower probabilities 
of illness and more severe for higher probabilities of illness.  The results for the 
Weibull-Gamma model using parameters estimated from the E. coli O157:H7 rabbit 
data are shown in Figure 4.7b, with a 0.95 probability of exceeding a probability of 
illness of 0.25, with a 90% uncertainty range of 0.91-0.98.  There is a 0.88 probability 
of exceeding a probability of illness of 0.75, with a 90% confidence range from 0.80-
0.95; however, when compared to the beta-Poisson model, the results of the Weibull-
Gamma model using E. coli O157:H7 parameter estimates are slightly less severe.  
Figure 4.7c gives the results for the Weibull-Gamma model using parameters 
estimated from the S. dysenteriae data.  There is approximately a 1.00 probability of 
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exceeding a probability of illness of 0.25; there is a 0.99 probability of exceeding a 
probability of illness of 0.75, with a 90% confidence interval of 0.97-1.00.  For the S. 
dysenteriae data set, the results of the Weibull-Gamma model are slightly less severe.  
Lastly, Figure 4.7d shows the results for the AHP weighted-average Weibull-Gamma 
model.  This model results in a 1.00 probability of exceeding a probability of illness 
of 0.25; there is a 0.85 probability of exceeding a probability of illness of 0.75, with a 
90% confidence interval of 0.77-0.93.  The results of the AHP weighted average 
models for the beta-Poisson and Weibull-Gamma relationships are very similar, with 
the Weibull-Gamma model resulting in slightly lower probabilities of exceedance.  It 
should be noted that the differences between the beta-Poisson and Weibull-Gamma 
models for the S. dysenteriae data set and the AHP weighted-average are not 
significant, as the uncertainty ranges for these models overlap.  
      4.3.2.7  Number of Illnesses Given Dose 
 The baseline case study investigates an E. coli O157:H7 cheese-related 
outbreak affecting 1,500 people.  Since the normal and susceptible populations are 
assumed to have the same vulnerability to illness, the number of illnesses in the 
outbreak is the same for the normal and susceptible populations.  The probability of 
illness estimated from the dose-response model is used to estimate the number of 
people in the outbreak that become ill given the ingested dose.  Thus, the estimate of 
the number of illnesses given the ingested dose is dependent on both the dose-
response model selected and the data sets selected for the parameter estimates of the 
model, as well as the number of people affected in the outbreak.  Figure 4.8 
represents the number of illnesses given the dose based on the beta-Poisson dose-
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response model for the all human E. coli, E. coli O157:H7 rabbit, and S. dysenteriae 
data sets, as well as the AHP weighted average model; the mean Weibull-Gamma 
number of illnesses given the ingested dose is superimposed for the purpose of model 
comparison.  A numerical comparison of the number of illnesses for the various beta-
Poisson dose-response models is shown for the 5th percentile, mean, and 95th 
percentile of the 0.50 probability of exceedance.  
 
 All human 
E. coli 
E. coli O157:H7 
rabbit 
S. dysenteriae AHP 
5th percentile 1000 1400 1325 1300 
Mean 1100 1500 1400 1350 
95th percentile 1200 1500 1500 1400 
 
Figure 4.8: Variability and uncertainty for number of illnesses given ingested dose using beta-
Poisson model for (a) all human E. coli, (b) E. coli O157:H7 rabbit, (c) S. dysenteriae, and (d) 
AHP weighted-average, superimposed with mean Weibull-Gamma results 
 
 
Figure 4.8a shows the number of illnesses given the ingested dose for an 
exposed population of 1,500 people based on the beta-Poisson model using 
parameters estimated from the all human E. coli data.  There is a 0.95 probability of 
exceeding 200 illnesses, and the 90% confidence interval for the probability of 
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probability of exceeding 800 illnesses, with a 90% confidence interval of 0.64-0.84.  
Figure 4.8b shows the results for the number of illnesses given the ingested dose 
using the beta-Poisson model with parameters estimated from the E. coli O157:H7 
rabbit data.  This results in a 0.99 probability of exceeding 200 illnesses, with a 90% 
confidence interval of 0.98-1.00; there is a 0.94 probability of exceeding 800 
illnesses, with a 90% confidence range for the probability of exceedance from 0.89-
0.98.  The results in Figure 4.8c are based on the beta-Poisson model using 
parameters estimated from the S. dysenteriae data.  There is a 1.00 probability of 
exceeding both 200 and 800 illnesses; in fact, there is a 0.52 probability of exceeding 
1400 illnesses, with a 90% confidence interval for the probability of exceedance 
ranging from 30.9-0.65.  Figure 4.8d shows the number of illnesses for the AHP 
weighted-average beta-Poisson model.  This model results in a 1.00 probability of 
exceeding 200 illnesses; the probability of exceeding 800 illnesses is 0.97, with a 
90% confidence interval of 0.94-1.00.   
As stated before, the estimate of the number of illnesses given the ingested 
dose is dependent on the dose-response model and the data sets selected for the 
parameter estimates of the model.  Therefore, the most conservative estimate of the 
number of illnesses is given by the dose-response model using the S. dysenteriae data 
set.  As expected, the variability and uncertainty among the results of the beta-
Poisson models in Figure 4.6 carries over to the estimates for the number of illnesses 
given the ingested dose in Figure 4.8.  Although only the mean is plotted for the 
Weibull-Gamma model, the variability is the same as seen in Figure 4.7, and it is 
assumed the uncertainty would carry over as well.   
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      4.3.2.8  Population Specific Risk Consequences 
As previously stated, the normal and susceptible populations are assumed to 
have a similar vulnerability to illness following the ingestion of E. coli O157:H7, but 
the susceptible population has an increased propensity for severe health outcomes 
progressing from illness.  The population-specific adverse health outcomes that can 
be estimated from the model include:  number of hospitalizations given illness, 
number of HUS cases given hospitalization, number of deaths given HUS, number of 
HUS cases given illness, and number of deaths given illness.  To illustrate the 
differences in health consequences between the normal and healthy populations, the 
number of hospitalizations given illness, number of HUS cases given illness, and 
number of deaths given illness are investigated for the two population types.   
For the baseline case study, these consequences are examined in detail for the 
beta-Poisson all human E. coli data set and the beta-Poisson AHP weighted-average 
model, with the mean Weibull-Gamma model results superimposed.  As with the 
estimate of the number of illnesses, the results generated for these adverse health 
outcomes are also dependent on both the dose-response model and data set used for 
the parameter estimates of the model.  The parameter and model uncertainty 
illustrated in Figures 4.6 and 4.7 is carried through to the estimates of the adverse 
health consequences.  
The all human E. coli data set and AHP weighted-average models are selected 
because of the diversity in the results obtained.  As seen in the estimates for the 
probability of illness, the dose-response model using the all human E. coli data set 
provides the least conservative prediction of illness; thus, the dose-response model 
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using the all human E. coli data set can be considered the “best case” result.  In 
contrast, the AHP weighted-average model provides a much more conservative 
estimate (similar to the dose-response models using the E. coli O157:H7 rabbit and S. 
dysenteriae data sets), but has the added benefit of addressing the data uncertainty 
associated with the dose-response model parameters.   
         4.3.2.8.1  Number of Hospitalizations Given Illness 
Based on the probability of illness given the ingested dose resulting from the 
dose-response model, the population specific probability of hospitalization given 
illness, and the number of people exposed in the outbreak, the number of 
hospitalizations given illness is estimated for the population type.  Figure 4.9 
represents the number of hospitalizations given illness based on the beta-Poisson all 
human E. coli data set and the beta-Poisson AHP weighted-average model for the 
normal and susceptible populations, with the mean Weibull-Gamma results 
superimposed.  A numerical comparison of the number of hospitalizations for the 
beta-Poisson all human E. coli data set and beta-Poisson AHP weighted-average 
model for the normal and susceptible populations is also shown for the 5th percentile, 









All human E. coli AHP  
Normal Susceptible Normal Susceptible 
5th percentile 260 250 345 330 
Mean 300 270 365 335 
95th percentile 325 205 375 350 
 
Figure 4.9:  Variability and uncertainty for number of hospitalizations given illness using all 
human E. coli beta-Poisson model for (a) normal population and (b) susceptible population, and 
AHP weighted-average beta-Poisson model for (c) normal population and (d) susceptible 
population, superimposed with mean Weibull-Gamma results 
 
 
Figure 4.9a shows the number of hospitalizations given illness for the normal 
population, based on the beta-Poisson model with the all human E. coli data set.  The 
probability of exceeding 250 hospitalizations is 0.67, with a 90% uncertainty range of 
0.55-0.77.  Figure 4.9b shows the results for the susceptible population, with a 0.62 
probability of exceeding 250 hospitalizations and a 90% confidence range of 0.50-
0.72.  Figure 4.9c depicts the number of hospitalizations given illness for the normal 
population, based on the AHP weighted-average beta-Poisson model.  The probability 
of exceeding 250 hospitalizations is 0.95, with a 90% uncertainty range of 0.90-0.98.  
Figure 4.9d gives these same results for the susceptible population; there is a 0.92 
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probability of exceedance ranging from 0.84-0.96.  It is worth noting that the 
differences between the beta-Poisson and Weibull-Gamma models are not significant. 
Figure 4.9 shows that there is not a significant difference in the number of 
hospitalizations given illness for the normal and susceptible populations for any of the 
models investigated.  This is due to inconsistency in the consequence data for this 
particular adverse health outcome.  The data collected for the susceptible population 
appears to under-estimate the number of hospitalizations given illness as compared to 
the normal population.  Additional consequence data for the susceptible population 
may help to alleviate this discrepancy.   
         4.3.2.8.2  Number of HUS Cases Given Illness 
Based on the probability of illness given the ingested dose resulting from the 
dose-response model, the population specific probability of HUS given illness, and 
the number of people exposed, the number of HUS cases given illness is estimated.  
Figure 4.10 represents uncertainty and variability for the number of HUS cases given 
illness based on the beta-Poisson all human E. coli data set and the beta-Poisson AHP 
weighted-average model for the normal and susceptible populations, with the mean 
Weibull-Gamma results superimposed.  A numerical comparison of the number of 
HUS cases for the beta-Poisson all human E. coli data set and beta-Poisson AHP 
weighted-average model for the normal and susceptible populations is shown for the 
5th percentile, mean, and 95th percentile of the 0.50 probability of exceedance. 
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All human E. coli AHP  
Normal Susceptible Normal Susceptible 
5th percentile 49 65 64 88 
Mean 55 72 67 90 
95th percentile 60 80 70 93 
 
Figure 4.10:  Variability and uncertainty for number of HUS cases given illness using all human 
E. coli beta-Poisson model for (a) normal population and (b) susceptible population and AHP 
weighted-average beta-Poisson model for (c) normal population and (d) susceptible population, 
superimposed with mean Weibull-Gamma results 
 
 
 Figure 4.10a depicts the number of HUS cases given illness for the normal 
population based on the beta-Poisson model with the all human E. coli data set.  The 
probability of exceeding 50 HUS cases is 0.62 with a 90% uncertainty range of 0.47-
0.72.  Figure 4.10b shows the probability of exceeding 50 HUS cases is 0.77 for the 
susceptible population, with a 90% confidence interval of 0.65-0.85.  In addition, 
there is a 0.15 probability of exceeding 100 HUS cases, with a 90% confidence 
interval of 0.10-0.18.  Figures 4.10c-d depicts the number of HUS cases given illness 
based on the AHP weighted-average beta-Poisson model for the normal and 
susceptible populations, respectively.  The probability of exceeding 50 HUS cases is 
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contrast, the probability of exceeding 50 HUS cases is 0.98 for the susceptible 
populations, with a 90% uncertainty range of 0.95-1.00.  Additionally, there is a 0.33 
probability of exceeding 100 HUS cases, with a 90% confidence interval of 0.26-
0.39.  
For both models investigated, there is a significant difference in the number of 
HUS cases for the normal and susceptible populations.  As expected, both models 
show that the susceptible population has a greater propensity for developing HUS as 
compared to the normal population.  Again, only small differences are noted between 
the estimates based on the beta-Poisson and Weibull-Gamma models.  The mean 
results of the Weibull-Gamma models are, in general, well within the uncertainty 
ranges for the beta-Poisson models, suggesting that the difference between the models 
is not significant.   
         4.3.2.8.3  Number of Deaths Given Illness 
Finally, based on the probability of illness given the ingested dose resulting 
from the dose-response model, the population specific probability of death given 
illness, and the number of people exposed, the number of deaths given illness is 
estimated.  Figure 4.11 depicts the number of deaths given illness based on the beta-
Poisson all human E. coli data set and the beta-Poisson AHP weighted-average model 
for the normal and susceptible populations, with the mean Weibull-Gamma results 
superimposed.  A numerical comparison of the number of deaths for the beta-Poisson 
all human E. coli data set and beta-Poisson AHP weighted-average model for the 
normal and susceptible populations is shown for the 5th percentile, mean, and 95th 




All human E. coli AHP  
Normal Susceptible Normal Susceptible 
5th percentile 6.7 59 8.3 78 
Mean 7.0 65 8.7 80 
95th percentile 7.5 70 9.0 83 
 
Figure 4.11:  Variability and uncertainty for number of deaths given illness using all human E. 
coli beta-Poisson model for (a) normal population and (b) susceptible population and AHP 
weighted-average beta-Poisson model for (c) normal population and (d) susceptible population, 
superimposed with mean Weibull-Gamma results 
 
 
Figure 4.11a depicts the number of deaths given illness for the normal 
population based on the beta-Poisson model with the all human E. coli data set.  The 
probability of exceeding 5 deaths is 0.75 with a 90% uncertainty range of 0.64-0.85.  
Figure 4.11b shows the probability of exceeding 50 deaths is 0.71 for the susceptible 
population, with a 90% confidence interval of 0.60-0.81.  Figures 4.11c-d depict the 
number of deaths given illness based on the AHP weighted-average beta-Poisson 
model for the normal and susceptible populations, respectively.  The probability of 
exceeding 5 deaths is 0.97 with a 90% confidence interval of 0.94-0.99 for the normal 
population, while the probability of exceeding 50 deaths is 0.95 for the susceptible 
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 For both models investigated, there is a factor of ten difference in the number 
of deaths for the normal and susceptible populations.  As seen with the estimates for 
the number of illnesses, hospitalizations, and HUS cases, the mean results of the 
Weibull-Gamma models are well within the uncertainty ranges for the beta-Poisson 
models, suggesting that the difference between the models is not significant.   
   4.3.3  Mitigation Strategies 
 Obviously, the baseline case study demonstrates how a moderate level of 
initial contamination in combination with moderate abuse during the production and 
distribution phases can result in potentially high levels of E. coli O157:H7 
contamination in cheese.  If ingested, these high levels of contamination result in a 
large number of illnesses, hospitalizations, HUS cases, and even deaths.  Several 
factors are identified in the baseline case study as critical points in the exposure path 
that influence not only the E. coli O157:H7 contamination level, but also the 
associated human health risk.  By changing the model selections at these critical 
points, risk management options can be compared.   
The factors identified as critical points in the exposure path correspond with 
the steps in either the production or distribution phases.  However, it should be noted 
that only certain steps in the production phase can be changed to improve the 
contamination level.  For example, since the baseline case study emulates cheddar 
cheese production, changing the cooking temperature or type of salting is not an 
option.  The factors identified as possible mitigation strategies for the production 
phase include:  milk storage time and temperature (step A1), milk heat treatment (step 
A2), and ripening time (step A9).  The factors identified as possible mitigation 
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strategies for the distribution phase are the temperature conditions during the various 
storage and transportation steps (steps B1-B5).  The influence of these various steps 
on the E. coli O157:H7 contamination are investigated separately as single step 
mitigations and in combination as multiple step mitigations. 
      4.3.3.1  Single Step Mitigation Strategies 
 Several single step mitigation strategies are explored for the baseline case 
study.  The conditions at a particular step are changed and the effects of the 
mitigation strategy are then compared to the baseline results.  Comparisons are made 
for the contamination level after production, the contamination level after 
distribution, the contamination level per dose, and the number of illnesses given the 
ingested dose for the all human E. coli beta-Poisson model and AHP weighted-
average dose-response model.  The first mitigation explored involves reducing the 
milk storage time and temperature, from 2 days to 1 day and from 5-8°C to less than 
5°C.  Second, the effect of lengthening the ripening time, from 75 days to 150 days, 
on E. coli O157:H7 contamination level is investigated.  The third mitigation explores 
the effect of pasteurization on contamination levels.  Finally, the temperatures during 
the distribution phase are reduced to 5°C for all steps; although several steps are 
involved in this mitigation, it is treated as a single step mitigation as the same option 
(i.e., temperature) is changed at the various steps.   
         4.3.3.1.1  Contamination after Production 
  The number of E. coli O157:H7 in 1 kg of cheese after production is estimated 
for each of the four single step mitigation strategies imposed.  Figure 4.12 shows the 
predicted distribution of E. coli O157:H7 after production for the various mitigation 
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strategies along with the baseline mean.  A numerical comparison of the 
contamination level after production for the various single step mitigations is shown 
for the 5th percentile, mean, and 95th percentile of the 0.50 probability of exceedance. 
 
 Storage  
Time & Temp 
Ripening Time Pasteurization Distribution 
Temp 
5th percentile 5.40 6.60 -1.50 6.67 
Mean 6.25 7.10 -1.00 7.25 
95th percentile 6.80 7.75 -0.10 8.05 
 
Figure 4.12:  Variability and uncertainty for probability of exceeding contamination level per 1 
kg cheese after production for various mitigation strategies:  (a) reduction in storage time and 
temperature, (b) increase in ripening time, (c) pasteurization, and (d) reduction in distribution 
temperatures, superimposed with mean baseline results 
 
  
 Figure 4.12a shows the probability of exceeding the contamination level per 1 
kg cheese after production for the reduced storage time and temperature mitigation 
strategy.  There is a 0.40 probability of exceeding an E. coli O157:H7 contamination 
level of 6.5 CFU/kg, with a 90% uncertainty range from 0.20-0.66.  Figure 4.12b 
shows the results for the increased ripening time mitigation strategy.  The probability 
of exceeding an E. coli O157:H7 contamination level of 6.5 CFU/kg is 0.69, with a 






























































































on the estimated contamination levels after production.  These results show a 0.00 
probability of exceeding a contamination level of 6.5 CFU/kg.  In fact, there is only a 
0.19 probability of exceeding a contamination level of 1 CFU/kg, with a 90% 
confidence interval from 0.11-0.28.  Finally, Figure 4.12d shows the same 
contamination level after production since the changes to the distribution temperature 
do not impact the production phase.   
 When compared with the mean baseline result, which has a 0.79 probability of 
exceeding an E. coli O157:H7 contamination level of 6.5 CFU/kg, with a 90% 
confidence interval from 0.65-0.94, it is apparent that the reduced milk storage time 
and temperature provides a significant reduction in the E. coli O157:H7 
contamination levels after production.  The increased ripening time also decreases 
contamination; however, the mean for this mitigation strategy is still within the 
uncertainty range for the baseline results, suggesting the difference is not significant.   
However, as expected, the pasteurization mitigation provides the most dramatic and 
significant decrease in contamination.   
         4.3.3.1.2  Contamination after Distribution 
The number of E. coli O157:H7 in 1 kg of cheese after distribution is 
estimated for each of the four single step mitigation strategies imposed.  Figure 4.13 
shows the predicted distribution of E. coli O157:H7 after distribution for the various 
mitigation strategies along with the baseline mean.  A numerical comparison of the 
contamination level after distribution for the various single step mitigations is shown 




 Storage  
Time & Temp 
Ripening Time Pasteurization Distribution 
Temp 
5th percentile 8.25 8.90 1.00 6.75 
Mean 8.75 9.50 1.50 7.30 
95th percentile 9.40 10.10 2.10 8.00 
 
Figure 4.13:  Variability and uncertainty for probability of exceeding contamination level per 1 
kg cheese after distribution for various mitigation strategies:  (a) reduction in storage time and 
temperature, (b) increase in ripening time, (c) pasteurization, and (d) reduction in distribution 
temperatures, superimposed with mean baseline results 
 
 
Figure 4.13a shows the probability of exceeding the contamination level per 1 
kg cheese after distribution for the reduced storage time and temperature mitigation 
strategy.  There is a 0.88 probability of exceeding an E. coli O157:H7 contamination 
level of 6.5 CFU/kg, with a 90% uncertainty range from 0.83-0.94.  Figure 4.13b 
shows the results for the increased ripening time mitigation strategy.  The probability 
of exceeding an E. coli O157:H7 contamination level of 6.5 CFU/kg is 0.94, with a 
90% confidence interval of 0.91-0.97.  Figure 4.13c shows the result of pasteurization 
on the estimated contamination levels after distribution.  These results show a 0.20 
probability of exceeding a contamination level of 6.5 CFU/kg, with a 90% confidence 






























































































distribution for the reduced distribution temperatures.  The probability of exceeding 
an E. coli O157:H7 contamination level of 6.5 CFU/kg is 0.80, with a 90% 
uncertainty range of 0.62-0.95.   
 When compared with the mean baseline result, which has a 0.97 probability of 
exceeding an E. coli O157:H7 contamination level of 6.5 CFU/kg, with a 90% 
confidence interval from 0.95-1.00, it is apparent that the reduced milk storage time 
and temperature and the increased ripening time mitigations provide only a small 
decrease in the E. coli O157:H7 contamination levels after distribution.  The 
decreased distribution temperatures result in a significant decrease in the 
contamination level after distribution; however, the pasteurization mitigation provides 
the most dramatic decrease in contamination.   
         4.3.3.1.3  Contamination per Dose 
Next, the effect of the various single step mitigation strategies on the 
contamination of E. coli O157:H7 per dose is explored.  Again, the ingested dose 
varies depending on the number of servings consumed, and it is assumed that the 
average person consumes between 1-3 servings of contaminated cheese.  Based on 
the E. coli O157:H7 contamination per serving and the number of servings consumed, 
the dose is estimated for each mitigation strategy.  Figure 4.14 shows the predicted 
distribution of E. coli O157:H7 contamination per dose for the various mitigation 
strategies along with the baseline mean.  A numerical comparison of the 
contamination per dose for the various single step mitigations is shown for the 5th 




 Storage  
Time & Temp 
Ripening Time Pasteurization Distribution 
Temp 
5th percentile 6.90 7.40 -0.50 5.50 
Mean 7.50 8.25 0.25 6.10 
95th percentile 8.00 8.75 0.75 6.60 
 
Figure 4.14:  Variability and uncertainty for probability of exceeding contamination level per 
dose for various mitigation strategies:  (a) reduction in storage temp and time, (b) increase in 
ripening time, (c) pasteurization, and (d) reduction in distribution temperatures, superimposed 
with mean baseline results 
 
 
Figure 4.14a shows the probability of exceeding the contamination level per 
dose for the reduced storage time and temperature mitigation strategy.  This 
mitigation strategy results in a 0.72 probability of exceeding an E. coli O157:H7 
contamination level of 6.5 CFU/dose, with a 90% uncertainty range from 0.59-0.82.  
Figure 4.14b shows the results for the increased ripening time mitigation strategy.  
The probability of exceeding an E. coli O157:H7 contamination level of 6.5 
CFU/dose is 0.82, with a 90% confidence interval of 0.73-0.90.  Figure 4.14c depicts 
the results of pasteurization on the estimated contamination level per dose.  The 
results show a 0.00 probability of exceeding a contamination level of 6.5 CFU/dose.  
Effectively, there is only a 0.40 probability of exceeding a contamination level of 1 






























































































shows the results the decrease in distribution temperatures on the E. coli O157:H7 per 
dose.   There is a 0.34 probability of exceeding a contamination level of 6.5 
CFU/dose, with a 90% uncertainty range of 0.14-0.54.   
The baseline case study resulted in a 0.89 probability of exceeding an E. coli 
O157:H7 contamination level of 6.5 CFU/dose, with a 90% uncertainty range of 0.81-
0.94.  The reduced milk storage time and temperature, pasteurization, and decreased 
distribution temperatures all provide significant reductions in the E. coli O157:H7 
contamination per dose, as there is no overlap between the uncertainty ranges for 
these mitigations and the baseline uncertainty range.  However, the pasteurization 
mitigation provides the most dramatic decreases in contamination, followed by the 
decrease in distribution temperatures.  The increased ripening time alone decreases 
contamination as well; however, the mean for this mitigation strategy is still within 
the uncertainty range for the baseline results, suggesting the difference is not as 
significant as the other options.   
         4.3.3.1.4  Number of Illnesses Given Dose 
Finally, the effect of the various single step mitigation strategies on the 
number of illnesses given the ingested dose is examined for a population of 1,500 
people.  Again, the estimate of the number of illnesses given the ingested dose is 
dependent on both the dose-response model selected and the data sets selected for the 
parameter estimates of the model, as well as the number of people affected in the 
outbreak.  The number of illnesses is estimated for each of the mitigation strategies 
using the all human E. coli and AHP weighted-average beta-Poisson dose-response 
models.  The all human E. coli dose-response model is considered to provide the least 
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conservative estimate, while the AHP weighted-average provides a more conservative 
estimate.  Figure 4.15 shows the predicted distribution of the number of illnesses 
given the ingested dose for the various single step mitigation strategies along with the 
baseline mean based on the beta-Poisson dose-response model for the all human E. 
coli data set.  A numerical comparison of the number of illnesses for the all human E. 
coli beta-Poisson dose-response model for the various single step mitigation strategies 
is shown for the 5th percentile, mean, and 95th percentile of the 0.50 probability of 
exceedance.  
 
 Storage  
Time & Temp 
Ripening Time Pasteurization Distribution 
Temp 
5th percentile 600 950 0 130 
Mean 800 1100 0 300 
95th percentile 1000 1200 0 530 
 
Figure 4.15:  Variability and uncertainty for number of illnesses given ingested dose using all 
human E. coli beta-Poisson model for various mitigation strategies:  (a) reduction in storage 
temp and time, (b) increase in ripening time, (c) pasteurization, and (d) reduction in distribution 
temperatures, superimposed with mean baseline results 
 
 
Figure 4.15a shows the probability of exceeding the number of illnesses given 
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time and temperature mitigation strategy.  This mitigation strategy results in a 0.83 
probability of exceeding 200 illnesses, with a 90% uncertainty range from 0.73-0.90.  
Figure 4.15b depicts the results for the increased ripening time mitigation strategy.  
The probability of exceeding 200 illnesses is 0.88, with a 90% confidence interval of 
0.81-0.92.  Figure 4.15c shows the results of pasteurization on the estimated number 
of illnesses.  The results show a 0.13 probability of exceeding 1 illness, with a 90% 
uncertainty range of 0.08-0.17; it should be noted that the baseline mean is not plotted 
on Figure 4.15c due to the different x-axis scales.  Finally, Figure 4.15d depicts the 
results of decreased distribution temperatures on the estimated number of illnesses.  
There is a 0.64 probability of exceeding 200 illnesses, with a 90% uncertainty range 
of 0.37-0.82. 
  Comparison of the mitigation strategies to the baseline mean for the number 
of illnesses given the ingested dose based on the all human E. coli beta-Poisson 
model demonstrate a noticeable reduction in the number of illnesses.  The baseline 
case study resulted in a 0.95 probability of exceeding 200 illnesses, with a 90% 
uncertainty range of 0.90-0.99.  Again, the reduced milk storage time and 
temperature, pasteurization, and decreased distribution temperatures all provide 
significant reductions in the number of illnesses, as there is no overlap between the 
uncertainty ranges for these mitigations and the baseline uncertainty range.  The 
pasteurization mitigation provides the most dramatic decreases in the number of 
illnesses, as this mitigation essentially eliminates the possibility of illness.  The 
increased ripening time decreases the number of illnesses as well; however, the mean 
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for this mitigation strategy is still within the uncertainty range for the baseline results, 
suggesting the difference is not as significant as the other options.   
 The number of illnesses given the ingested dose is also estimated using the 
AHP weighted-average beta-Poisson model, as this model provides a more 
conservative estimate.  Figure 4.16 shows both the variability and uncertainty of the 
predicted distribution of the number of illnesses given the ingested dose for the 
various mitigation strategies along with the baseline mean based on the AHP 
weighted-average beta-Poisson dose-response model. A numerical comparison of the 
number of illnesses for the AHP weighted-average beta-Poisson dose-response model 
for the various single step mitigation strategies is shown for the 5th percentile, mean, 
and 95th percentile of the 0.50 probability of exceedance. 
 
 Storage  
Time & Temp 
Ripening Time Pasteurization Distribution 
Temp 
5th percentile 1150 1300 25 850 
Mean 1250 1330 40 1000 
95th percentile 1300 1350 90 1125 
 
Figure 4.16:  Variability and uncertainty for number of illnesses given ingested dose using AHP 
weighted-average beta-Poisson model for various mitigation strategies:  (a) reduction in storage 
temp and time, (b) increase in ripening time, (c) pasteurization, and (d) reduction in distribution 
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Figure 4.16a shows the probability of exceeding the number of illnesses given 
the ingested dose based on the AHP weighted-average beta-Poisson dose-response 
model for an exposed population of 1,500 people for the reduced storage time and 
temperature mitigation strategy.  There is a 1.00 probability of exceeding 200 
illnesses; there is a 0.88 probability of exceeding 800 illnesses, with a 90% 
confidence interval for the probability of exceedance of 0.81-0.93.  Figure 4.16b 
shows the results for the increased ripening time mitigation strategy.  The probability 
of exceeding 200 illnesses is 1.00; there is a 0.92 probability of exceeding 800 
illnesses, with a 90% uncertainty range of 0.86-0.96.  Figure 4.16c depicts the results 
of pasteurization on the estimated number of illnesses; the baseline mean is not 
plotted due to the different x-axis scales.  Figure 4.16c has a 0.28 probability of 
exceeding 200 illnesses, with a 90% confidence interval for the exceedance 
probability of 0.22-0.35.  There is a 0.03 probability of exceeding 800 illnesses, with 
a 90% uncertainty range of 0.01-0.04.  Finally, Figure 4.16d depicts the results of the 
decreased distribution temperature on the number of illnesses given the ingested dose, 
with a 1.00 probability of exceeding 200 illnesses.  There is a 0.78 probability of 
exceeding 800 illnesses, with a 90% uncertainty range of 0.60-0.90. 
 Comparison of the mitigation strategies to the baseline mean for the number 
of illnesses given the ingested dose based on the AHP weighted-average beta-Poisson 
model demonstrate a reduction in the number of illnesses given the ingested dose as 
well.  The baseline case study resulted in a 1.00 probability of exceeding 200 
illnesses; there is a 0.97 probability of exceeding 800 illnesses, with a 90% 
uncertainty range of 0.94-1.00.  The reduced milk storage time and temperature, 
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pasteurization, and decreased distribution temperatures all provide significant 
reductions in the number of illnesses, as there is no overlap between the uncertainty 
ranges for these mitigations and the baseline uncertainty range.  The pasteurization 
mitigation provides the most dramatic decreases in the number of illnesses, as this 
mitigation reduces the number of illnesses by more than factor of ten.  The increased 
ripening time decreases the number of illnesses as well; however, the mean for this 
mitigation strategy is still within the uncertainty range for the baseline results, 
suggesting the difference is not as significant as the other options.   
      4.3.3.2  Multiple Step Mitigation Strategies 
 The single step mitigation strategies previously explored are combined in 
order to examine the effect of changes in multiple steps on the E. coli O157:H7 
contamination at various steps throughout the model.  From the single step 
mitigations examined, it is obvious that pasteurization provides the most significant 
impact on the contamination level and, therefore, the adverse health consequences; 
however, raw milk cheeses are still very popular.  The purpose of the multiple step 
mitigations is to determine if a series of improvements in the production and 
distribution phases can eliminate enough contamination to make a “safe” cheese.  In 
addition, pasteurization is added to these multiple step mitigations in order to show 
the best possible outcomes for the given initial contamination level.  The 
combinations explored in the multiple step mitigations are:  (a) reduced milk storage 
time and temperature and increased ripening time, (b) reduced milk storage time and 
temperature, increased ripening time, and reduced distribution temperatures, (c) 
reduced milk storage time and temperature, increased ripening time, and 
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pasteurization, and (d) reduced milk storage time and temperature, increased ripening 
time, reduced distribution temperatures, and pasteurization.  It should be noted that 
the reduced milk storage time and temperature, increased ripening time, reduced 
distribution temperatures, and pasteurization mitigation represents ideal handling and 
conditions throughout the production and distribution phases.  
         4.3.3.2.1  Contamination after Production 
The number of E. coli O157:H7 in 1 kg of cheese after production is estimated 
for each of the four multiple step mitigation strategies imposed.  Figure 4.17 shows 
the predicted distribution of E. coli O157:H7 after production for the multiple step 
mitigation strategies affecting the production phase along with the baseline mean.  A 
numerical comparison of the contamination level after production for the multiple 
step mitigations for the 5th percentile, mean, and 95th percentile of the 0.50 probability 
of exceedance is also shown. 
 
 Storage Time & Temp, 
Ripening Time 
Storage Time & Temp, 
Ripening Time, Pasteurization 
5th percentile 5.50 -2.50 
Mean 6.00 -2.00 
95th percentile 6.30 -1.50 
 
Figure 4.17:  Variability and uncertainty for probability of exceeding contamination level per 1 
kg cheese after production for multiple step mitigation strategies:  (a) reduction in storage time 
and temperature and increase in ripening time, (b) reduction in storage time and temperature, 





















































It should be noted that Figure 4.17 only shows the results for the multiple step 
mitigations that affect the production phase.  The affect of changes made to the 
distribution phase will not affect the contamination after production.  Figure 4.17a 
shows the probability of exceeding the contamination level per 1 kg cheese after 
production for the combined effects of reduced storage time and temperature and 
increased ripening time.  There is a 0.99 probability of exceeding an E. coli O157:H7 
contamination level of 1.0 CFU/kg, with a 90% uncertainty range from 0.98-1.00.  
The probability of exceeding an E. coli O157:H7 contamination level of 6.5 CFU/kg 
is 0.34, with a 90% uncertainty range of 0.16-0.58.  Figure 4.17b shows the results for 
the combination of reduced storage time and temperature, increase ripening time, and 
pasteurization.  The probability of exceeding an E. coli O157:H7 contamination level 
of 1.0 CFU/kg is 0.05, with a 90% confidence interval of 0.02-0.11.  The probability 
of exceeding a contamination level of 6.5 CFU/kg is 0.00.  
 The baseline result has a 0.79 probability of exceeding an E. coli O157:H7 
contamination level of 6.5 CFU/kg, with a 90% confidence interval from 0.65-0.94.  
The reduced storage time and temperature and increased ripening time mitigation 
provides a significant reduction in the contamination level, as there is no overlap of 
the uncertainty range with the baseline; however, the contamination level after 
production is still very high.  The addition of pasteurization to the reduced storage 
time and temperature and increased ripening time is noteworthy, as the contamination 




         4.3.3.2.2  Contamination after Distribution 
The number of E. coli O157:H7 in 1 kg of cheese after distribution is 
estimated for the multiple step mitigation strategies.  Figure 4.18 shows the predicted 
distribution of E. coli O157:H7 after distribution along with the baseline mean.  A 
numerical comparison of the contamination level after distribution for the various 
multiple step mitigations is shown for the 5th percentile, mean, and 95th percentile of 
the 0.50 probability of exceedance. 
 
 Storage Time & 
Temp, Ripening 
Time 















5th percentile 8.00 5.50 -0.10 -2.75 
Mean 8.50 6.00 0.50 -2.00 
95th percentile 9.10 6.30 1.00 -1.50 
 
Figure 4.18:  Variability and uncertainty for probability of exceeding contamination level per 1 
kg cheese after production for multiple step mitigation strategies:  (a) reduction in storage time 
and temperature and increase in ripening time, (b) reduction in storage time and temperature, 
increase in ripening time, and reduction in distribution temperatures, (c) reduction in storage 
time and temperature, increase in ripening time, and pasteurization, and (d) reduction in storage 
time and temperature, increase in ripening time, reduction in distribution temperatures, and 
































































































Figure 4.18a shows the results for the combined mitigation of reduced storage 
time and temperature and increased ripening time; there is a 0.82 probability of 
exceeding a contamination level of 6.5 CFU/kg, with a 90% uncertainty range of 
0.77-0.87.  For this combined mitigation, there is a 1.00 probability of exceeding a 
contamination level of 1.0 CFU/kg.  Figure 4.18b examines the effects of reduced 
storage time and temperature, increased ripening time, and reduced distribution 
temperatures.  This results in a 0.33 probability of exceeding 6.5 CFU/kg, with a 90% 
confidence interval for the probability of exceedance of 0.16-0.41.  There is a 0.99 
probability of exceeding 1.0 CFU/kg, with a 90% confidence interval of 0.98-1.00.  
Figure 4.18c shows the results for the combined effects of reduced storage time and 
temperature, increased ripening time, and pasteurization.  This multiple step 
mitigation results in a 0.00 probability of exceeding 6.5 CFU/kg.  The probability of 
exceeding a 1.0 CFU/kg contamination level is 0.41, with a 90% uncertainty range of 
0.32-0.51.  Finally, 4.18d explores the effects of reduced storage time and 
temperature, increased ripening time, reduced distribution temperatures, and 
pasteurization.  There is a 0.00 probability of exceeding a contamination level of 6.5 
CFU/kg.  In addition, there is a 0.07 probability of exceeding 1.0 CFU/kg, with a 90% 
confidence interval of 0.03-0.12.   
The baseline mean has a 0.97 probability of exceeding an E. coli O157:H7 
contamination level of 6.5 CFU/kg, with a 90% confidence interval from 0.95-1.00.  
When compared with the mean baseline result, the reduced storage time and 
temperature and increased ripening time mitigation provides the smallest reduction in 
contamination; the addition of reduced distribution temperatures to this mitigation 
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strategy results in a marked improvement.  However, pasteurization is still key in 
eliminating E. coli O157:H7 contamination.  It should be noted that the combination 
of reduced storage time and temperature, increased ripening time, decreased 
distribution temperatures, and pasteurization mitigation strategy represents proper 
handling of the cheese in the production and distribution phases.  The model shows 
that even with a moderate level of initial contamination, a relatively “safe” cheese can 
still be produced with pasteurization and proper handling.   
         4.3.3.2.3  Contamination per Dose 
The effect of the multiple step mitigation strategies on the contamination of E. 
coli O157:H7 per dose is also explored.  Based on the E. coli O157:H7 contamination 
per serving and the number of servings consumed, the dose is estimated for the 
various multiple step mitigation strategies.  Figure 4.19 shows the predicted 
distribution of E. coli O157:H7 contamination per dose for the multiple step 
mitigations along with the baseline mean.  A numerical comparison of the 
contamination level per dose for the various multiple step mitigations for the 5th 
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Temp, Ripening 
Time 















5th percentile 6.60 4.20 -1.50 -4.00 
Mean 7.25 4.75 -1.00 -3.50 
95th percentile 7.50 5.25 -0.25 -2.75 
 
Figure 4.19:  Variability and uncertainty for probability of exceeding contamination level per 
dose for multiple step mitigation strategies:  (a) reduction in storage time and temperature and 
increase in ripening time, (b) reduction in storage time and temperature, increase in ripening 
time, and reduction in distribution temperatures, (c) reduction in storage time and temperature, 
increase in ripening time, and pasteurization, and (d) reduction in storage time and temperature, 
increase in ripening time, reduction in distribution temperatures, and pasteurization, 
superimposed with mean baseline results 
 
 
Figure 4.19a shows the results for the combined mitigation of reduced storage 
time and temperature and increased ripening time; there is a 0.64 probability of 
exceeding a contamination level of 6.5 CFU/kg, with a 90% uncertainty range of 
0.53-0.75.  For this combined mitigation, there is a 0.99 probability of exceeding a 
contamination level of 1.0 CFU/kg, with a 90% uncertainty range of 0.98-1.00.  
Figure 4.19b examines the effects of reduced storage time and temperature, increased 
ripening time, and reduced distribution temperatures.  This results in a 0.05 






























































































probability of exceedance of 0.00-0.11.  There is a 0.97 probability of exceeding 1.0 
CFU/kg, with a 90% confidence interval of 0.96-0.98.  Figure 4.19c shows the results 
for the combined effects of reduced storage time and temperature, increased ripening 
time, and pasteurization.  This multiple step mitigation results in a 0.00 probability of 
exceeding 6.5 CFU/kg.  The probability of exceeding a 1.0 CFU/kg contamination 
level is 0.24, with a 90% uncertainty range of 0.18-0.27.  Finally, 4.19d explores the 
effects of reduced storage time and temperature, increased ripening time, reduced 
distribution temperatures, and pasteurization.  There is a 0.00 probability of 
exceeding a contamination level of 6.5 CFU/kg.  In addition, there is only a 0.01 
probability of exceeding 1.0 CFU/kg, with a 90% confidence interval of 0.00-0.01.   
The baseline mean has a 0.89 probability of exceeding an E. coli O157:H7 
contamination level of 6.5 CFU/kg, with a 90% confidence interval from 0.81-0.94.  
Again, when compared to the baseline mean, the most significant reductions in 
contamination are seen with the mitigation strategies involving pasteurization.  The 
mitigation strategy representing proper handling eliminates almost all contamination.  
The reduced storage time and temperature, increased ripening time, and 
pasteurization strategy also significantly reduces contamination.  However, 
comparison of these two mitigation strategies also demonstrates the significant impact 
temperature abuse during the distribution phase has on the contamination levels.     
 201
 
         4.3.3.2.4  Number of Illnesses Given Dose 
Finally, the effect of the multiple step mitigation strategies on the number of 
illnesses given the ingested dose is examined for a population of 1,500 people.  The 
number of illnesses is estimated for each of the mitigation strategies using the all 
human E. coli and AHP weighted-average beta-Poisson dose-response models.  
Figure 4.18 shows the predicted distribution of the number of illnesses given the 
ingested dose for the mitigation strategies along with the baseline mean for the all 
human E. coli beta-Poisson dose-response model.  A numerical comparison of the 
number of illnesses for the all human E. coli beta-Poisson dose-response model for 
the various multiple step mitigation strategies is shown for the 5th percentile, mean, 
and 95th percentile of the 0.50 probability of exceedance. 
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 Storage Time & 
Temp, Ripening 
Time 















5th percentile 500 25 0 0 
Mean 700 50 0 0 
95th percentile 900 80 0 0 
 
Figure 4.20:  Variability and uncertainty for number of illnesses given ingested dose using all 
human E. coli beta-Poisson model for multiple step mitigation strategies:  (a) reduction in 
storage time and temperature and increase in ripening time, (b) reduction in storage time and 
temperature, increase in ripening time, and reduction in distribution temperatures, (c) reduction 
in storage time and temperature, increase in ripening time, and pasteurization, and (d) reduction 
in storage time and temperature, increase in ripening time, reduction in distribution 
temperatures, and pasteurization, superimposed with mean baseline results 
 
 
Figure 4.20a shows the probability of exceeding the number of illnesses given 
the ingested dose based on the all human E. coli beta-Poisson dose-response model 
for an exposed population of 1,500 for the reduced storage time and temperature and 
increased ripening time mitigation strategy.  There is a 0.75 probability of exceeding 
200 illnesses, with a 90% uncertainty range of 0.67-0.83; in contrast, there is a 0.45 
probability of exceeding 800 illnesses, with a 90% confidence interval for the 
probability of exceedance of 0.34-0.57.  Figure 4.20b examines the effects of reduced 
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temperatures for the all human E. coli beta-Poisson dose-response model.  There is a 
0.19 probability of exceeding 200 illnesses, with a 90% uncertainty range of 0.05-
0.33.  Figures 4.20c and d show these same mitigations with the addition of 
pasteurization, but are shown a different scale.  For the reduced storage time and 
temperature, increased ripening time, and pasteurization mitigation strategy there is a 
0.04 probability of exceeding 1 illness, with a 90% uncertainty range from 0.02-0.07.  
For the reduced storage time and temperature, increased ripening time, reduced 
distribution temperatures, and pasteurization mitigation strategy essentially eliminates 
the possibility of illness, as there is a 0.00 probability of exceeding 1 illness.    
 For the all human E. coli beta-Poisson model, the baseline case study results 
in a 0.95 probability of exceeding 200 illnesses, with a 90% uncertainty range of 
0.90-0.99; the probability of exceeding 800 illnesses is 0.74, with a 90% confidence 
interval of 0.64-0.84.  Comparison of the reduced storage time and temperature and 
increased ripening time multiple step mitigation strategy to the baseline mean for the 
number of illnesses given the ingested dose demonstrates only a small reduction in 
the number of illnesses given the ingested dose.  The combined effects of reduced 
storage time and temperature, increased ripening time, and reduced distribution 
temperatures have more significant results as compared to the baseline.  However, the 
most dramatic decrease in illness is seen with the addition of pasteurization to the 
mitigation strategies; both multiple step mitigation strategies involving pasteurization 
effectively eliminate illness from occurring.     
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Figure 4.21 shows the results of the number of illnesses given the ingested dose for 
the multiple step mitigation strategies along with the baseline mean for the AHP 
weighted-average dose-response model.  A numerical comparison of the number of 
illnesses for the AHP weighted-average beta-Poisson dose-response model for the 
various multiple step mitigation strategies is shown for the 5th percentile, mean, and 
95th percentile of the 0.50 probability of exceedance. 
 
 Storage Time & 
Temp, Ripening 
Time 















5th percentile 1100 580 5 0 
Mean 1200 675 8 0 
95th percentile 1275 775 10 0 
 
Figure 4.21:  Variability and uncertainty for Number of Illnesses given Ingested Dose using AHP 
weighted-average beta-Poisson model for multiple step mitigation strategies:  (a) reduction in 
storage time and temperature and increase in ripening time, (b) reduction in storage time and 
temperature, increase in ripening time, and reduction in distribution temperatures, (c) reduction 
in storage time and temperature, increase in ripening time, and pasteurization, and (d) reduction 
in storage time and temperature, increase in ripening time, reduction in distribution 
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Figure 4.21a shows the probability of exceeding the number of illnesses given 
the ingested dose based on the AHP weighted-average beta-Poisson dose-response 
model for an exposed population of 1,500 for the reduced storage time and 
temperature and increased ripening time mitigation strategy.  There is a 0.99 
probability of exceeding 200 illnesses, with a 90% uncertainty range of 0.99-1.00; 
there is a 0.81 probability of exceeding 800 illnesses, with a 90% confidence interval 
for the probability of exceedance of 0.73-0.88.  Figure 4.21b examines the effects of 
reduced storage time and temperature, increased ripening time, and reduced 
distribution temperatures for the AHP weighted-average beta-Poisson dose-response 
model.  There is a 0.96 probability of exceeding 200 illnesses, with a 90% uncertainty 
range of 0.93-0.98.  In addition, there is a 0.30 probability of exceeding 800 illnesses, 
with a 90% uncertainty range of 0.13-0.45.  Figures 4.21c and d show these same 
mitigations with the addition of pasteurization.  Figure 4.21c shows there is a 0.16 
probability of exceeding 200 illnesses, with a 90% uncertainty range of 0.10-0.21.  
There is a 0.00 probability of exceeding 800 illnesses.  Figure 4.21d shows a 0.14 
probability of exceeding 1 illnesses, with a 90% uncertainty range of 0.07-0.19. 
 For the AHP weighted-average beta-Poisson model, the baseline case study 
results in a 1.00 probability of exceeding 200 illnesses; the probability of exceeding 
800 illnesses is 0.97, with a 90% confidence interval of 0.94-1.00.  Comparison of the 
reduced storage time and temperature and increased ripening time multiple step 
mitigation strategy to the baseline mean for the number of illnesses given the ingested 
dose demonstrates only a small reduction in the number of illnesses given the 
ingested dose.  The combined effects of reduced storage time and temperature, 
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increased ripening time, and reduced distribution temperatures have more significant 
results as compared to the baseline.  However, the most dramatic decrease in illness is 
seen with the addition of pasteurization to the mitigation strategies.  Reduced storage 
time and temperature, increased ripening time, and pasteurization leads to a factor of 
ten reduction in the number of illnesses, while the addition of decreased distribution 
temperatures to this mitigation strategy results in a factor of 100 reduction in the 
number of illnesses.   
   4.3.4  Worst-Case Sensitivity Analyses 
In addition to being a risk assessment and risk management tool, the model 
can also be used for sensitivity analysis.  The baseline case study represents a 
moderate level of initial contamination and moderately abusive production and 
distribution phases; the results show that under these conditions, potentially high 
levels of E. coli O157:H7 can develop in the cheese and resulting in serious adverse 
health consequences.  The results of the mitigation strategies demonstrate that 
pasteurization is a key step in the reduction of E. coli O157:H7 contamination in 
cheese.  The purpose of the worst-case analysis is to examine the effects of 
pasteurization under high levels of initial contamination and severe abuse during the 
production and distribution phases.   
Two worst-case analyses are investigated in order to determine the sensitivity 
of the model to pasteurization, severe abuse, and initial contamination.  Table 4.5 
provides a comparison between the baseline selections and the worst-case selections 
for the production and distribution phases.  The results of these worst-case analyses 
are compared to the baseline results for the contamination level after production, the 
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contamination level after distribution, the contamination level per dose, and the 
number of illnesses given the ingested dose for the all human E. coli beta-Poisson 
model and AHP weighted-average dose-response model.   
 
 
Table 4.5:  Production and Distribution Selections for Baseline and Worst-Case Simulations 
Step Sub-System 
Element Description  






A0 Initial E. coli O157:H7 
Contamination (CFU/ml) 
10 ± 10 CFU/ml 10 ± 10 CFU/ml 100 ± 100 CFU/ml 
A1 Contamination after Milk 
Storage 
2 days; 5˚C<T< 8˚C 5 days; T> 8˚C 5 days; T> 8˚C 








A3 Contamination after 
Addition of Coagulant 
Mesophilic Mesophilic Mesophilic 
A4 Contamination after 
Cutting of Curd 
--- --- --- 
A5 Contamination after 
Cooking of Curd 
36˚C ≤ Temp ≤ 40˚C 
 
36˚C ≤ Temp ≤ 40˚C 
 
36˚C ≤ Temp ≤ 40˚C 
 
A6 Contamination after 
Separation of Curd and 
Whey 
--- --- --- 
A7 Contamination after 
Salting 
Dry Dry Dry 
A8 Contamination after 
Hooping and Pressing 
--- --- --- 
A9 Contamination after 
Packaging and Ripening 
75 days 45 days 45 days 
B1 Contamination after 
Storage, before 
Transportation 
pH 6.0; 1-24 hours; 5˚C pH 6.0; 1-24 hours; 10˚C pH 6.0; 1-24 hours; 5˚C 
B2 Contamination after 
Transportation to Retail 
1-12 hours; 10˚C 1-12 hours; 10˚C 1-12 hours; 5˚C 
B3 Contamination after Retail 
Storage 
1-120 hours; 5˚C 1-120 hours; 10˚C 1-120 hours; 5˚C 
B4 Contamination after 
Transportation  to 
Consumer 
1-2 hours; 12˚C 1-2 hours; 10˚C 1-2 hours; 5˚C 
B5 Contamination after 
Consumer Storage 
1-336 hours; 5˚C 1-336 hours; 10˚C 1-336 hours; 5˚C 
 
 
      4.3.4.1  Contamination after Production 
The number of E. coli O157:H7 in 1 kg of cheese after production is estimated 
for both of the worst-case analyses.  Figure 4.22 shows the predicted distribution of 
E. coli O157:H7 after production for the worst-case analyses along with the baseline 
mean.  A numerical comparison of the contamination level after production for the 
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worst-case analyses for the 5th percentile, mean, and 95th percentile of the 0.50 
probability of exceedance is also shown. 
 
 Worst-Case  
Production & Distribution 
Worst-Case Initial 
Contamination & Production 
5th percentile -0.50 0.25 
Mean -0.10 0.75 
95th percentile 0.60 1.30 
 
Figure 4.22:  Variability and uncertainty for probability of exceeding contamination level per 1 
kg cheese after production for worst case analyses (a) worst-case production and distribution 
selections, (b) worst-case initial contamination and production selections, superimposed with 
mean baseline results 
 
  
 Figure 4.22a shows the probability of exceeding the contamination level per 1 
kg cheese after production for the worst-case production and distribution selections.  
There is a 0.29 probability of exceeding an E. coli O157:H7 contamination level of 
1.0 CFU/kg, with a 90% uncertainty range from 0.21-0.42.  Figure 4.22b shows the 
results for the worst-case initial contamination and production selections.  The 
probability of exceeding an E. coli O157:H7 contamination level of 1.0 CFU/kg is 
0.47, with a 90% confidence interval of 0.38-0.56.  In comparison, the baseline result 
has a 1.00 probability of exceeding a contamination level of 1.0 CFU/kg.  Both worst-
case analyses demonstrate that despite severe abuse conditions, pasteurization still 




















































case analyses shows that the higher initial contamination level results in a 
significantly higher contamination after production. 
      4.3.4.2  Contamination after Distribution 
The number of E. coli O157:H7 in 1 kg of cheese after distribution is 
estimated for both of the worst-case analyses imposed.  Figure 4.23 shows the 
predicted distribution of E. coli O157:H7 after distribution for the worst cases 
analyses along with the baseline mean.  A numerical comparison of the contamination 
level after distribution for the worst-case analyses is shown for the 5th percentile, 
mean, and 95th percentile of the 0.50 probability of exceedance. 
 
 Worst-Case  
Production & Distribution 
Worst-Case Initial 
Contamination & Production 
5th percentile 5.00 0.25 
Mean 6.50 0.75 
95th percentile 7.50 1.30 
 
Figure 4.23:  Variability and uncertainty for probability of exceeding contamination level per 1 
kg cheese after distribution for worst case analyses (a) worst-case production and distribution 
selections, (b) worst-case initial contamination and production selections, superimposed with 
mean baseline results 
 
 Figure 4.23a shows the probability of exceeding the contamination level per 1 
kg cheese after distribution for the worst-case production and distribution selections.  
There is a 0.87 probability of exceeding an E. coli O157:H7 contamination level of 
1.0 CFU/kg, with a 90% uncertainty range from 0.79-0.96.  Figure 4.23b shows the 




















































probability of exceeding an E. coli O157:H7 contamination level of 1.0 CFU/kg is 
0.47, with a 90% confidence interval of 0.38-0.56.  In comparison, the baseline result 
has a 1.00 probability of exceeding a contamination level of 1.0 CFU/kg.  It is 
apparent that pasteurization makes a significant impact on the level of contamination 
after distribution as compared to the baseline.  However, the worst-case selections for 
distribution temperatures significantly increase the E. coli O157:H7 contamination 
level.  In fact, the worst-case distribution temperatures have more of an impact on the 
contamination level after distribution than high levels of initial contamination.  In 
addition, when the worst-case initial contamination and production analysis is 
compared to the contamination after production in Figure 4.22b, it is also apparent 
that when distribution temperatures are kept at 5ºC, no increase in contamination 
occurs.   
      4.3.4.3  Contamination per Dose 
 The effect of the worst-case analyses on the contamination of E. coli 
O157:H7 per dose is also explored.  Based on the E. coli O157:H7 contamination per 
serving and the number of servings consumed, the dose is estimated for the worst-
case analyses.  Figure 4.24 shows the predicted distribution of E. coli O157:H7 
contamination per dose along with the baseline mean.  A numerical comparison of the 
contamination per dose for the worst-case analyses for the 5th percentile, mean, and 
95th percentile of the 0.50 probability of exceedance is also shown. 
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 Worst-Case  
Production & Distribution 
Worst-Case Initial 
Contamination & Production 
5th percentile 4.00 -1.00 
Mean 5.00 -0.50 
95th percentile 6.50 0.05 
 
Figure 4.24:  Variability and uncertainty for probability of exceeding contamination level per 
dose for worst case analyses (a) worst-case production and distribution selections, (b) worst-case 
initial contamination and production selections, superimposed with mean baseline results 
 
 
Figure 4.24a shows the probability of exceeding the contamination level per 1 
dose for the worst-case production and distribution selections.  There is a 0.80 
probability of exceeding an E. coli O157:H7 contamination level of 1.0 CFU/kg, with 
a 90% uncertainty range from 0.68-0.90.  Figure 4.23b shows the results for the 
worst-case initial contamination and production selections.  The probability of 
exceeding an E. coli O157:H7 contamination level of 1.0 CFU/kg is 0.27, with a 90% 
confidence interval of 0.18-0.35.  In comparison, the baseline result has a 1.00 
probability of exceeding a contamination level of 1.0 CFU/kg.  Again, the 
temperature abuse during the distribution phase has a significant impact on the 
contamination level per dose.   
      4.3.4.4  Number of Illnesses Given Dose 
The effect of both worst-case analyses on the number of illnesses given the 
ingested dose is examined for a population of 1,500 people. The number of illnesses 




















































weighted-average beta-Poisson dose-response models.  Figure 4.25 shows the 
predicted distribution of the number of illnesses given the ingested dose for the worst-
case analyses along with the baseline.  A numerical comparison of the number of 
illnesses for the all human E. coli beta-Poisson and AHP weighted-average beta-
Poisson dose-response models for the worst-case analyses is shown for the 5th 
percentile, mean, and 95th percentile of the 0.50 probability of exceedance. 
 











Initial Cont. & 
Production 
5th percentile 75 0 550 5 
Mean 100 0 750 8 
95th percentile 500 0 1100 10 
 
Figure 4.25:  Variability and uncertainty for number of illnesses given ingested dose for worst 
case analyses using all human E. coli beta-Poisson dose-response model for (a) worst-case 
production and distribution selections, (b) worst-case initial contamination and production 
selections, and using AHP weighted-average beta-Poisson dose-response model for (c) worst-case 
production and distribution selections, (d) worst-case initial contamination and production 
selections, superimposed with mean baseline results 
 
 
Figure 4.25a shows the probability of exceeding the number of illnesses given 
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for an exposed population of 1,500 for the worst case production and distribution 
selections.  There is a 0.46 probability of exceeding 200 illnesses, with a 90% 
uncertainty range of 0.37-0.57.  Figure 4.25b examines the effects of the worst case 
initial contamination and production selections for the all human E. coli beta-Poisson 
dose-response model.  There is a 0.05 probability of exceeding 1 illness, with a 90% 
confidence range from 0.02-0.08.  Figure 4.25c shows the probability of exceeding 
the number of illnesses given the ingested dose based on the AHP weighted-average 
beta-Poisson dose-response model for an exposed population of 1,500 for the worst-
case production and distribution selections.  There is a 0.76 probability of exceeding 
200 illnesses, with a 90% uncertainty range of 0.64-0.89.  Figure 4.25d examines the 
effects of the worst-case initial contamination and production selections for the all 
human E. coli beta-Poisson dose-response model.  There is a 0.37 probability of 
exceeding 20 illnesses, with a 90% uncertainty range of 0.29-0.48.   
 For the all human E. coli beta-Poisson model, the baseline case study resulted 
in a 0.95 probability of exceeding 200 illnesses, with a 90% uncertainty range of 
0.90-0.99.  Again, these worst-case analyses indicate that pasteurization is extremely 
effective in reducing the consequences of E. coli O157:H7 contamination.  It is also 
interesting to note that temperature abuse during the distribution phase is worse, in 
terms of number of resulting illnesses, than a high level of initial contamination.  For 
the AHP weighted-average beta-Poisson model, the baseline case study resulted in a 
100% probability of exceeding 200 illnesses.  Even with the more conservative 
estimates of the AHP weighted-average model, the impact of pasteurization is 
obvious.  Again, the results for the AHP weighted-average beta-Poisson model 
 214
emphasize the fact that initial contamination levels are less important than controlling 
temperature abuse during the distribution phase.     
 
4.4  Discussion of Results 
Several conclusions can be made from the successful application of the 
engineering-based decomposition methodology to the problem of E. coli O157:H7 
contamination in cheese.  First, in terms of model uncertainty, the results show there 
is not a significant difference between the beta-Poisson and Weibull-Gamma models 
for the data sets investigated; this holds true for the AHP weighted-average models as 
well.  Although there are slight differences in the shapes of the curves, in general, the 
areas of uncertainty of the two models overlap indicating that the difference is not 
significant.   
In terms of the parameter uncertainty of the dose-response models, there is 
wide dispersion among the results.  The differences in the probability of illness 
estimated with the three data sets emphasize the difficulty of developing the dose-
response parameters for E. coli O157:H7.  Due to ethical considerations, surrogate 
pathogen and E. coli O157:H7 animal data must be used for parameter estimation.  
The three data sets (i.e., all human E. coli, E. coli O157:H7 rabbit, and S. dysenteriae) 
used for parameter estimation of the beta-Poisson and Weibull-Gamma models are 
those data sets that resulted in significant fits (i.e., the minimum deviance did not 
exceed the 5th percentile of the χ2 distribution); however, the results generated using 
these data sets are significantly different.  The results show that the all human E. coli 
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data set provides the least conservative estimate of the probability of illness, followed 
by the E. coli O157:H7 rabbit and S. dysenteriae data sets.   
While the parameter uncertainty can be assessed through comparison of the 
results, the AHP weighted-average method provides an alternative way to address the 
data uncertainty by considering all of the relevant available data and ranking the 
importance of this data.  The results show that the weighted-average models 
developed with the AHP method provide reasonable probabilities of illness.  As 
expected, the AHP weighted-average dose-response model provides a compromise 
between the least conservative probability of illness estimated with the all human E. 
coli data set and most conservative probability of illness estimated with the S. 
dysenteriae data set.  In addition, the AHP weighted-average models are validated 
with both clinical trial data and outbreak data.  The results show that the AHP 
weighted-average models provide reasonable fits to the outbreak data and the best fit 
(as compared to the all human E. coli, E. coli O157:H7 rabbit, and S. dysenteriae 
dose-response models) to the clinical trial data.  These positive results from the 
validation lend confidence to the results generated with the AHP weighted-average 
models.   
In terms of sensitivity analysis, the results show that milk heat treatment is the 
most important factor in controlling E. coli O157:H7 contamination in cheese.  In 
fact, pasteurization alone is effective in controlling contamination in a moderately 
abusive production and distribution scenario, as well as in worst-case scenarios.  The 
results also show that distribution temperatures have a significant impact on E. coli 
O157:H7 contamination.  The worst-case sensitivity analyses show that worst-case 
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distribution temperatures have more of an impact on the contamination level than 
high levels of initial contamination.  Obviously, pasteurization is effective in 
eliminating the majority of initial contamination, but temperature abuse during the 
distribution phase allows any remaining contamination to grow significantly.  The 
results of this model are also somewhat sensitive to milk storage time and 
temperature; however, ripening time had very little impact on E. coli O157:H7 
contamination levels.   
The mitigation strategies investigated also emphasize the importance of 
pasteurization.  Whether used as a single mitigation or in combination with other 
mitigations, pasteurization is the key element in eliminating E. coli O157:H7 
contamination in cheese.  In fact, even in a moderately abusive scenario, the multiple 
step mitigations that do not involve pasteurization are not enough to control 
contamination levels.   
The results shown in this chapter demonstrate the successful application of the 
engineering decomposition methodology to a food safety problem.  The reduction of 
the problem to its basic elements through the use of the DML methodology allows 
this model to represent a wide variety of cheese types, assess possible mistreatment of 
the cheese during production and distribution, evaluate potential mitigation strategies, 
and perform sensitivity analyses.  Thus, the engineering-based approach to QMRA 
results in a more flexible risk model which can be used as both a risk assessment and 
risk management tool.   
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5.  DISCUSSION 
 
5.l  Discussion Overview 
The probabilistic risk assessment model to study E. coli O157:H7 
contamination in cheese accomplishes all of the goals of a traditional quantitative 
microbial risk assessment (QMRA).  This model quantitatively accounts for the 
uncertainty of E. coli O157:H7 contamination in cheese, estimates the likelihood and 
magnitude of E. coli O157:H7 contamination at various points along the exposure 
path, predicts the various human health risks associated with ingestion of E. coli 
O157:H7 contaminated cheese, and identifies the risk-significant contributors and 
possible mitigation strategies.  However, this risk model offers advancements over 
the traditional approach as well.  First, by integrating microbial data and probabilistic-
based engineering models and methods within the traditional QMRA framework, this 
model addresses some of the deficiencies of the traditional approach.  The use of 
these non-traditional methods allows the model to account for data, parameter, and 
model uncertainty, as well as variability throughout the cheese manufacturing and 
distribution processes.  Second, the recognition and characterization of both aleatory 
and epistemic uncertainty throughout the model allows for the separation of these 
elements, and this disaggregation of total uncertainty results in a more powerful risk 
management tool.  Third, validation of the dose-response model lends credence to the 
results of the risk model; therefore, the results of the risk model can be used both as 
an absolute assessment of the risk and as a relative measurement of mitigation and 
control strategies.  Finally, the adaptation of the reductionist approach results in a 
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more systematic approach to food safety problems which captures the 
interdependencies and interrelationships of the basic elements.  While this research 
provides many improvements over previous risk assessments, it is also acknowledged 
that there are areas for improvement.  Both the advancements of this research as well 
as the areas needing improvement are discussed relative to the exposure assessment, 
dose-response assessment, and risk characterization.   
 
5.2  Advancements and Areas for Improvement 
   5.2.1  Exposure Assessment 
The use of the Dynamic Master Logic (DML) methodology in the structuring 
of the exposure assessment results in a more powerful process risk model.  Previous 
process risk models (PRM) have investigated only one specific scenario.  The DML 
methodology decomposes the system into system elements, sub-system elements, 
basic elements, and options, thus identifying the variability throughout the cheese 
manufacturing and distribution processes.  By basing both the underlying 
mathematical model and the Probabilistic Risk Assessment of E. coli O157:H7 in 
Cheese (PRAEC) interface on this hierarchical framework, any number of different 
scenarios can be analyzed.  Thus, scenarios can represent different cheese types and 
different processes among manufacturers, as well as assess the impact of abuse during 
production and distribution.  In addition, the DML concept models the relationships 
between the basic elements, thereby capturing the interdependencies.  This systematic 
approach to food safety risk assessment ensures that all relevant activities, events, 
processes, etc. are captured in the risk model, and that the associations between these 
 219
elements are also captured.  While the DML structure provides an excellent 
foundation for the model, this structure could be expanded at the top-level to provide 
an even more accurate representation of the cheese manufacturing process.  The 
scope of the exposure assessment is restricted to cheese production, distribution, and 
consumption, with the user selecting the distribution of initial contamination.  The 
model could be expanded to include the on-farm processes associated with milk 
production, and DML decomposition could be used to identify the system elements, 
sub-system elements, basic elements, and options of this process.   
Another advancement of this research is the recognition, characterization, and 
separation of aleatory and epistemic uncertainty throughout the model.  The use of a 
hierarchical structure is vital in recognizing and separating these uncertainties, with 
the DML structure identifying the variability throughout the process.  The separation 
of the aleatory and epistemic uncertainty results in the ability to identify which part of 
the total uncertainty is due to lack of knowledge and/or variability.  This 
disaggregation of total uncertainty results in a more powerful risk management tool, 
as it is possible to determine the steps that can be taken to reduce the total uncertainty 
of the model.  Additional information will reduce the epistemic uncertainty and 
improve future risk estimates, while potential changes to the physical system will 
reduce the aleatory uncertainty.  In addition, data and parameter uncertainties are 
accounted for throughout the model in a variety of ways.  These advancements in the 
characterization of uncertainty, as well as areas for improvement, are discussed 
relative to the production, distribution, and consumption phases.   
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      5.2.1.1  Production 
Modeling the growth and survival of E. coli O157:H7 in cheese during 
manufacturing and ripening is a multifaceted problem due to the complexity of cheese 
and the disparity within the experimental data.  The multiplicative factors (MF) 
method models the increase or decrease in E. coli O157:H7 contamination and 
provides a technique for addressing inconsistency, deficiency, and uncertainty 
associated with the experimental data used to describe contamination in the 
production phase; the Bayesian updating process accounts for the parameter 
uncertainty associated with the MF distributions.   
First, the cheese-making process is extremely complex because cheese itself is 
biologically and biochemically dynamic, and understanding cheese manufacturing 
and ripening involves a wide range of scientific disciplines including biology, 
microbiology, chemistry, enzymology, molecular genetics, rheology, etc. (Fox, 1993).  
Therefore, understanding the growth and survival of pathogens in cheese is also 
complex, as there are a number of factors (i.e., time, temperature, pH, salt content, 
moisture content, fat content, starter cultures, secondary cultures, etc.) that influence 
microbial growth.  The wide variety of cheeses and the variability in the cheese-
making process only further complicates the analysis of this process.   
Second, this risk assessment is based solely on experimental data and 
information available in the open literature.  Although many experiments have 
examined E. coli O157:H7 contamination levels during cheese manufacturing and 
ripening, there is much disparity among the data.  Typically, these experiments add a 
given amount of E. coli O157:H7 to milk (either pasteurized or unpasteurized) and 
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monitor the contamination level at various points during the cheese production 
process.  The amount of initial contamination and the points during production at 
which the contamination is measured varies among the experiments.  In addition, the 
contamination level during production is dependent on a number of influencing 
factors, and these experiments differ in the influencing factors monitored.  Finally, 
these experiments examine a wide variety of cheese types, leading to much variability 
in the cheese production process used.   
The MF method offers not only a simplified approach to microbial modeling, 
but also a method for dealing with multiple data sources and data limitations.  The 
MF approach deals with the data inconsistency by developing a multiplier to move 
from step to step along the production path.  Thus, the MF is concerned not with 
absolute level of contamination, but rather with the relative increase or decrease in 
contamination level.  So, despite the experimental inconsistencies in the initial 
contamination level, the MF method can be applied.  In addition, the MF method is 
flexible in that a MF can be calculated for whichever points in the cheese production 
process are monitored in the experimental data.  Finally, the MF method ignores the 
influencing factors for which there are not enough data to develop a multiplier.  This 
results in some influencing factors not being singled out in the decomposition 
process, but rather rolled into the MF.   
While the MF clearly simplifies a very complex problem and allows for 
maximum use of the experimental data, it is acknowledged that this modeling concept 
may oversimplify the problem of microbial growth in cheese.  While this method has 
the advantage of being applicable to areas which lack data, perhaps the use of 
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predictive microbial models to areas in which sufficient data exists should be 
explored.  Another possibility is to further decompose the steps with sufficient data in 
order to consider more than two influencing factors.  Results using these more 
complex MFs could then be compared to results generated with traditional microbial 
predictive models in order to determine the worthiness of the MF method.  Regardless 
of the model used to estimate the growth and survival of E. coli O157:H7 during 
manufacturing, the production phase may benefit from additional steps and further 
gradation of those steps.  For example, steps could be added in the production phase 
to allow for the possibility of re-contamination after the milk heat treatment step.   
      5.2.1.2  Distribution 
Similar to the production phase, the distribution phase uses the Bayesian 
updating procedure to account for the parameter uncertainty associated with the 
Gompertz parameters.  Furthermore, the distribution phase could also benefit from 
additional steps and further gradation.  Steps could be added to the distribution phase 
to account for both the death/inactivation of the bacteria and the growth limitations 
caused by insufficient nutrients, metabolic wastes, and competition from other 
bacteria.  The starter and secondary cultures added in the cheese-making process 
continue to allow the cheese to ripen and may inhibit the growth of microbial 
pathogens, such as E. coli O157:H7.  The effects of ripening need to be accounted for 
during the distribution phase.  This might be accomplished either through the addition 
of a dampening factor to the Gompertz equation or by using an additional model that 
considers microbial community dynamics.  One such model is the Lotka-Volterra 
competition model which provides a basic model for the population growth of two 
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interacting species (Powell et al., 2004).  Further gradation of the options at each step 
would increase the accuracy of the model as well.  For example, the distribution steps 
modeling growth of E. coli O157:H7 might be expanded to include the effects of 
sodium chloride concentration on E. coli O157:H7 growth, although data is needed to 
include this option.  Finally, the DML structure could be expanded to account for 
additional model uncertainty.  Specifically, there are a number of equations which 
model bacterial growth (i.e., Gompertz, Baranyi, three-phase linear, etc.).  The risk 
model could be improved by allowing for selection among various growth, 
inactivation, and competition models in the distribution phase.   
      5.2.1.3  Consumption 
The consumption phase could be improved through the addition of a step that 
considers the likelihood of consumption.  Currently, the model assumes that all 
people exposed in an outbreak consume the E. coli O157:H7-contaminated cheese; in 
other words, it is assumed that all people in an outbreak are equally likely to consume 
contaminated cheese.  This may not be realistic, particularly for cheese with high 
levels of contamination, and may lead to over-estimation of the number of illnesses 
and adverse health consequences.  A likelihood function for consumption would 
relate the likelihood of consuming E. coli O157:H7-contaminated cheese to the level 
of contamination.  This function would consider both mitigations to behavior and 
prohibitions to consumption in order to more accurately describe the probability of 
consuming contaminated cheese.    
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   5.2.2  Dose-Response Assessment 
The dose-response assessment clearly benefits from the adaptation of 
engineering models and methods.  First, the DML methodology allows for selection 
among various traditional and newly proposed dose-response models, thereby 
accounting for model uncertainty.  Second, the uncertainty associated with the dose-
response model is addressed in two ways.  The parameters for the dose-response 
models are estimated from a number of different data sets and the resultant 
probability of illness, calculated from the various data sets, is compared in order to 
assess the uncertainty.  Additionally, the Analytical Hierarchy Process (AHP) method 
provides an alternative way to address the data uncertainty associated with dose-
response data.  Previous research shows that various Shigella spp. and E. coli strains 
have some biological similarities to E. coli O157:H7 in terms of pathogenicity.  In 
addition, animal studies involving E. coli O157:H7 may also provide insight on 
human responses to E. coli O157:H7.  While none of these alternatives provide an 
exact relationship for an E. coli O157:H7 dose-response model, alternatives that are 
biologically similar to E. coli O157:H7 should be considered when developing a 
dose-response model for E. coli O157:H7.  The AHP method accomplishes this 
objective by developing weighted-average beta-Poisson and Weibull-Gamma dose-
response models that consider all of the available data and rank the importance of this 
data.   
Another advancement of this research is the validation of the dose-response 
model.  QMRAs have been performed to determine the risk of E. coli O157:H7 
infection from various foods, but the dose-response models used in these risk 
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assessments have yet to be fully validated.  Comparison of actual observations in 
outbreak data to the predicted observation lends credence to the developed dose-
response models.  Furthermore, the results of a validated risk model can be used both 
as an absolute assessment of the risk and as a relative measurement of mitigation and 
control strategies.  It is desirable to validate dose-response models with human 
epidemiological information; this is especially important in the case of E. coli 
O157:H7 since the underlying data are based on animal studies and surrogate 
pathogens.  Validation of the dose-response model ensures accuracy and assesses 
uncertainty.   
This research validates the dose-response models developed using the clinical 
trial data and the AHP weighted-average dose-response relationships by comparing 
the model estimates with actual human outbreak information.  The AHP weighted-
average models provide reasonable fits to the outbreak data.  In addition, it the AHP 
weighted-average models provide the best fit to all of the available clinical trial data.  
However, there are some problems with this validation.  First, the outbreak data 
available typically occurred at lower doses, whereas the clinical trial data that these 
models are based on typically utilize higher doses, making validation at lower doses 
difficult.  Despite this, the AHP weighted-average models provide a reasonable fit to 
the outbreak data.  Second, the outbreak data available for validation is very limited 
and additional outbreak data are required for further validation of all of the dose-
response models investigated in this research.  Third, the vehicles of transmission in 
the outbreak data varied widely and only one of the outbreaks is caused by 
contaminated cheese.   
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Although the dose-response models are successfully validated, there is a 
larger concern with the underlying assumption that the normal and susceptible 
populations have similar vulnerabilities to illness.  This assumption stems from the 
fact that the feeding studies used to develop the dose-response model involving health 
adults, indicating that the dose-response relationship is likely to be inaccurate for the 
susceptible population.  However, there is no data available to develop a dose-
response model specifically for the susceptible population.  Thus, the differences 
between the susceptible and normal populations are captured in the severe health 
outcomes progressing from illness.   
   5.2.3  Risk Characterization 
The risk characterization also benefits from the use of the DML methodology, 
as any number of different risks can be estimated.  In addition, the uncertainty 
associated with the severe health outcomes progressing from illness is also addressed 
through Bayesian inference for both the normal and susceptible populations.  
However, additional data for the susceptible population is needed; contrary to expert 
opinion, the data collected for the susceptible population indicates the same 
propensity for hospitalization given illness as the normal population.   
Another advantage of the DML framework is that it lends itself to risk 
mitigation and control strategy assessment as well as sensitivity analysis.  The 
PRAEC interface allows options in a scenario to be easily changed, making it simple 
to assess the impact of the change on the contamination level or human health risk; in 
this way, the risk model provides a means to analyze the relationship between the risk 
and the factors that might be used to mitigate the risk.   
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5.3  Engineering-Based Probabilistic Risk Assessment Limitations 
This research introduces a new methodology for QMRA using adapted 
engineering tools and techniques.  The application of this engineering-based approach 
to the problem of E. coli O157:H7 contamination in cheese lends confidence that this 
methodology can be applied to other food safety problems.  However, while the 
advancements and contributions of this new methodology have been previously 
discussed, it should also be acknowledged that there are limitations to the 
engineering-based approach.  The engineering-based methodology can be more 
intensive in terms of the time and labor required to establish the model and acquire 
the data needed to quantify this more detailed model; thus, the engineering-based 
approach could be most costly to implement.   
This engineering-based methodology can be labor intensive due to the 
reductionist approach.  As the system is further decomposed into more refined basic 
elements, the engineering-based approach requires more data.  The more detailed the 
model, the more data is required, as there are more combinations of the various 
options of the basic elements.  Each of these combinations has an underlying model 
that requires data in order to be quantified.  Thus, it takes time not only to establish 
all of the basic elements of the model, but also to find data to quantify these basic 
elements.  Another limitation of the engineer-based approach is that it can be limited 
or driven by the available data.  The risk model for a particular problem can be 
decomposed only to the level permitted by the data.  Therefore, for foods and 
pathogens which have a substantial amount of associated experiment data, the risk 
model can be far more detailed than for food-pathogen combinations which lack 
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experimental data.  However, the engineering-based approach is still valuable in cases 
where data is limited.  The risk model can be derived to the level possible, and the 
results of this model can be used to evaluate the relative risk and assess possible 
mitigation or control strategies.  In addition, the systematic approach of the 
engineering-based methodology can be useful in identifying areas where additional 
research and data is needed.     
 
5.4  Conclusion 
Despite the areas needing improvement, this research has successfully adapted 
probabilistic-based engineering methods and techniques to a food safety problem.  
The adaptation of these engineering methods results in numerous advancements, 
while still accomplishing the main goals of a QMRA.  The risk model developed in 
this research provides a more systematic approach to food safety problems, and also 
captures the relationships and dependencies between basic elements.  In addition, the 
engineering-based risk assessment methodology adapts methods for characterizing 
and propagating both aleatory and epistemic uncertainty about the mathematical 
models and the model parameters.  The disaggregation of the aleatory and epistemic 
uncertainties throughout the risk model results in a more powerful risk management 
tool.  The validation of the dose-response relationship lends confidence and 
credibility to the results of the model, while also ensuring accuracy and assessing 
uncertainty; consequently, the model can be used both as an absolute assessment of 
the risk and as a relative measurement of the effectives of mitigation and control 
strategies.  The successful application of the engineering-based risk assessment 
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methodology to E. coli O157:H7 contamination in cheese suggests that these adapted 
methodologies and techniques can be applied to food safety problems.   
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Appendix I:  User-Interface 
 
 
Again, the Dynamic Master Logic (DML) modeling concept is a knowledge 
management methodology, relying on the fact that complex systems can generally be 
decomposed into hierarchies.  This hierarchy model is primarily used to explain and 
simulate system behavior, by modeling system elements and the relationships 
between those elements.  The system elements are further decomposed into sub-
system elements, basic element, and various options for each basic element in order 
to account for the variability within the cheese-making process.  Thus, the DML 
methodology is used not only to structure the overall cheese model, but also to 
develop the Probabilistic Risk Assessment of E. coli O157:H7 in Cheese (PRAEC) 
software interface.   
For each of the system elements (i.e., production, distribution, consumption, 
and risk characterization) a user-interface module is developed.  The sub-system 
elements, basic elements, and options for the basic elements, as identified in the DML 
decomposition, are given in each of the user-interface modules.  The user then selects 
among the various options in order to develop the scenario to be analyzed.  The 
PRAEC interface is developed within Microsoft Excel using the @RISK add-in, and 
linked to the database with Visual Basic for Applications (VBA).  Developing the risk 
model in this way lends itself to Monte Carlo simulation, in which the simulation 
represents not only the variability throughout cheese process, but also the uncertainty 
in the mathematical model of the process.  Figures AI.1-AI.3 show the PRAEC 
interface modules for the various system elements.  It should be noted that the 
consumption and risk characterization modules are combined.   
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Appendix II:  Multiplicative Factor Parameter Development 
 
 
The multiplicative factor (MF) is the mathematical predictive model used to 
propagate the contamination through the production phase.  The MF is essentially a 
“multiplier” that allows the contamination to be propagated through the model.  If a 
selection increases the contamination, the multiplier will be greater than 1; if a 
selection decreases the contamination, the multiplier will be between 0 and 1.  These 
multipliers are calculated by obtaining the contamination level at the input and output 
of the step from the experimental data in the literature.   
In order to consider the uncertainty associated with the multiplicative factors 
(MF), the MFs are in the form of a distribution.  Although the MFs are assumed to 
follow a lognormal distribution, no prior knowledge of the parameters of the 
distribution is assumed.  For each MF distribution, non-informative uniform prior 
distributions are assumed for both the mean and standard deviation.  Using data from 
the literature, multipliers are calculated for each option from the level of 
contamination at the input and output of a step.  These multipliers are the “observed” 
data and used as evidence for developing the likelihood function in the Bayesian 
updating process.  The Bayesian updating results in posterior distributions for the 
mean and standard deviation of the MF distribution.   
Tables AII.1-AII.9 contain the @RISK functions used in the risk model for 
the various options at each step of the production phase.  These tables include the 
posterior parameter distributions determined from the Bayesian updating procedure, 
as well as the MF distributions that are created from the parameter distributions.  In 
addition, the sources from which the likelihood data is obtained are referenced.  
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Tables AII.10-AII.24 provide the data from which these parameter distributions are 




Table AII.1:  Milk Storage Multiplicative Factor Distributions 
Parameter Distribution 
(@RISK Function) 
Step MF Options Selected MF Distribution 
(@RISK Function) 
iAμ 1 a iAσ 1  
References 
A11 1 day; t > 8°C =RiskLognorm( 11Aμ , 11Aσ ) =RiskLognormAlt(5%, 
1.744, 50%, 12.24, 95%, 
28.06)b 
=RiskLognormAlt(5%, 
3.222, 50%, 56.00, 95%, 
258.9) 
A12 1 day; t = 8°C =RiskLognorm( 21Aμ , 21Aσ ) =RiskLognormAlt(5%, 
1.011, 50%, 2.300, 95%, 
13.23) 
=RiskLognormAlt(5%, 
0.9709, 50%, 4.563, 95%, 
16.2134) 
A13 1 day; 5°C < t < 8°C =RiskLognorm( 31Aμ , 31Aσ , 
RiskTruncate(1,10))c 
=RiskLognormAlt(5%, 
1.110, 50%, 2.791, 95%, 
8.745) 
=RiskLognormAlt(5%, 
1.82, 50%, 31.17, 95%, 
241.0) 
A14 1 day; t < 5°C =RiskLognorm( 41Aμ , 41Aσ ) =RiskLognormAlt(5%, 
0.04448, 50%, 0.4544, 
95%, 0.9380) 
=RiskLognormAlt(5%, 
0.8888, 50%, 19.36, 95%, 
236.2) 
A15 2 day; t > 8°C =RiskLognorm( 51Aμ , 51Aσ , 
RiskTruncate(1,50)) 
=RiskLognormAlt(5%, 
2.176, 50%, 16.35, 95%, 
37.29) 
=RiskLognormAlt(5%, 
4.207, 50%, 62.17, 95%, 
258.0) 
A16 2 day; t = 8°C =RiskLognorm( 61Aμ , 61Aσ , 
RiskTruncate(1,20)) 
=RiskLognormAlt(5%, 
1.86, 50%, 12.07, 95%, 
27.91) 
=RiskLognormAlt(5%, 
3.531, 50%, 58.22, 95%, 
256.4) 
A17 2 day; 5°C < t < 8°C =RiskLognorm( 71Aμ , 71Aσ , 
RiskTruncte(1,10)) 
=RiskLognormAlt(5%, 
1.067, 50%, 1.691, 95%, 
7.733) 
=RiskLognormAlt(5%, 
0.07307, 50%, 1.480, 
95%, 28.48) 
A18 2 day; t < 5°C =RiskLognorm( 81Aμ , 81Aσ ) =RiskLognormAlt(5%, 
0.04314, 50%, 0.4651, 
95%, 0.9426) 
=RiskLognormAlt(5%, 
1.298, 50%, 22.360, 95%, 
226.90) 
A19 3 day; t > 8°C =RiskLognorm( 91Aμ , 91Aσ , 
RiskTruncate(1,100)) 
=RiskLognormAlt(5%, 
2.002, 50%, 12.930, 95%, 
28.110) 
=RiskLognormAlt(5%, 
4.742, 50%, 56.580, 95%, 
255.2) 
A1 
A110 3 day; t = 8°C =RiskLognorm( 101Aμ , 101Aσ , 
RiskTruncate(1,50)) 
=RiskLognormAlt(5%, 
1.976, 50%, 12.39, 95%, 
27.940) 
=RiskLognormAlt(5%, 
3.873, 50%, 54.320, 95%, 
254.2) 
Altieri et al., 1997; 
Heuvelink et al., 1998; 
Mamani et al., 2003; 
Massa et al., 1999; 
Palumbo et al., 1997; 
Wang et al., 1997; 






A111 3 day; 5°C < t < 8°C =RiskLognorm( 111Aμ , 111Aσ , 
RiskTruncate(1,20)) 
=RiskLognormAlt(5%, 
1.370, 50%, 4.958, 95%, 
9.374) 
=RiskLognormAlt(5%, 
1.790, 50%, 28.58, 95%, 
242.6) 
A112 3 day; t < 5°C =RiskLognorm( 121Aμ , 121Aσ ) =RiskLognormAlt(5%, 
0.04201, 50%, 0.4791, 
95%, 0.9404) 
=RiskLognormAlt(5%, 
1.402, 50%, 24.130, 95%, 
231.4) 
A113 4 day; t > 8°C =RiskLognorm( 131Aμ , 131Aσ , 
RiskTruncate(1, )) 
=RiskLognormAlt(5%, 
3.120, 50%, 42.730, 95%, 
118.40) 
=RiskLognormAlt(5%, 
7.149, 50%, 101.50, 95%, 
273.7) 
A114 4 day; t = 8°C =RiskLognorm( 141Aμ , 141Aσ , 
RiskTruncate(1,150)) 
=RiskLognormAlt(5%, 
3.337, 50%, 42.610, 95%, 
117.00) 
=RiskLognormAlt(5%, 
7.747, 50%, 106.20, 95%, 
272.1) 
A115 4 day; 5°C < t < 8°C =RiskLognorm( 151Aμ , 151Aσ ) =RiskLognormAlt(5%, 
1.749, 50%, 12.120, 95%, 
28.01) 
=RiskLognormAlt(5%, 
2.872, 50%, 49.630, 95%, 
251.7) 
A116 4 day; t < 5°C =RiskLognorm( 161Aμ , 161Aσ ) =RiskLognormAlt(5%, 
0.04405, 50%, 0.4711, 
95%, 0.9412) 
=RiskLognormAlt(5%, 
1.684, 50%, 24.330, 95%, 
251.7) 
A117 5 day; t > 8°C =RiskLognorm( 171Aμ , 71Aσ , 
RiskTruncate(1,200)) 
=RiskLognormAlt(5%, 
4.553, 50%, 78.620, 95%, 
373.4) 
=RiskLognormAlt(5%, 
12.000, 50%, 147.80, 
95%, 286.0) 
A118 5 day; t = 8°C =RiskLognorm( 181Aμ , 181Aσ , 
RiskTruncate(1,200)) 
=RiskLognormAlt(5%, 
3.913, 50%, 57.120, 95%, 
202.2) 
=RiskLognormAlt(5%, 
9.693, 50%, 125.20, 95%, 
278.2) 
A119 5 day; 5°C < t < 8°C =RiskLognorm( 191Aμ , 191Aσ , 
RiskTruncate(1,)) 
=RiskLognormAlt(5%, 
1.426, 50%, 3.178, 95%, 
20.870) 
=RiskLognormAlt(5%, 
0.9731, 50%, 3.318, 95%, 
74.34) 
A120 5 day; t < 5°C =RiskLognorm( 201Aμ , 201Aσ ) =RiskLognormAlt(5%, 
0.04786, 50%, 0.4725, 
95%, 0.9444) 
=RiskLognormAlt(5%, 
2.262, 50%, 32.600, 95%, 
241.2) 
awhere i represents a specific multiplicative factor based on the options selected; for A1, i=20 
bRiskLognormAlt is an @RISK function which specifies a lognormal distribution, based on the 5th, 50th, and 95th percentiles 
cRiskTruncate is an @RISK function that truncates the input distribution; truncating a distribution restricts samples drawn from the distribution to values within 






Table AII.2: Milk Heat Treatment Multiplicative Factor Distributions 
Parameter Distribution 
(@RISK Function) 
Step MF Options Selected MF Distribution 
(@RISK Function) 
iA2μ  iA2σ  
References 
A21 Pasteurized =RiskLognorm( 12Aμ , 12Aσ , 
RiskTruncate(0,0.0001)) 
=RiskLognormAlt(5%, 
5.08E-5, 50%, 4.96E-4, 
95%, 9.50E-4) 
=RiskLognormAlt(5%, 
11.55, 50%, 18.51, 95%, 
35.74) 
A22 Unpasteurized =RiskLognorm( 22Aμ , 22Aσ ) =RiskLognorm(1.000, 
0.1)a 
=RiskLognorm(0.1, 0.1) 
A23 Heat Treatment, 
50°C, TBD seconds 
=RiskLognorm( 32Aμ , 32Aσ ) N/Ab N/A 
A24 Heat Treatment, 
56°C, TBD seconds 
=RiskLognorm( 42Aμ , 42Aσ ) N/A N/A 
A25 Heat Treatment, 
60°C, TBD seconds 
=RiskLognorm( 52Aμ , 52Aσ ) N/A N/A 
A26 Heat Treatment, 
63°C, TBD seconds 
=RiskLognorm( 62Aμ , 62Aσ ) N/A N/A 
A27 Heat Treatment, 
65°C, TBD seconds 
=RiskLognorm( 72Aμ , 72Aσ ) N/A N/A 
A28 Heat Treatment, 
68°C, TBD seconds 
=RiskLognorm( 82Aμ , 82Aσ ) N/A N/A 
A29 Heat Treatment, 
72°C, TBD seconds 
=RiskLognorm( 92Aμ , 92Aσ ) N/A N/A 
A210 Heat Treatment, 
76°C, TBD seconds 
=RiskLognorm( 102Aμ , 102Aσ ) N/A N/A 
A211 Heat Treatment, 
80°C, TBD seconds 
=RiskLognorm( 112Aμ , 112Aσ ) N/A N/A 
A212 Heat Treatment, 
89°C, TBD seconds 
=RiskLognorm( 122Aμ , 122Aσ ) N/A N/A 
A213 Heat Treatment, 
90°C, TBD seconds 
=RiskLognorm( 132Aμ , 132Aσ ) N/A N/A 
A214 Heat Treatment, 
94°C, TBD seconds 
=RiskLognorm( 142Aμ , 142Aσ ) N/A N/A 
A2 
 
A215 Heat Treatment, 
96°C, TBD seconds 
=RiskLognorm( 152Aμ , 152Aσ ) N/A N/A 
FSIS, 2004; Goff, 1995; 
Gunasekera et al., 2002; 
Rosenau, 2006; Stabel, 





A216 Heat Treatment, 
100°C, TBD seconds 
=RiskLognorm( 162Aμ , 162Aσ ) N/A N/A 
aResults in a MF of 1, allowing all of the contamination from step A1 to proceed to step A3 




Table AII.3: Addition of Coagulant Multiplicative Factor Distributions 
Parameter Distribution 
(@RISK Function) 
Step MF Options Selected MF Distribution 
(@RISK Function) 




=RiskLognorm( 13Aμ , 13Aσ , 
RiskTruncate(1,20)) 
=RiskLognormAlt(5%, 
1.009, 50%, 1.019, 95%, 
1.275) 
=RiskLognormAlt(5%, 




=RiskLognorm( 23Aμ , 23Aσ , 
RiskTruncate(1,20)) 
=RiskLognormAlt(5%, 
1.018, 50%, 1.234, 95%, 
2.376) 
=RiskLognormAlt(5%, 




=RiskLognorm( 33Aμ , 33Aσ , 
RiskTruncate(1,20)) 
=RiskLognormAlt(5%, 
1.010, 50%, 1.141, 95%, 
1.616) 
=RiskLognormAlt(5%, 






=RiskLognorm( 43Aμ , 43Aσ , 
RiskTruncate(1,20)) 
=RiskLognormAlt(5%, 
1.008, 50%, 1.102, 95%, 
1.529) 
=RiskLognormAlt(5%, 
0.7331, 50%, 1.125, 95%, 
2.015) 
Barbosa et al., 1993a; 
Barbosa et al., 1993b; 
Govaris et al., 2002; 
Hudson et al., 1997; 
Kornacki and Marth, 
1982; Leuschner and 
Boughflower, 2002; 
Maher et al., 2001; Park 
et al., 1973; Ramsaran et 
al., 1998; Reitsma and 
Henning, 1996; Spano et 














Table AII.4:  Cutting of Curd Multiplicative Factor Distributions 
Parameter Distribution 
(@RISK Function) 
Step MF Options Selected MF Distribution 
(@RISK Function) 
iA4μ  iAσ 4  
References 
A41 Pasteurized =RiskLognorm( 14Aμ , 14Aσ , 
RiskTruncate(1,50)) 
=RiskLognormAlt(5%, 
1.009, 50%, 1.108, 95%, 
1.317) 
=RiskLognormAlt(5%, 







A42 Unpasteurized =RiskLognorm( 24Aμ , 24Aσ , 
RiskTruncate(1,50)) 
=RiskLognormAlt(5%, 
1.029, 50%, 1.398, 95%, 
2.711) 
=RiskLognormAlt(5%, 
2.647, 50%, 3.702, 95%, 
5.693) 
Bachman and Spahr, 
1995; Barbosa et al., 
1993a; Fox et al., 2000; 
Frank et al., 1977; Frank 
et al., 1978; Govaris et al., 
2002; Hudson et al., 1997; 
Kornacki and Marth, 
1982; Leuschner and 
Boughflower, 2002; 
Maher et al., 2001; Park 
et al., 1973; Reitsma and 



















Table AII.5: Cooking of Curd Multiplicative Factor Distributions 
Parameter Distribution 
(@RISK Function) 
Step MF Options Selected MF Distribution 
(@RISK Function) 




=RiskLognorm( 15Aμ , 15Aσ , 
RiskTruncate(1,30)) 
=RiskLognormAlt(5%, 
1.418, 50%, 1.828, 95%, 
2.400) 
=RiskLognormAlt(5%, 
0.8261, 50%, 1.072, 95%, 
1.469) 
A52 Unpasteurized, 30°C 
≤t≤32°C 
=RiskLognorm( 25Aμ , 25Aσ , 
RiskTruncate(1,30)) 
=RiskLognormAlt(5%, 
1.418, 50%, 1.828, 95%, 
2.400) 
=RiskLognormAlt(5%, 
0.8261, 50%, 1.072, 95%, 
1.469) 
A53 Pasteurized, 33°C 
≤t≤35°C 
=RiskLognorm( 35Aμ , 35Aσ , 
RiskTruncate(1,30)) 
=RiskLognormAlt(5%, 
1.166, 50%, 2.474, 95%, 
10.800) 
=RiskLognormAlt(5%, 
1.137, 50%, 2.932, 95%, 
20.53) 
A54 Unpasteurized, 33°C 
≤t≤35°C 
=RiskLognorm( 45Aμ , 45Aσ , 
RiskTruncate(1,30)) 
=RiskLognormAlt(5%, 
1.166, 50%, 2.474, 95%, 
10.800) 
=RiskLognormAlt(5%, 
1.137, 50%, 2.932, 95%, 
20.53) 
A55 Pasteurized, 36°C 
≤t≤40°C 
=RiskLognorm( 55Aμ , 55Aσ , 
RiskTruncate(1,30)) 
=RiskLognormAlt(5%, 
1.050, 50%, 1.675, 95%, 
4.952) 
=RiskLognormAlt(5%, 
2.691, 50%, 4.802, 95%, 
11.39) 
A56 Unpasteurized, 36°C 
≤t≤40°C 
=RiskLognorm( 65Aμ , 65Aσ , 
RiskTruncate(1,30)) 
=RiskLognormAlt(5%, 
1.050, 50%, 1.675, 95%, 
4.952) 
=RiskLognormAlt(5%, 
2.691, 50%, 4.802, 95%, 
11.39) 
A57 Pasteurized, t>40°C =RiskLognorm( 75Aμ , 75Aσ , 
RiskTruncate(1,30)) 
=RiskLognormAlt(5%, 
1.050, 50%, 1.675, 95%, 
4.952) 
=RiskLognormAlt(5%, 






=RiskLognorm( 85Aμ , 85Aσ , 
RiskTruncate(1,30)) 
=RiskLognormAlt(5%, 
1.050, 50%, 1.675, 95%, 
4.952) 
=RiskLognormAlt(5%, 
2.691, 50%, 4.802, 95%, 
11.39) 
Barbosa et al., 1993b; Fox 
et al., 2000; Frank et al., 
1978; Hudson et al., 1997; 
Kornacki and Marth, 
1982; Maher et al., 2001; 
Reitsma and Henning, 









Table AII.6: Separation of Curd and Whey Multiplicative Factor Distributions 
Parameter Distribution 
(@RISK Function) 
Step MF Options Selected MF Distribution 
(@RISK Function) 
iAμ 6  iAσ 6  
References 
A61 Pasteurized =RiskLognorm( 16Aμ , 16Aσ ; 
RiskTruncate(1, 30)) 
=RiskLognormAlt(5%, 
1.852, 50%, 12.680, 95%, 
28.200) 
=RiskLognormAlt(5%, 






A62 Unpasteurized =RiskLognorm( 26Aμ , 26Aσ ; 
RiskTruncate(1, 30)) 
=RiskLognormAlt(5%, 
1.834, 50%, 12.220, 95%, 
27.970) 
=RiskLognormAlt(5%, 
3.016, 50%, 47.040, 95%, 
254.500) 
Barbosa et al., 1993a; 
Frank et al., 1977; Frank 
et al., 1978; Leuschner 
and Boughflower, 2002; 
Park et al., 1973; 
Ramsaran et al., 1998; 
Rash and Kosikowski, 
1982a; Rash and 
Kosikowski, 1982b; Teo 




Table AII.7: Salting Multiplicative Factor Distributions 
Parameter Distribution 
(@RISK Function) 
Step MF Options Selected MF Distribution 
(@RISK Function) 
iAμ 7  iAσ 7  
References 
A71 Pasteurized, Dry =RiskLognorm( 17Aμ , 17Aσ , 
RiskTruncate(1,30)) 
=RiskLognormAlt(5%, 
1.003, 50%, 1.044, 95%, 
1.186) 
=RiskLognormAlt(5%, 
1.567, 50%, 1.818, 95%, 
2.153) 
A72 Unpasteurized, Dry =RiskLognorm( 27Aμ , 27Aσ , 
RiskTruncate(1,30)) 
=RiskLognormAlt(5%, 
1.009, 50%, 1.097, 95%, 
1.402) 
=RiskLognormAlt(5%, 
0.6356, 50%, 0.8950, 
95%, 1.373) 
A73 Pasteurized, Brine =RiskLognorm( 37Aμ , 37Aσ , 
RiskTruncate(1,30)) 
=RiskLognormAlt(5%, 
2.218, 50%, 2.990, 95%, 
3.940) 
=RiskLognormAlt(5%, 




A74 Unpasteurized, Brine =RiskLognorm( 47Aμ , 47Aσ , 
RiskTruncate(1,30)) 
=RiskLognormAlt(5%, 
1.047, 50%, 1.637, 95%, 
3.940) 
=RiskLognormAlt(5%, 
3.255, 50%, 4.993, 95%, 
9.245) 
Frank et al., 1978; Fox et 
al., 2000; Govaris et al., 
2002; Hudson et al., 1997; 
Kornacki and Marth, 
1982; Maher et al., 2001; 
Park et al., 1973; 
Ramsaran et al., 1998; 
Rash and Kosikowski, 
1982a; Reitsma and 






Table AII.8: Hooping and Pressing Multiplicative Factor Distributions 
Parameter Distribution 
(@RISK Function) 
Step MF Options Selected MF Distribution 
(@RISK Function) 
iAμ 8  iAσ 8  
References 
A81 Pasteurized =RiskLognorm( 18Aμ , 18Aσ , 
RiskTruncate(1,50)) 
=RiskLognormAlt(5%, 
1.022, 50%, 1.264, 95%, 
1.887) 
=RiskLognormAlt(5%, 





A82 Unpasteurized =RiskLognorm( 28Aμ , 28Aσ , 
RiskTruncate(1,50)) 
=RiskLognormAlt(5%, 
1.070, 50%, 1.976, 95%, 
7.960) 
=RiskLognormAlt(5%, 
1.750, 50%, 3.949, 95%, 
15.720) 
Frank et al., 1978; Fox et 
al., 2000; Govaris et al., 
2002; Hudson et al., 1997; 
Kornacki and Marth, 
1982; Manolopoulou et al, 
2003; Reitsma and 





Table AII.9: Packaging and Ripening Multiplicative Factor Distributions 
Parameter Distribution 
(@RISK Function) 
Step MF Options Selected MF Distribution 
(@RISK Function) 
iAμ 9  iAσ 9  
References 
A91 Pasteurized, 14 days =RiskLognorm( 19Aμ , 19Aσ , 
RiskTruncate(0,)) 
=RiskLognormAlt(5%, 
0.01722, 50%, 0.2457, 
95%, 0.8333) 
=RiskLognormAlt(5%, 
0.7383, 50%, 1.495, 95%, 
4.060) 
A92 Unpasteurized, 14 
days 
=RiskLognorm( 29Aμ , 29Aσ , 
RiskTruncate(0,)) 
=RiskLognormAlt(5%, 
0.01722, 50%, 0.2457, 
95%, 0.8333) 
=RiskLognormAlt(5%, 
0.7383, 50%, 1.495, 95%, 
4.060) 
A93 Pasteurized, 27 days =RiskLognorm( 39Aμ , 39Aσ , 
RiskTruncate(0,)) 
=RiskLognormAlt(5%, 
0.202, 50%, 0.2675, 95%, 
0.8513) 
=RiskLognormAlt(5%, 




A94 Unpasteurized, 27 
days 
=RiskLognorm( 49Aμ , 49Aσ , 
RiskTruncate(0,)) 
=RiskLognormAlt(5%, 
0.202, 50%, 0.2675, 95%, 
0.8513) 
=RiskLognormAlt(5%, 
2.088, 50%, 3.061, 95%, 
5.030) 
Bachman and Spahr, 
1995; Barbosa et al., 
1993a; Barbosa et al., 
1993b; Fox et al., 2000; 
Frank et al., 1977; Frank 
et al., 1978; Govaris et al., 
2002; Hudson et al., 1997; 
Kornacki and Marth, 
1982; Leuschner and 
Boughflower, 2002; 
Maher et al., 2001; 





A95 Pasteurized, 45 days =RiskLognorm( 59Aμ , 59Aσ , 
RiskTruncate(0,)) 
=RiskLognormAlt(5%, 
0.01707, 50%, 0.2218, 
95%, 0.7652) 
=RiskLognormAlt(5%, 
1.134, 50%, 1.710, 95%, 
3.099) 
A96 Unpasteurized, 45 
days 
=RiskLognorm( 69Aμ , 69Aσ , 
RiskTruncate(0,)) 
=RiskLognormAlt(5%, 
0.01707, 50%, 0.2218, 
95%, 0.7652) 
=RiskLognormAlt(5%, 
1.134, 50%, 1.710, 95%, 
3.099) 
A97 Pasteurized, 75 days =RiskLognorm( 79Aμ , 79Aσ , 
RiskTruncate(0,)) 
=RiskLognormAlt(5%, 
0.01008, 50%, 0.1379, 
95%, 0.6121) 
=RiskLognormAlt(5%, 
1.351, 50%, 1.863, 95%, 
2.783) 
A98 Unpasteurized, 75 
days 
=RiskLognorm( 89Aμ , 89Aσ , 
RiskTruncate(0,)) 
=RiskLognormAlt(5%, 
0.01807, 50%, 0.2248, 
95%, 0.7875) 
=RiskLognormAlt(5%, 
0.9317, 50%, 1.534, 95%, 
3.244) 
A99 Pasteurized, 90 days =RiskLognorm( 99Aμ , 99Aσ , 
RiskTruncate(0,1)) 
=RiskLognormAlt(5%, 
0.0515, 50%, 0.4422, 
95%, 0.9296) 
=RiskLognormAlt(5%, 
0.4376, 50%, 1.505, 95%, 
14.570) 
A910 Unpasteurized, 90 
days 
=RiskLognorm( 109Aμ , 109Aσ , 
RiskTruncate(0,1)) 
=RiskLognormAlt(5%, 
0.04048, 50%, 0.4464, 
95%, 0.9420) 
=RiskLognormAlt(5%, 
1.839, 50%, 3.861, 95%, 
13.520) 
A911 Pasteurized, 104 days =RiskLognorm( 119Aμ , 119Aσ , 
RiskTruncate(0,1)) 
=RiskLognormAlt(5%, 
0.01277, 50%, 0.1672, 
95%, 0.6682) 
=RiskLognormAlt(5%, 
1.523, 50%, 2.210, 95%, 
3.498) 
A912 Unpasteurized, 104 
days 
=RiskLognorm( 129Aμ , 129Aσ , 
RiskTruncate(0,1)) 
=RiskLognormAlt(5%, 
0.03423, 50%, 0.3823, 
95%, 0.9298) 
=RiskLognormAlt(5%, 
0.8569, 50%, 2.866, 95%, 
36.670) 
A913 Pasteurized, 150 days =RiskLognorm( 139Aμ ; 139Aσ , 
RiskTruncate(0,1)) 
=RiskLognormAlt(5%, 
0.01684, 50%, 0.2176, 
95%, 0.7649) 
=RiskLognormAlt(5%, 
1.339, 50%, 1.950, 95%, 
3.146) 
A914 Unpasteurized, 150 
days 
=RiskLognorm( 149Aμ ; 149Aσ , 
RiskTruncate(0,1)) 
=RiskLognormAlt(5%, 
0.0216, 50%, 0.3094, 
95%, 0.8954) 
=RiskLognormAlt(5%, 
0.4823, 50%, 1.771, 95%, 
17.890) 
Park et al., 1973; 
Ramsaran et al., 1998; 
Rash and Kosikowski, 
1982a; Rash and 
Kosikowski, 1982b; 
Reitsma and Henning, 









Table AII.10:  Milk Storage Multiplicative Factor Data (Step A1)  
Multiplicative Factor, Step A1 Type of Milk Holding 
Temperature 
Reference 
24 hours 48 hours 72 hours 96 hours 120 hours 
Pasteurized 5°C Wang et al., 1997 0.759 0.575 0.427 0.331 0.251 
Pasteurized 5°C Altieri et al., 1997 N/Aa 19.498 N/A 194.985 N/A 
Pasteurized 5°C Altieri et al., 1997 N/A 3.981 N/A 100.000 N/A 
Pasteurized 8°C Weeratna and Doyle, 1997 N/A N/A 10.000 N/A N/A 
Pasteurized 8°C Wang et al., 1997 1.995 3.981 7.943 15.849 31.623 
Pasteurized 8°C Palumbo et al., 1997 1.000 1.000 1.259 1.995 3.162 
Pasteurized 8°C Palumbo et al., 1997 1.585 3.162 3.981 5.012 6.310 
Pasteurized 8°C Palumbo et al., 1997 1.995 1.995 2.239 2.239 630.957 
Pasteurized 8°C Palumbo et al., 1997 1.000 0.794 1.000 1.259 1.585 
Pasteurized 8°C Palumbo et al., 1997 1.585 7.943 79.433 79.432 79.432 
Pasteurized 8°C Palumbo et al., 1997 0.631 0.398 0.316 0.251 0.316 
Pasteurized 8°C Palumbo et al., 1997 2.511 6.310 25.119 31.623 39.811 
Pasteurized 8°C Palumbo et al., 1997 1.000 0.794 0.794 0.631 0.501 
Pasteurized 8°C Palumbo et al., 1997 1.995 6.310 19.953 25.119 31.623 
Pasteurized 8°C Palumbo et al., 1997 1.000 0.794 0.631 0.631 0.501 
Pasteurized 8°C Palumbo et al., 1997 7.943 15.849 63.100 79.432 100.000 
Pasteurized 8°C Palumbo et al., 1997 1.000 1.259 1.000 1.000 1.585 
Pasteurized 12°C Palumbo et al., 1997 3.162 10.000 100.00 398.107 10000.000 
Pasteurized 12°C Palumbo et al., 1997 31.623 100.000 794.328 3162.278 6309.573 
Pasteurized 12°C Palumbo et al., 1997 10.000 39.811 316.228 1258.925 316.228 
Pasteurized 12°C Palumbo et al., 1997 15.849 63.096 251.189 501.187 1258.925 
Pasteurized 12°C Palumbo et al., 1997 1.259 6.310 15.849 100.000 316.228 
Pasteurized 12°C Palumbo et al., 1997 1.000 1.000 1.000 79.433 1584.893 
Pasteurized 12°C Palumbo et al., 1997 2.511 15.849 100.00 158.489 251.189 
Pasteurized 12°C Palumbo et al., 1997 3.162 10.000 31.622 100.00 398.107 
Pasteurized 12°C Palumbo et al., 1997 2.511 19.953 100.000 125.893 199.526 
Pasteurized 12°C Palumbo et al., 1997 1.995 10.000 39.811 125.893 398.107 
Pasteurized 12°C Palumbo et al., 1997 10.000 63.096 316.228 398.107 630.957 
Pasteurized 12°C Palumbo et al., 1997 6.309 100.00 501.187 1584.893 3162.278 
Pasteurized 15°C Wang et al., 1997 12.023 144.544 1737.801 20892.960 251188.600 
Pasteurized 15°C Palumbo et al., 1997 79.433 10000.000 63095.730 1995262.000 630957.300 





Pasteurized 15°C Palumbo et al., 1997 100.000 10000.000 100000.000 1000000.000 125892.500 
Pasteurized 15°C Palumbo et al., 1997 158.489 1258.925 100000.000 15848.930 15848.930 
Pasteurized 22°C Wang et al., 1997 10.964 120.226 1318.257 14454.400 158489.300 
Pasteurized 25°C Weeratna and Doyle, 1997 350000.000 400000.000 400000.000 500000.000 N/A 
Pasteurized 25°C Altieri et al., 1997 N/A 331.131 N/A 131.826 N/A 
Pasteurized 25°C Altieri et al., 1997 N/A 1000.000 N/A 3981.072 N/A 
UHTb 4°C Mamani et al., 2003 2.188 1.072 0.851 0.269 0.214 
UHT 4°C Mamani et al., 2003 0.631 0.158 0.100 0.040 0.025 
UHT 4°C Mamani et al., 2003 0.200 0.200 0.158 0.126 0.100 
UHT 5°C Palumbo et al., 1997 1.000 1.000 1.000 1.000 1.000 
UHT 5°C Palumbo et al., 1997 1.000 1.000 1.000 1.000 1.000 
UHT 5°C Palumbo et al., 1997 1.000 1.000 1.000 1.000 1.000 
UHT 5°C Palumbo et al., 1997 1.000 1.000 1.000 1.000 1.000 
UHT 7°C Heuvelink et al., 1998 0.562 0.316 0.316 0.355 0.316 
UHT 8°C Palumbo et al., 1997 1.000 0.794 1.000 0.794 0.631 
UHT 8°C Palumbo et al., 1997 1.000 1.259 3.162 3.981 5.011 
UHT 8°C Palumbo et al., 1997 1.259 1.585 3.981 19.953 39.810 
UHT 8°C Palumbo et al., 1997 0.794 0.158 0.251 2.512 0.316 
UHT 12°C Palumbo et al., 1997 3.162 31.623 316.228 6309.573 100000.000 
UHT 12°C Palumbo et al., 1997 6.310 19.953 316.228 3162.278 21622.780 
UHT 12°C Palumbo et al., 1997 7.943 158.489 3162.278 25118.860 251188.600 
UHT 12°C Palumbo et al., 1997 1.585 15.849 79.432 794.328 1995.262 
UHT 15°C Heuvelink et al., 1998 15.849 1000.000 1258.925 2511.886 3162.278 
UHT 15°C Palumbo et al., 1997 63.096 10000.000 630957.300 630957.300 630957.300 
UHT 15°C Palumbo et al., 1997 31.623 3162.278 158489.300 1000000.000 1000000.000 
UHT 15°C Palumbo et al., 1997 1000.000 158489.300 1000000.000 1000000.000 1995262.000 
UHT 15°C Palumbo et al., 1997 39.811 6309.573 630957.300 630957.300 630957.300 
UHT 20°C Mamani et al., 2003 1000.000 16218.100 12022.640 8912.509 6606.934 
UHT 20°C Mamani et al., 2003 14791.080 1288250.000 741310.200 524807.500 371535.200 
UHT 20°C Mamani et al., 2003 58884.370 6025596.000 4365158.000 3162278.000 2290868.000 
Unpasteurized 5°C Wang et al., 1997 0.759 0.575 0.437 0.331 0.251 
Unpasteurized 7°C Heuvelink et al., 1998 1.259 3.162 5.012 10.000 15.849 
Unpasteurized 8°C Massa et al., 1999 0.944 0.899 0.889 0.693 0.589 
Unpasteurized 8°C Massa et al., 1999 0.938 0.879 0.844 0.687 0.591 





Unpasteurized 8°C Massa et al., 1999 1.000 2.169 2.071 8.309 11.378 
Unpasteurized 8°C Massa et al., 1999 1.000 20.054 26.667 95.477 133.188 
Unpasteurized 8°C Massa et al., 1999 1.154 18.685 11.538 127.774 182.319 
Unpasteurized 8°C Massa et al., 1999 1.167 1.831 0.758 8.379 11.652 
Unpasteurized 8°C Wang et al., 1997 1.259 1.585 1.995 2.511 3.162 
Unpasteurized 8°C Palumbo et al., 1997 1.000 1.000 1.000 1.000 1.000 
Unpasteurized 12°C Palumbo et al., 1997 1.000 1.000 1.000 1.000 1.000 
Unpasteurized 15°C Wang et al., 1997 3.802 54.954 54.954 208.930 794.328 
Unpasteurized 15°C Heuvelink et al., 1998 50.119 39.811 39.811 63.096 100.00 
Unpasteurized 22°C Wang et al., 1997 3.981 2.511 2.511 1.000 0.794 




Table AII.11:  Milk Heat Treatment Multiplicative Factor Data (Step A2) 
Type of Milk Reference Multiplicative Factor, Step A2 
Unpasteurized Goff, 1995 0.000000000001 
Unpasteurized Stabel, 2003 0.00001 
Unpasteurized Rosenau, 2006 0.00001 
Unpasteurized Gunasekera et al., 2002 0.0001 
Unpasteurized USDA, 2004 0.00001 















Table AII.12:  Addition of Coagulant Multiplicative Factor Data (Step A3)  
Type of Cheese Type of Milk Starter Culture Type of Salt Cooking 
Temperature 
Reference Multiplicative 
Factor, Step A3 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 1.000 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 1.000 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 0.411 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 1.333 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 0.400 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 0.550 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 0.420 
Romano Pasteurized Thermophilic Brine 46°C Hudson et al., 1997 1.260 
Feta Pasteurized Mesophilic Brine 30°C Hudson et al., 1997 2.510 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 3.160 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 3.160 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 2.510 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 2.510 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 3.980 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 3.980 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 3.980 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 3.980 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 3.160 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 3.160 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 6.310 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 6.310 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 1.000 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 1.000 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.790 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.890 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 1.120 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 1.260 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 1.000 
Feta Unpasteurized Mesophilic Brine 30°C Ramsaran et al., 1998 6.310 
Feta Unpasteurized Mesophilic Brine 30°C Ramsaran et al., 1998 3.980 
Feta Pasteurized Mesophilic Brine 30°C Ramsaran et al., 1998 19.950 





Camembert Unpasteurized Mesophilic Dry 33°C Ramsaran et al., 1998 2.000 
Camembert Pasteurized Mesophilic Dry 33°C Ramsaran et al., 1998 2.000 
Smear-Ripened Unpasteurized Mesophilic Brine 37°C Maher et al., 2001 0.910 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 1.260 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 1.000 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 1.000 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 1.260 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 1.260 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 1.260 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 1.000 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 1.000 
Feta Pasteurized Thermophilic Brine 30°C Govaris et al., 2002 2.000 
Feta Pasteurized Mesophilic Brine 30°C Govaris et al., 2002 1.410 
Telemes Pasteurized Thermophilic Brine 31-35°C Govaris et al., 2002 2.510 
Telemes Pasteurized Thermophilic Brine 31-35°C Govaris et al., 2002 2.510 
Parmesan Pasteurized Thermophilic Brine 52°C Barbosa et al., 1993b 1.000 
Soft-Cheese Pasteurized Mesophilic Dry 45°C Leuschner and Boughflower, 2002 3.160 
Soft-Cheese Pasteurized Mesophilic Dry 45°C Leuschner and Boughflower, 2002 3.160 



















Table AII.13:  Cutting of Curd Multiplicative Factor Data (Step A4)  
Type of Cheese Type of Milk Starter Culture Type of Salt Cooking 
Temperature 
Reference Multiplicative 
Factor, Step A4 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 2.667 
Cheddar Pasteurized Mesophilic Dry 38°C Fox et al., 2000 6.400 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 0.893 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 1.125 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 1.262 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 1.125 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 1.262 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 0.356 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 0.796 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 10.000 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 5.623 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 10.000 
Swiss Unpasteurized Thermophilic Brine 53°C Bachman and Spahr, 1995 0.0001 
Semi-Hard Unpasteurized Thermophilic Brine 42°C Bachman and Spahr, 1995 50.119 
Colby Pasteurized Mesophilic Dry 39°C Hudson et al., 1997 1.585 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 2.239 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 1.778 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 2.239 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 3.162 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 3.162 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 3.162 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 3.162 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 25.119 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 25.119 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 14.125 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 14.125 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 3.981 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 3.981 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 7.943 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 3.981 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 1.000 





Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.790 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.890 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 1.120 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 1.260 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 1.000 
Smear-Ripened  Unpasteurized Mesophilic Brine 37°C Maher et al., 2001 2.512 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 1.000 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 1.256 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 1.000 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 1.000 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 1.000 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 1.000 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 1.256 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 1.256 
Feta Pasteurized Thermophilic Brine 30°C Govaris et al., 2002 5.623 
Feta Pasteurized Mesophilic Brine 30°C Govaris et al., 2002 3.548 
Telemes Pasteurized Thermophilic Brine 31-35°C Govaris et al., 2002 10.000 
Telemes Pasteurized Thermophilic Brine 31-35°C Govaris et al., 2002 6.310 
Parmesan Pasteurized Thermophilic Brine 52°C Barbosa et al., 1993b 1.122 
Soft-Cheese Pasteurized Mesophilic Dry 45°C Leuschner and Boughflower, 2002 1.096 

















Table AII.14:  Cooking of Curd Multiplicative Factor Data (Step A5)  
Type of Cheese Type of Milk Starter Culture Type of Salt Cooking 
Temperature 
Reference Multiplicative 
Factor, Step A5 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 2.500 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.842 
Cheddar Pasteurized Mesophilic Dry 38°C Fox et al., 2000 2.500 
Colby Pasteurized Mesophilic Dry 39°C Hudson et al., 1997 3.162 
Romano Pasteurized Thermophilic Brine 46°C Hudson et al., 1997 25.119 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 1.412 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 3.162 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 1.412 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 19.953 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 19.953 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 25.119 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 25.119 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 6.310 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 6.310 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 11.220 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 11.220 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 7.943 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 7.943 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 12.589 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 12.589 
Smear-Ripened  Unpasteurized Mesophilic Brine 37°C Maher et al., 2001 1.585 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 0.050 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 0.040 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 0.079 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 0.063 










Table AII.15:  Separation of Curd & Whey Multiplicative Factor Data (Step A6)  
Type of Cheese Type of Milk Starter Culture Type of Salt Cooking 
Temperature 
Reference Multiplicative 
Factor, Step A6 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 44.375 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 40.625 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 6.475 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 14.125 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 17.783 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 15.849 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 17.783 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 50.119 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 31.623 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 44.668 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 10.000 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 17.783 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 10.000 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 2.818 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 2.818 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 2.818 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 5.012 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 10.000 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 6.310 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 6.310 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 1.995 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 3.981 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 1.256 
Feta Unpasteurized Mesophilic Brine 30°C Ramsaran et al., 1998 1.995 
Feta Unpasteurized Mesophilic Brine 30°C Ramsaran et al., 1998 1.585 
Feta Pasteurized Mesophilic Brine 30°C Ramsaran et al., 1998 1.259 
Camembert Unpasteurized Mesophilic Dry 33°C Ramsaran et al., 1998 2.512 
Camembert Unpasteurized Mesophilic Dry 33°C Ramsaran et al., 1998 3.162 
Camembert Pasteurized Mesophilic Dry 33°C Ramsaran et al., 1998 3.162 
Smear-Ripened Unpasteurized Mesophilic Brine 37°C Maher et al., 2001 0.910 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 120.226 





Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 13.490 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 27.542 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 45.709 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 61.660 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 269.153 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 891.251 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 30902.950 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 85113.800 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 100000.000 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 45.709 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 6.607 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 1380.384 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 208.923 
Parmesan Pasteurized Thermophilic Brine 52°C Barbosa et al., 1993b 0.001 
Soft-Cheese Pasteurized Mesophilic Dry 45°C Leuschner and Boughflower, 2002 1.445 



















Table AII.16:  Salting Multiplicative Factor Data (Step A7)  
Type of Cheese Type of Milk Starter Culture Type of Salt Cooking 
Temperature 
Reference Multiplicative 
Factor, Step A7 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.550 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.550 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 3.750 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 3.750 
Cheddar Pasteurized Mesophilic Dry 38°C Fox et al., 2000 0.510 
Colby Pasteurized Mesophilic Dry 39°C Hudson et al., 1997 2.239 
Romano Pasteurized Thermophilic Brine 46°C Hudson et al., 1997 1.000 
Romano Pasteurized Thermophilic Brine 46°C Hudson et al., 1997 1.000 
Feta Pasteurized Mesophilic Brine 30°C Hudson et al., 1997 10.000 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 2.818 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 2.818 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 2.818 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.585 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.995 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.585 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.995 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.585 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.995 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.585 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.995 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.259 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.259 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.259 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.259 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.259 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.259 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.259 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.259 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 2.512 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.259 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 2.512 





Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.585 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.585 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.585 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.585 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 10.000 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.100 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 19.953 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.501 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 15.849 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.398 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 15.849 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.501 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 3.981 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.005 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 8.913 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.224 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 6.310 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 251188.600 
Feta Unpasteurized Mesophilic Brine 30°C Ramsaran et al., 1998 10.000 
Feta Unpasteurized Mesophilic Brine 30°C Ramsaran et al., 1998 10.000 
Feta Pasteurized Mesophilic Brine 30°C Ramsaran et al., 1998 5.012 
Camembert Unpasteurized Mesophilic Dry 33°C Ramsaran et al., 1998 19.953 
Camembert Unpasteurized Mesophilic Dry 33°C Ramsaran et al., 1998 19.953 
Camembert Pasteurized Mesophilic Dry 33°C Ramsaran et al., 1998 25.119 
Smear-Ripened  Unpasteurized Mesophilic Brine 37°C Maher et al., 2001 2.138 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 0.013 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 0.010 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 0.016 
Mozzarella Unpasteurized Thermophilic Brine 35°C Spano et al., 2003 0.063 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 1.122 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 0.955 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 1.259 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 0.447 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 0.631 
Feta Pasteurized Thermophilic Brine 30°C Govaris et al., 2002 1.413 





Telemes Pasteurized Thermophilic Brine 31-35°C Govaris et al., 2002 1.413 

































Table AII.17:  Hooping & Pressing Multiplicative Factor Data (Step A8)  
Type of Cheese Type of Milk Starter Culture Type of Salt Cooking 
Temperature 
Reference Multiplicative 
Factor, Step A8 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 2.455 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.083 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 1.502 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 1.062 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 0.069 
Cheddar Pasteurized Mesophilic Dry 38°C Fox et al., 2000 2.549 
Romano Pasteurized Thermophilic Brine 46°C Hudson et al., 1997 0.0001 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 112.202 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 0.891 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 35.481 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 1.000 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 8.913 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 1.122 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.585 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.585 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.585 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.585 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.259 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.259 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.585 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.585 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 3.162 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 3.162 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.585 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.585 
Feta Pasteurized Mesophilic Brine 30°C Manolopoulou et al, 2003 4.169 
Feta Pasteurized Mesophilic Brine 30°C Manolopoulou et al, 2003 67.608 
Feta Pasteurized Mesophilic Brine 30°C Manolopoulou et al, 2003 131.825 








Table AII.18:  Ripening (14 days) Multiplicative Factor Data (Step A9)  
Type of Cheese Type of Milk Starter Culture Type of Salt Cooking 
Temperature 
Reference Multiplicative 
Factor, Step A9 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.070 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.111 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.103 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.103 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.130 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 2.600 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 0.594 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 1.297 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 0.756 
Cheddar Pasteurized Mesophilic Dry 38°C Fox et al., 2000 0.115 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 0.141 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 1.259 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 0.562 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 0.200 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 0.050 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 0.447 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 0.708 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 0.316 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 0.708 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.050 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.316 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.794 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.794 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.032 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.562 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.631 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.891 





Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.200 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.259 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.398 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 1.000 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 5.623 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 7.943 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.501 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 1.412 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.631 
Smear-Ripened Unpasteurized Mesophilic Brine 37°C Maher et al., 2001 0.200 
Feta Pasteurized Mesophilic Brine 30°C Manolopoulou et al, 2003 0.004 
Feta Pasteurized Mesophilic Brine 30°C Manolopoulou et al, 2003 0.089 
Feta Pasteurized Mesophilic Brine 30°C Manolopoulou et al, 2003 1.202 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 2.691 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 1.175 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 0.871 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 1.413 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 1.047 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 4.169 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 1.905 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 1.514 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 0.692 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 0.741 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 0.246 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 1.047 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 1.096 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 2.455 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 2.188 
Parmesan Pasteurized Thermophilic Brine 52°C Barbosa et al., 1993b 0.398 










Table AII.19:  Ripening (27 days) Multiplicative Factor Data (Step A9)  
Type of Cheese Type of Milk Starter Culture Type of Salt Cooking 
Temperature 
Reference Multiplicative 
Factor, Step A9 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.368 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.067 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.089 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.093 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.090 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.077 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 1.105 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 0.277 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 0.500 
Cheddar Pasteurized Mesophilic Dry 38°C Fox et al., 2000 0.120 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 0.891 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 0.891 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 1.000 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 0.501 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 0.631 
Camembert Pasteurized Mesophilic Dry 32°C Frank et al., 1977 0.794 
Semi-Hard Unpasteurized Thermophilic Brine 42°C Bachman and Spahr, 1995 0.002 
Colby Pasteurized Mesophilic Dry 39°C Hudson et al., 1997 0.100 
Romano Pasteurized Thermophilic Brine 46°C Hudson et al., 1997 1.000 
Feta Pasteurized Mesophilic Brine 30°C Hudson et al., 1997 0.001 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 0.708 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 0.794 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 0.708 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.100 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.158 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.316 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.501 





Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.526 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.526 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.526 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.316 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.316 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.100 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.251 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.398 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.562 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.316 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.631 
Feta Unpasteurized Mesophilic Brine 30°C Ramsaran et al., 1998 0.398 
Feta Unpasteurized Mesophilic Brine 30°C Ramsaran et al., 1998 0.079 
Feta Pasteurized Mesophilic Brine 30°C Ramsaran et al., 1998 1.259 
Camembert Unpasteurized Mesophilic Dry 33°C Ramsaran et al., 1998 5.011 
Camembert Unpasteurized Mesophilic Dry 33°C Ramsaran et al., 1998 0.079 
Camembert Pasteurized Mesophilic Dry 33°C Ramsaran et al., 1998 1.122 
Smear-Ripened Unpasteurized Mesophilic Brine 37°C Maher et al., 2001 0.398 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 0.214 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 0.589 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 1.288 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 0.302 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982a 0.692 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 0.275 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 0.871 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 1.349 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 0.955 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 0.447 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 0.347 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 0.269 
Parmesan Pasteurized Thermophilic Brine 52°C Barbosa et al., 1993b 0.794 








Table AII.20:  Ripening (45 days) Multiplicative Factor Data (Step A9)  
Type of Cheese Type of Milk Starter Culture Type of Salt Cooking 
Temperature 
Reference Multiplicative 
Factor, Step A9 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.400 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.010 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.424 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.323 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 1.327 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 0.100 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 0.187 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 2.000 
Cheddar Pasteurized Mesophilic Dry 38°C Fox et al., 2000 0.556 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 0.501 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 0.794 
Brick Pasteurized Mesophilic Brine 37°C Frank et al., 1978 0.794 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.000 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.200 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 1.000 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.100 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.794 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.708 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.891 
Colby Pasteurized Mesophilic Dry 40°C Kornacki and Marth, 1982 0.501 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.316 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.501 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.224 
Camembert Pasteurized Mesophilic Dry 33°C Park et al., 1973 0.158 
Feta Unpasteurized Mesophilic Brine 30°C Ramsaran et al., 1998 1.413 
Feta Unpasteurized Mesophilic Brine 30°C Ramsaran et al., 1998 1.995 





Camembert Unpasteurized Mesophilic Dry 33°C Ramsaran et al., 1998 0.316 
Camembert Unpasteurized Mesophilic Dry 33°C Ramsaran et al., 1998 3.162 
Camembert Pasteurized Mesophilic Dry 33°C Ramsaran et al., 1998 2.239 
Smear-Ripened  Unpasteurized Mesophilic Brine 37°C Maher et al., 2001 0.158 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 0.741 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 0.562 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 0.468 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 2.239 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 1.202 
Camembert Pasteurized Mesophilic Dry 33°C Rash and Kosikowski, 1982b 0.490 
Parmesan Pasteurized Thermophilic Brine 52°C Barbosa et al., 1993b 1.259 




























Table AII.21:  Ripening (75 days) Multiplicative Factor Data (Step A9)  
Type of Cheese Type of Milk Starter Culture Type of Salt Cooking 
Temperature 
Reference Multiplicative 
Factor, Step A9 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 2.839 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.167 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 3.128 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 4.731 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.142 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 0.167 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 4.000 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 0.324 
Cheddar Pasteurized Mesophilic Dry 38°C Fox et al., 2000 1.273 
Feta Unpasteurized Mesophilic Brine 30°C Ramsaran et al., 1998 0.355 
Feta Unpasteurized Mesophilic Brine 30°C Ramsaran et al., 1998 0.631 
Feta Pasteurized Mesophilic Brine 30°C Ramsaran et al., 1998 3.981 
Smear-Ripened  Unpasteurized Mesophilic Brine 37°C Maher et al., 2001 0.891 
Parmesan Pasteurized Thermophilic Brine 52°C Barbosa et al., 1993b 0.251 
Prato Pasteurized Mesophilic Brine 42°C Barbosa et al., 1993a 0.063 
 
 
Table AII.22:  Ripening (90 days) Multiplicative Factor Data (Step A9)  
Type of Cheese Type of Milk Starter Culture Type of Salt Cooking 
Temperature 
Reference Multiplicative 
Factor, Step A9 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 10.857 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 0.033 
Smear-Ripened  Unpasteurized Mesophilic Brine 37°C Maher et al., 2001 0.708 
Parmesan Pasteurized Thermophilic Brine 52°C Barbosa et al., 1993b 1.585 






Table AII.23:  Ripening (104 days) Multiplicative Factor Data (Step A9)  
Type of Cheese Type of Milk Starter Culture Type of Salt Cooking 
Temperature 
Reference Multiplicative 
Factor, Step A9 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 2.307 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.500 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.202 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.008 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 1.234 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 10.600 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 1.632 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 0.290 
Parmesan Pasteurized Thermophilic Brine 52°C Barbosa et al., 1993b 0.631 
 
 
Table AII.24:  Ripening (150 days) Multiplicative Factor Data (Step A9)  
Type of Cheese Type of Milk Starter Culture Type of Salt Cooking 
Temperature 
Reference Multiplicative 
Factor, Step A9 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 3.636 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 1.000 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.500 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 20.000 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.241 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Pasteurized Mesophilic Dry 38°C Reitsma and Henning, 1996 0.200 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 0.800 
Cheddar Unpasteurized Mesophilic Dry 38°C Teo et al., 2000 0.561 






Appendix III:  Gompertz Equation Parameter Development 
 
 
The Gompertz equation is used to describe the effect of temperature and pH 
on the growth of E. coli O157:H7 during the distribution phase.  Based on the data 
obtained from the literature, distributions for the Gompertz equation parameters B, M, 
and C are estimated using a Bayesian approach similar to the one described for the 
multiplicative factors.  Again, a lognormal distribution is assumed for each of the 
Gompertz parameters (i.e., B, M, and C), as these parameters describe bacterial 
survival.  However, no prior knowledge of the parameters (i.e., mean and standard 
deviation) of the lognormal distribution describing the Gompertz parameters is 
assumed; therefore, non-informative uniform prior distributions are assumed for both 
the mean and the standard deviation.  Data for B, M, and C are obtained from the 
literature, and this data serves as the likelihood in the Bayesian updating process.  The 
Bayesian updating results in posterior distributions of the mean and standard 
deviation of the Gompertz parameters.  
Tables AIII.1-AIII.3 contain the @RISK functions used in the risk model for 
the various combinations of pH and temperature for B, M, and C of the Gompertz 
equation; these combinations for B, M, and C apply to all of the steps in the 
distribution phase.  The tables include the posterior distributions for the mean and 
standard deviation, determined from the Bayesian updating procedure, as well as the 
distributions for B, M, and C that are created from the parameter distributions.  In 
addition, the sources from which the likelihood data is obtained are referenced.  Table 




Table AIII.1:  Step B1-B5 Gompertz Equation Distributions, Parameter B 






Gompertz Parameter B 
Distribution 
(@RISK Function) µBia σBi 
References 
B1 5ºC, pH 4.5 =RiskLognorm(µB1; σB1 , 
RiskTruncate(0,1))b, c 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
B2 8ºC, pH 4.5 =RiskLognorm(µB2; σB2, 
RiskTruncate(0,1)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 






B4 12ºC, pH 4.5 =RiskLognorm(µB4; σB4, 
RiskTruncate(0,1)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
























B9 5ºC, pH 5.0 =RiskLognorm(µB9; σB9, 
RiskTruncate(0,1)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 






























Buchanan and Bagi, 
1997; Buchanan et al., 
1993; Buchanan et al., 
1997; Buchanan and 
Klawitter, 1992; 
Coleman et al., 2003; 
Hao and Brackett, 1993; 
Rajkowski and Marmer, 
1995; Sutherland et al., 


















B17 5ºC, pH 5.5 =RiskLognorm(µB17; σB17, 
RiskTruncate(0,1)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
B18 8ºC, pH 5.5 =RiskLognorm(µB18; σB18, 
RiskTruncate(0,1)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 




































B25 5ºC, pH 6.0 =RiskLognorm(µB25; σB25, 
RiskTruncate(0,1)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
B26 8ºC, pH 6.0 =RiskLognorm(µB26; σB26, 
RiskTruncate(0,1)) 
=RiskLognorm (0.002, 0.01) =RiskLognorm(0.0031, 
0.01552) 








































B33 5ºC, pH 6.5 =RiskLognorm(µB33; σB33, 
RiskTruncate(0,1)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
B34 8ºC, pH 6.5 =RiskLognorm(µB34; σB34, 
RiskTruncate(0,1)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 




































B41 5ºC, pH 7.0 =RiskLognorm(µB41; σB41, 
RiskTruncate(0,1)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 














































B49 5ºC, pH 7.5 =RiskLognorm(µB49; σB49, 
RiskTruncate(0,1)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
B50 8ºC, pH 7.5 =RiskLognorm(µB50; σB50, 
RiskTruncate(0,1)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 




































B57 5ºC, pH 8.0 =RiskLognorm(µB57; σB57, 
RiskTruncate(0,1)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
B58 8ºC, pH 8.0 =RiskLognorm(µB58; σB58, 
RiskTruncate(0,1)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 








































B65 5ºC, pH 8.5 =RiskLognorm(µB65; σB65, 
RiskTruncate(0,1)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
B66 8ºC, pH 8.5 =RiskLognorm(µB66; σB66, 
RiskTruncate(0,1)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 




































awhere i represents a specific parameter B based on the pH and temperature options selected; i=72 
bRiskLognorm is an @RISK function which specifies a lognormal distribution based on the mean and standard deviation 
cRiskTruncate is an @RISK function that truncates the input distribution; truncating a distribution restricts samples drawn from the distribution to values within 













Table AIII.2:  Step B1-B5 Gompertz Equation Distributions, Parameter M 






Gompertz Parameter M 
Distribution 
(@RISK Function) µMi σMi 
References 
M1 5ºC, pH 4.5 =RiskLognorm(µM1; σM1 , 
RiskTruncate(0,500)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
M2 8ºC, pH 4.5 =RiskLognorm(µM2; σM2, 
RiskTruncate(0,500)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
M3 10ºC, pH 4.5 =RiskLognorm(µM3; σM3, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 2.502, 
50%, 39.47, 95%, 204.1)a 
=RiskLognorm(73.83, 
29.78) 
M4 12ºC, pH 4.5 =RiskLognorm(µM4; σM4, 
RiskTruncate(0,500)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
M5 19ºC, pH 4.5 =RiskLognorm(µM5; σM5, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 




M6 28ºC, pH 4.5 =RiskLognorm(µM6; σM6, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 4.874, 
50%, 25.78, 95%, 132.3) 
=RiskLognorm(29.45, 
35.45) 
M7 37ºC, pH 4.5 =RiskLognorm(µM7; σM7, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 




M8 42ºC, pH 4.5 =RiskLognorm(µM8; σM8, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 0.8277, 
50%, 7.794, 95%, 66.05) 
=RiskLognorm(4.509, 
25.43) 
M9 5ºC, pH 5.0 =RiskLognorm(µM9; σM9, 
RiskTruncate(0,500)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
M10 8ºC, pH 5.0 =RiskLognorm(µM10; σM10, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 6.229, 
50%, 88.11, 95%, 340.2) 
=RiskLognorm(187.2, 
65.34) 
M11 10ºC, pH 5.0 =RiskLognorm(µM11; σM11, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 49.18, 
50%, 147.4, 95%, 353.0) 
=RiskLognorm(126.2, 
88.15) 
M12 12ºC, pH 5.0 =RiskLognorm(µM12; σM12, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 0, 50%, 
62.12, 95%, 173.3) 
=RiskLognorm(41.93, 
21.35) 
M13 19ºC, pH 5.0 =RiskLognorm(µM13; σM13, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 9.554, 
50%, 24.08, 95%, 61.07) 
=RiskLognorm(9.34, 26.56) 
Buchanan and Bagi, 
1997; Buchanan et al., 
1993; Buchanan et al., 
1997; Buchanan and 
Klawitter, 1992; 
Coleman et al., 2003; 
Hao and Brackett, 1993; 
Rajkowski and Marmer, 
1995; Sutherland et al., 






M14 28ºC, pH 5.0 =RiskLognorm(µM14; σM14, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 1.936, 
50%, 9.749, 95%, 45.38) 
=RiskLognorm(12.43, 
18.45) 
M15 37ºC, pH 5.0 =RiskLognorm(µM15; σM15, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 




M16 42ºC, pH 5.0 =RiskLognorm(µM16; σM16, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 0.8277, 
50%, 7.794, 95%, 66.05) 
=RiskLognorm(4.509, 
25.43) 
M17 5ºC, pH 5.5 =RiskLognorm(µM17; σM17, 
RiskTruncate(0,500)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
M18 8ºC, pH 5.5 =RiskLognorm(µM18; σM18, 
RiskTruncate(0,500)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
M19 10ºC, pH 5.5 =RiskLognorm(µM19; σM19, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 1.265, 
50%, 37.73, 95%, 298.9) 
=RiskLognorm(55.91, 
93.13_ 
M20 12ºC, pH 5.5 =RiskLognorm(µM20; σM20, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 0.5364, 
50%, 25.94, 95%, 254.1) 
=RiskLognorm(36.12, 
61.20) 
M21 19ºC, pH 5.5 =RiskLognorm(µM21; σM21, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 9.874, 
50%, 27.74, 95%, 77.45) 
=RiskLognorm(24.31, 
47.34) 
M22 28ºC, pH 5.5 =RiskLognorm(µM22; σM22, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 0.4148, 
50%, 12.38, 95%, 132.3) 
=RiskLognorm(25.83, 
40.69) 
M23 37ºC, pH 5.5 =RiskLognorm(µM23; σM23, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 1.510, 
50%, 8.486, 95%, 49.8) 
=RiskLognorm(12.88, 
11.93) 
M24 42ºC, pH 5.5 =RiskLognorm(µM24; σM24, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 0.8277, 
50%, 7.794, 95%, 66.05) 
=RiskLognorm(4.509, 
25.43) 
M25 5ºC, pH 6.0 =RiskLognorm(µM25; σM25, 
RiskTruncate(0,500)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
M26 8ºC, pH 6.0 =RiskLognorm(µM26; σM26, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 49.18, 
50%, 103.4, 95%, 321.0) 
=RiskLognorm(164.5, 72.5) 
M27 10ºC, pH 6.0 =RiskLognorm(µM27; σM27, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 45.26, 
50%, 149.5, 95%, 317.6) 
=RiskLognorm(64.73, 
80.52) 
M28 12ºC, pH 6.0 =RiskLognorm(µM28; σM28, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 45.13, 







M29 19ºC, pH 6.0 =RiskLognorm(µM29; σM29, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 5.881, 
50%, 16.63, 95%, 47.11) 
=RiskLognorm(8.498, 
24.60) 
M30 28ºC, pH 6.0 =RiskLognorm(µM30; σM30, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 1.191, 
50%, 12.428, 95%, 92.83) 
=RiskLognorm(14.36, 
12.36) 
M31 37ºC, pH 6.0 =RiskLognorm(µM31; σM31, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 1.510, 
50%, 8.486, 95%, 49.8) 
=RiskLognorm(12.88, 
11.93) 
M32 42ºC, pH 6.0 =RiskLognorm(µM32; σM32, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 0.8277, 
50%, 7.794, 95%, 66.05) 
=RiskLognorm(4.509, 
25.43) 
M33 5ºC, pH 6.5 =RiskLognorm(µM33; σM33, 
RiskTruncate(0,500)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
M34 8ºC, pH 6.5 =RiskLognorm(µM34; σM34, 
RiskTruncate(0,500)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
M35 10ºC, pH 6.5 =RiskLognorm(µM35; σM35, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 58.19, 
50%, 102.4, 95%, 148.8) 
=RiskLognorm(6.123, 
36.94) 
M36 12ºC, pH 6.5 =RiskLognorm(µM36; σM36, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 5.474, 
50%, 83.81, 95%, 302.9) 
=RiskLognorm(73.04, 
89.01) 
M37 19ºC, pH 6.5 =RiskLognorm(µM37; σM37, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 10.17, 
50%, 29.45, 95%, 86.04) 
=RiskLognorm(18.34, 
65.37) 
M38 28ºC, pH 6.5 =RiskLognorm(µM38; σM38, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 3.907, 
50%, 11.20, 95%, 34.58) 
=RiskLognorm(7.49, 5.32) 
M39 37ºC, pH 6.5 =RiskLognorm(µM39; σM39, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 0.9664, 
50%, 7.121, 95%, 47.82) 
=RiskLognorm(4.988, 
6.453) 
M40 42ºC, pH 6.5 =RiskLognorm(µM40; σM40, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 0.8277, 
50%, 7.794, 95%, 66.05) 
=RiskLognorm(4.509, 
25.43) 
M41 5ºC, pH 7.0 =RiskLognorm(µM41; σM41, 
RiskTruncate(0,500)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
M42 8ºC, pH 7.0 =RiskLognorm(µM42; σM42, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 5.113, 
50%, 67.34, 95%, 265.1) 
=RiskLognorm(190.2, 
65.34) 
M43 10ºC, pH 7.0 =RiskLognorm(µM43; σM43, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 5.929, 
50%, 86.66, 95%, 313.1) 
=RiskLognorm(96.90, 
71.35) 
M44 12ºC, pH 7.0 =RiskLognorm(µM44; σM44, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 21.46, 







M45 19ºC, pH 7.0 =RiskLognorm(µM45; σM45, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 8.40, 
50%, 35.34, 95%, 156.4) 
=RiskLognorm(38.49, 
75.34) 
M46 28ºC, pH 7.0 =RiskLognorm(µM46; σM46, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 4.665, 
50%, 9.03, 95%, 18.03) 
=RiskLognorm(3.245, 
2.366) 
M47 37ºC, pH 7.0 =RiskLognorm(µM47; σM47, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 0.9664, 
50%, 7.121, 95%, 47.82) 
=RiskLognorm(4.988, 
6.453) 
M48 42ºC, pH 7.0 =RiskLognorm(µM48; σM48, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 0.8576, 
50%, 5.910, 95%, 41.90) 
=RiskLognorm(4.362, 
3.246) 
M49 5ºC, pH 7.5 =RiskLognorm(µM49; σM49, 
RiskTruncate(0,500)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
M50 8ºC, pH 7.5 =RiskLognorm(µM50; σM50, 
RiskTruncate(0,500)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
M51 10ºC, pH 7.5 =RiskLognorm(µM51; σM51, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 5.929, 
50%, 86.66, 95%, 313.1) 
=RiskLognorm(96.90, 
71.35) 
M52 12ºC, pH 7.5 =RiskLognorm(µM52; σM52, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 5.113, 
50%, 69.34, 95%, 275.1) 
=RiskLognorm(54.67, 
20.81) 
M53 19ºC, pH 7.5 =RiskLognorm(µM53; σM53, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 2.502, 
50%, 29.47, 95%, 204.1) 
=RiskLognorm(62.83, 
29.78) 
M54 28ºC, pH 7.5 =RiskLognorm(µM54; σM54, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 2.371, 
50%, 10.23, 95%, 44.97) 
=RiskLognorm(9.34, 27.34) 
M55 37ºC, pH 7.5 =RiskLognorm(µM55; σM55, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 0.7003, 
50%, 8.540, 95%, 76.86) 
=RiskLognorm(6.435, 
9.347) 
M56 42ºC, pH 7.5 =RiskLognorm(µM56; σM56, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 0.8576, 
50%, 5.910, 95%, 41.90) 
=RiskLognorm(4.362, 
3.246) 
M57 5ºC, pH 8.0 =RiskLognorm(µM57; σM57, 
RiskTruncate(0,500)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
M58 8ºC, pH 8.0 =RiskLognorm(µM58; σM58, 
RiskTruncate(0,500)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
M59 10ºC, pH 8.0 =RiskLognorm(µM59; σM59, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 5.929, 
50%, 86.66, 95%, 313.1) 
=RiskLognorm(96.90, 
71.35) 
M60 12ºC, pH 8.0 =RiskLognorm(µM60; σM60, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 42.01, 







M61 19ºC, pH 8.0 =RiskLognorm(µM61; σM61, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 18.26, 
50%, 45.91, 95%, 99.65) 
=RiskLognorm(6.943, 
18.24) 
M62 28ºC, pH 8.0 =RiskLognorm(µM62; σM62, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 0.7937, 
50%, 2.238, 95%, 31.83) 
=RiskLognorm(2.356, 
40.94) 
M63 37ºC, pH 8.0 =RiskLognorm(µM63; σM63, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 0.7003, 
50%, 8.540, 95%, 76.86) 
=RiskLognorm(6.435, 
9.347) 
M64 42ºC, pH 8.0 =RiskLognorm(µM64; σM64, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 0.8576, 
50%, 5.910, 95%, 41.90) 
=RiskLognorm(4.362, 
3.246) 
M65 5ºC, pH 8.5 =RiskLognorm(µM65; σM65, 
RiskTruncate(0,500)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
M66 8ºC, pH 8.5 =RiskLognorm(µM66; σM66, 
RiskTruncate(0,500)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
M67 10ºC, pH 8.5 =RiskLognorm(µM67; σM67, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 5.929, 
50%, 86.66, 95%, 313.1) 
=RiskLognorm(96.90, 
71.35) 
M68 12ºC, pH 8.5 =RiskLognorm(µM68; σM68, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 59.30, 
50%, 110.7, 95%, 185.0) 
=RiskLognorm(58.34, 
24.95) 
M69 19ºC, pH 8.5 =RiskLognorm(µM69; σM69, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 18.26, 
50%, 45.91, 95%, 99.65) 
=RiskLognorm(6.943, 
18.24) 
M70 28ºC, pH 8.5 =RiskLognorm(µM70; σM70, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 1.750, 
50%, 13.47, 95%, 89.73) 
=RiskLognorm(8.945, 
7.355) 
M71 37ºC, pH 8.5 =RiskLognorm(µM71; σM71, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 0.7003, 
50%, 8.540, 95%, 76.86) 
=RiskLognorm(6.435, 
9.347) 
M72 42ºC, pH 8.5 =RiskLognorm(µM72; σM72, 
RiskTruncate(0,500)) 
=RiskLognormAlt(5%, 0.8576, 
50%, 5.910, 95%, 41.90) 
=RiskLognorm(4.362, 
3.246) 











Table AIII.3:  Step B1-B5 Gompertz Equation Distributions, Parameter C 






Gompertz Parameter C 
Distribution 
(@RISK Function) µCi σCi 
References 
C1 5ºC, pH 4.5 =RiskLognorm(µC1; σC1 , 
RiskTruncate(0,9)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
C2 8ºC, pH 4.5 =RiskLognorm(µC2; σC2, 
RiskTruncate(0,9)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
C3 10ºC, pH 4.5 =RiskLognorm(µC3; σC3, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 0.1621, 
50%, 0.3781, 95%, 0.9256) 
=RiskLognorm(0.7059, 
0.05673) 
C4 12ºC, pH 4.5 =RiskLognorm(µC4; σC4, 
RiskTruncate(0,9)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
C5 19ºC, pH 4.5 =RiskLognorm(µC5; σC5, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 0.4503, 
50%, 4.836, 95%, 9.495) 
=RiskLognorm(3.595, 
2.455) 
C6 28ºC, pH 4.5 =RiskLognorm(µC6; σC6, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 3.502, 
50%, 5.544, 95%, 9.328) 
=RiskLognorm(1.730, 
0.08838) 
C7 37ºC, pH 4.5 =RiskLognorm(µC7; σC7, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 1.203, 
50%, 5.170, 95%, 9.644) 
=RiskLognorm(1.685, 
0.4249) 
C8 42ºC, pH 4.5 =RiskLognorm(µC8; σC8, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 5.312, 
50%, 6.608, 95%, 8.083) 
=RiskLognorm(0.1477, 
0.8607) 
C9 5ºC, pH 5.0 =RiskLognorm(µC9; σC9, 
RiskTruncate(0,9)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
C10 8ºC, pH 5.0 =RiskLognorm(µC10; σC10, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 0.1621, 
50%, 0.4281, 95%, 0.9756) 
=RiskLognorm(1.004, 
0.04408) 
C11 10ºC, pH 5.0 =RiskLognorm(µC11; σC11, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 




C12 12ºC, pH 5.0 =RiskLognorm(µC12; σC12, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 0.01153, 
50%, 6.440, 95%, 12.98) 
=RiskLognorm(2.430, 
11.26) 
C13 19ºC, pH 5.0 =RiskLognorm(µC13; σC13, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 5.111, 
50%, 6.653, 95%, 8.368) 
=RiskLognorm(1.898, 
0.06373) 
Buchanan and Bagi, 
1997; Buchanan et al., 
1993; Buchanan et al., 
1997; Buchanan and 
Klawitter, 1992; 
Coleman et al., 2003; 
Hao and Brackett, 1993; 
Rajkowski and Marmer, 
1995; Sutherland et al., 






C14 28ºC, pH 5.0 =RiskLognorm(µC14; σC14, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 4.521, 
50%, 5.369, 95%, 6.357) 
=RiskLognorm(0.5668, 
0.05693) 
C15 37ºC, pH 5.0 =RiskLognorm(µC15; σC15, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 1.203, 
50%, 5.170, 95%, 9.644) 
=RiskLognorm(1.685, 
0.4249) 
C16 42ºC, pH 5.0 =RiskLognorm(µC16; σC16, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 5.312, 
50%, 6.608, 95%, 8.083) 
=RiskLognorm(0.1477, 
0.8607) 
C17 5ºC, pH 5.5 =RiskLognorm(µC17; σC17, 
RiskTruncate(0,9)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
C18 8ºC, pH 5.5 =RiskLognorm(µC18; σC18, 
RiskTruncate(0,9)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
C19 10ºC, pH 5.5 =RiskLognorm(µC19; σC19, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 0.5580, 
50%, 3.530, 95%, 8.875) 
=RiskLognorm(3.623, 
1.980) 
C20 12ºC, pH 5.5 =RiskLognorm(µC20; σC20, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 3.863, 
50%, 6.724, 95%, 10.34) 
=RiskLognorm(1.926, 
0.1253) 
C21 19ºC, pH 5.5 =RiskLognorm(µC21; σC21, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 4.803, 
50%, 7.206, 95%, 10.98) 
=RiskLognorm(2.006, 
0.08349) 
C22 28ºC, pH 5.5 =RiskLognorm(µC22; σC22, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 2.906, 
50%, 6.032, 95%, 9.659) 
=RiskLognorm(1.827, 
0.1788) 
C23 37ºC, pH 5.5 =RiskLognorm(µC23; σC23, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 4.946, 
50%, 7.154, 95%, 9.611) 
=RiskLognorm(1.378, 
0.0725) 
C24 42ºC, pH 5.5 =RiskLognorm(µC24; σC24, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 5.312, 
50%, 6.608, 95%, 8.083) 
=RiskLognorm(0.1477, 
0.8607) 
C25 5ºC, pH 6.0 =RiskLognorm(µC25; σC25, 
RiskTruncate(0,9)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
C26 8ºC, pH 6.0 =RiskLognorm(µC26; σC26, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 1.872, 
50%, 2.007, 95%, 2.238) 
=RiskLognorm(3.158, 
1.239) 
C27 10ºC, pH 6.0 =RiskLognorm(µC27; σC27, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 2.458, 
50%, 5.326, 95%, 8.663) 
=RiskLognorm(1.689, 
0.2036) 
C28 12ºC, pH 6.0 =RiskLognorm(µC28; σC28, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 6.005, 
50%, 6.934, 95%, 7.986) 
=RiskLognorm(1.938, 
0.02839) 
C29 19ºC, pH 6.0 =RiskLognorm(µC29; σC29, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 5.589, 







C30 28ºC, pH 6.0 =RiskLognorm(µC30; σC30, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 0.5139, 
50%, 4.824, 95%, 9.470) 
=RiskLognorm(1.820, 
0.0909) 
C31 37ºC, pH 6.0 =RiskLognorm(µC31; σC31, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 4.946, 
50%, 7.154, 95%, 9.611) 
=RiskLognorm(1.378, 
0.0725) 
C32 42ºC, pH 6.0 =RiskLognorm(µC32; σC32, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 5.312, 
50%, 6.608, 95%, 8.083) 
=RiskLognorm(0.1477, 
0.8607) 
C33 5ºC, pH 6.5 =RiskLognorm(µC33; σC33, 
RiskTruncate(0,9)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
C34 8ºC, pH 6.5 =RiskLognorm(µC34; σC34, 
RiskTruncate(0,9)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
C35 10ºC, pH 6.5 =RiskLognorm(µC35; σC35, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 3.586, 
50%, 7.154, 95%, 10.89) 
=RiskLognorm(0.6322, 
0.4835) 
C36 12ºC, pH 6.5 =RiskLognorm(µC36; σC36, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 0.4654, 
50%, 4.731, 95%, 9.460) 
=RiskLognorm(3.112, 
1.239) 
C37 19ºC, pH 6.5 =RiskLognorm(µC37; σC37, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 4.844, 
50%, 6.966, 95%, 9.251) 
=RiskLognorm(1.949, 
0.06707) 
C38 28ºC, pH 6.5 =RiskLognorm(µC38; σC38, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 4.781, 
50%, 6.839, 95%, 9.105) 
=RiskLognorm(1.930, 
0.07057) 
C39 37ºC, pH 6.5 =RiskLognorm(µC39; σC39, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 5.827, 
50%, 6.896, 95%, 8.068) 
=RiskLognorm(0.5668, 
0.05693) 
C40 42ºC, pH 6.5 =RiskLognorm(µC40; σC40, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 5.312, 
50%, 6.608, 95%, 8.083) 
=RiskLognorm(0.1477, 
0.8607) 
C41 5ºC, pH 7.0 =RiskLognorm(µC41; σC41, 
RiskTruncate(0,9)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
C42 8ºC, pH 7.0 =RiskLognorm(µC42; σC42, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 0.0774, 
50%, 0.7228, 95%, 1.553) 
=RiskLognorm(2.040, 
0.08349) 
C43 10ºC, pH 7.0 =RiskLognorm(µC43; σC43, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 2.132, 
50%, 5.420, 95%, 9.115) 
=RiskLognorm(1.753, 
0.2254) 
C44 12ºC, pH 7.0 =RiskLognorm(µC44; σC44, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 5.720, 
50%, 6.990, 95%, 8.358) 
=RiskLognorm(0.5479, 
0.2477) 
C45 19ºC, pH 7.0 =RiskLognorm(µC45; σC45, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 3.036, 







C46 28ºC, pH 7.0 =RiskLognorm(µC46; σC46, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 5.166, 
50%, 6.634, 95%, 8.400) 
=RiskLognorm(0.7359, 
0.05673) 
C47 37ºC, pH 7.0 =RiskLognorm(µC47; σC47, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 5.827, 
50%, 6.896, 95%, 8.068) 
=RiskLognorm(0.5668, 
0.05693) 
C48 42ºC, pH 7.0 =RiskLognorm(µC48; σC48, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 0.4879, 
50%, 4.806, 95%, 9.442) 
=RiskLognorm(3.212, 
1.239) 
C49 5ºC, pH 7.5 =RiskLognorm(µC49; σC49, 
RiskTruncate(0,9)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
C50 8ºC, pH 7.5 =RiskLognorm(µC50; σC50, 
RiskTruncate(0,9)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
C51 10ºC, pH 7.5 =RiskLognorm(µC51; σC51, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 2.132, 
50%, 5.420, 95%, 9.115) 
=RiskLognorm(1.753, 
0.2254) 
C52 12ºC, pH 7.5 =RiskLognorm(µC52; σC52, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 0.4838, 
50%, 4.867, 95%, 9.412) 
=RiskLognorm(1.930, 
0.1354) 
C53 19ºC, pH 7.5 =RiskLognorm(µC53; σC53, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 3.762, 
50%, 6.208, 95%, 8.926) 
=RiskLognorm(1.845, 
0.1101) 
C54 28ºC, pH 7.5 =RiskLognorm(µC54; σC54, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 3.763, 
50%, 6.419, 95%, 9.156) 
=RiskLognorm(1.278, 
0.1169) 
C55 37ºC, pH 7.5 =RiskLognorm(µC55; σC55, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 5.581, 
50%, 7.140, 95%, 8.814) 
=RiskLognorm(0.4568, 
0.05693) 
C56 42ºC, pH 7.5 =RiskLognorm(µC56; σC56, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 0.4879, 
50%, 4.806, 95%, 9.442) 
=RiskLognorm(3.212, 
1.239) 
C57 5ºC, pH 8.0 =RiskLognorm(µC57; σC57, 
RiskTruncate(0,9)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
C58 8ºC, pH 8.0 =RiskLognorm(µC58; σC58, 
RiskTruncate(0,9)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
C59 10ºC, pH 8.0 =RiskLognorm(µC59; σC59, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 2.132, 
50%, 5.420, 95%, 9.115) 
=RiskLognorm(1.753, 
0.2254) 
C60 12ºC, pH 8.0 =RiskLognorm(µC60; σC60, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 6.027, 
50%, 7.586, 95%, 9.980) 
=RiskLognorm(0.1087, 
0.09556) 
C61 19ºC, pH 8.0 =RiskLognorm(µC61; σC61, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 1.442, 







C62 28ºC, pH 8.0 =RiskLognorm(µC62; σC62, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 7.168, 
50%, 7.499, 95%, 7.853) 
=RiskLognorm(0.1355, 
0.8288) 
C63 37ºC, pH 8.0 =RiskLognorm(µC63; σC63, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 5.581, 
50%, 7.140, 95%, 8.814) 
=RiskLognorm(0.4568, 
0.05693) 
C64 42ºC, pH 8.0 =RiskLognorm(µC64; σC64, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 0.4879, 
50%, 4.806, 95%, 9.442) 
=RiskLognorm(3.212, 
1.239) 
C65 5ºC, pH 8.5 =RiskLognorm(µC65; σC65, 
RiskTruncate(0,9)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
C66 8ºC, pH 8.5 =RiskLognorm(µC66; σC66, 
RiskTruncate(0,9)) 
=RiskLognorm (1E-10, 5E-10) =RiskLognorm(1E-7, 5E-7) 
C67 10ºC, pH 8.5 =RiskLognorm(µC67; σC67, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 2.132, 
50%, 5.420, 95%, 9.115) 
=RiskLognorm(1.753, 
0.2254) 
C68 12ºC, pH 8.5 =RiskLognorm(µC68; σC68, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 6.027, 
50%, 7.586, 95%, 9.980) 
=RiskLognorm(0.1087, 
0.09556) 
C69 19ºC, pH 8.5 =RiskLognorm(µC69; σC69, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 1.442, 
50%, 8.189, 95%, 15.12) 
=RiskLognorm(2.073, 
0.4672) 
C70 28ºC, pH 8.5 =RiskLognorm(µC70; σC70, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 7.168, 
50%, 7.499, 95%, 7.853) 
=RiskLognorm(0.1355, 
0.8288) 
C71 37ºC, pH 8.5 =RiskLognorm(µC71; σC71, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 6.768, 
50%, 6.989, 95%, 7.353) 
=RiskLognorm(0.1710, 
0.7099) 
C72 42ºC, pH 8.5 =RiskLognorm(µC72; σC72, 
RiskTruncate(0,9)) 
=RiskLognormAlt(5%, 0.4879, 















Table AIII.4:  Gompertz B, M, and C Parameter Data 
Gompertz Parameter Temperature pH Reference 
B (log (CFU/ml)/h) M (h) C (log CFU/ml) 
5ºC 4.5 Buchanan et al., 1993 0 0 0 
5ºC 4.5 Buchanan et al., 1993 0 0 0 
5ºC 5.5 Buchanan and Klawitter, 1992 0 0 0 
5ºC 5.5 Buchanan and Klawitter, 1992 0 0 0 
5ºC 5.5 Buchanan et al., 1993 0 0 0 
5ºC 6.5 Buchanan and Klawitter, 1992 0 0 0 
5ºC 6.5 Buchanan and Klawitter, 1992 0 0 0 
5ºC 6.5 Buchanan et al., 1993 0 0 0 
5ºC 7.5 Buchanan and Klawitter, 1992 0 0 0 
5ºC 7.5 Buchanan and Klawitter, 1992 0 0 0 
5ºC 7.5 Buchanan et al., 1993 0 0 0 
5ºC 8.5 Buchanan et al., 1993 0 0 0 
8ºC 5.0 Rajkowski and Marmer, 1995 0.0028 451.90 2.02 
8ºC 5.0 Rajkowski and Marmer, 1995 0 0 0 
8ºC 5.0 Rajkowski and Marmer, 1995 0 0 0 
8ºC 5.0 Rajkowski and Marmer, 1995 0 0 0 
8ºC 5.5 Buchanan and Klawitter, 1992 0 0 0 
8ºC 5.5 Buchanan and Klawitter, 1992 0 0 0 
8ºC 6.0 Buchanan and Klawitter, 1992 0 0 0 
8ºC 6.0 Buchanan and Klawitter, 1992 0 0 0 
8ºC 6.0 Rajkowski and Marmer, 1995 0.0063 291.90 6.68 
8ºC 6.0 Rajkowski and Marmer, 1995 0.0057 341.20 6.75 
8ºC 6.0 Rajkowski and Marmer, 1995 0 0 0 
8ºC 6.0 Rajkowski and Marmer, 1995 0 0 0 
8ºC 6.5 Buchanan and Klawitter, 1992 0 0 0 
8ºC 6.5 Buchanan and Klawitter, 1992 0 0 0 
8ºC 7.0 Buchanan and Klawitter, 1992 0 0 0 
8ºC 7.0 Buchanan and Klawitter, 1992 0 0 0 
8ºC 7.0 Rajkowski and Marmer, 1995 0.01 566.50 5.01 
8ºC 7.0 Rajkowski and Marmer, 1995 0 0 0 
8ºC 7.0 Rajkowski and Marmer, 1995 0 0 0 





8ºC 7.5 Buchanan and Klawitter, 1992 0 0 0 
8ºC 7.5 Buchanan and Klawitter, 1992 0 0 0 
8ºC 8.5 Buchanan and Klawitter, 1992 0 0 0 
8ºC 8.5 Buchanan and Klawitter, 1992 0  0 0 
10ºC 4.5 Buchanan and Klawitter, 1992 0  0 0 
10ºC 4.5 Buchanan and Klawitter, 1992 0  0 0 
10ºC 4.5 Buchanan et al., 1997 0.011 153.43 3.99 
10ºC 5.0 Rajkowski and Marmer, 1995 0.006 247.50 6.04 
10ºC 5.0 Rajkowski and Marmer, 1995 0.0041 306.7 6.35 
10ºC 5.0 Rajkowski and Marmer, 1995 0  0 0 
10ºC 5.0 Rajkowski and Marmer, 1995 0  0 0 
10ºC 5.0 Sutherland et al., 1997 0.0056 179.77 3.80 
10ºC 5.5 Buchanan and Klawitter, 1992 0.022 82.99 8.00 
10ºC 5.5 Buchanan and Klawitter, 1992 0  0 0 
10ºC 5.5 Coleman et al., 2003 0.014 154.88 9.00 
10ºC 5.5 Coleman et al., 2003 0.023 98.12 9.70 
10ºC 5.5 Coleman et al., 2003 0.0082 143.91 7.60 
10ºC 5.5 Coleman et al., 2003 0.016 81.95 8.80 
10ºC 5.5 Buchanan and Klawitter, 1992 0.011 129.69 7.60 
10ºC 5.5 Buchanan and Klawitter, 1992 0 0 0 
10ºC 5.5 Buchanan et al., 1997 0.23 77.31 6.70 
10ºC 6.0 Sutherland et al., 1997 0.0045 170.11 5.40 
10ºC 6.0 Rajkowski and Marmer, 1995 0.013 96.00 6.40 
10ºC 6.0 Rajkowski and Marmer, 1995 0.013 117.60 6.31 
10ºC 6.0 Rajkowski and Marmer, 1995 0.013 213.60 6.44 
10ºC 6.0 Rajkowski and Marmer, 1995 0.022 251.40 3.61 
10ºC 6.5 Buchanan and Klawitter, 1992 0.017 102.76 7.80 
10ºC 6.5 Buchanan and Klawitter, 1992 0.017 107.56 7.20 
10ºC 6.5 Buchanan et al., 1997 0.20 98.74 6.82 
10ºC 7.0 Rajkowski and Marmer, 1995 0.016 136.79 6.35 
10ºC 7.0 Rajkowski and Marmer, 1995 0.013 130.41 6.23 
10ºC 7.0 Rajkowski and Marmer, 1995 0  0 0 
10ºC 7.0 Rajkowski and Marmer, 1995 0  0 0 
12ºC 5.0 Rajkowski and Marmer, 1995 0.13 74.00 6.57 





12ºC 5.0 Rajkowski and Marmer, 1995 0  0 0 
12ºC 5.0 Rajkowski and Marmer, 1995 0  0 0 
12ºC 5.5 Buchanan and Klawitter, 1992 0.20 75.21 8.10 
12ºC 5.5 Buchanan and Klawitter, 1992 0.018 104.91 7.40 
12ºC 5.5 Buchanan and Klawitter, 1992 0.026 64.34 7.00 
12ºC 5.5 Buchanan and Klawitter, 1992 0.020 89.35 6.80 
12ºC 5.5 Buchanan et al., 1993 0 0 0 
12ºC 5.5 Buchanan et al., 1997 0.016 75.71 8.28 
12ºC 6.0 Buchanan and Klawitter, 1992 0.021 69.72 7.80 
12ºC 6.0 Buchanan and Klawitter, 1992 0.020 80.37 7.50 
12ºC 6.0 Buchanan and Klawitter, 1992 0.025 62.93 7.20 
12ºC 6.0 Buchanan and Klawitter, 1992 0.031 76.29 6.80 
12ºC 6.0 Buchanan et al., 1997 0.022 63.26 7.01 
12ºC 6.0 Rajkowski and Marmer, 1995 0.043 56.90 6.77 
12ºC 6.0 Rajkowski and Marmer, 1995 0.018 76.10 6.33 
12ºC 6.0 Rajkowski and Marmer, 1995 0.087 93.40 6.68 
12ºC 6.0 Rajkowski and Marmer, 1995 0.011 125.90 6.54 
12ºC 6.5 Buchanan and Klawitter, 1992 0.020 75.74 7.70 
12ºC 6.5 Buchanan and Klawitter, 1992 0.0068 320.25 6.00 
12ºC 6.5 Buchanan and Klawitter, 1992 0 0 0 
12ºC 6.5 Buchanan and Klawitter, 1992 0.23 25.66 7.00 
12ºC 6.5 Buchanan and Klawitter, 1992 0.011 386.23 4.40 
12ºC 6.5 Buchanan and Klawitter, 1992 0 0 0 
12ºC 6.5 Buchanan et al., 1993 0.028 51.57 6.42 
12ºC 6.5 Buchanan et al., 1993 0.028 54.40 6.93 
12ºC 6.5 Buchanan et al., 1997 0.019 73.53 7.30 
12ºC 6.5 Buchanan et al., 1997 0 0 0 
12ºC 7.0 Buchanan and Klawitter, 1992 0.020 78.09 7.90 
12ºC 7.0 Buchanan and Klawitter, 1992 0.024 75.88 7.40 
12ºC 7.0 Rajkowski and Marmer, 1995 0.037 52.92 6.88 
12ºC 7.0 Rajkowski and Marmer, 1995 0.042 71.20 6.77 
12ºC 7.0 Rajkowski and Marmer, 1995 0.018 86.63 6.59 
12ºC 7.0 Rajkowski and Marmer, 1995 0.012 128.83 6.51 
12ºC 7.5 Buchanan and Klawitter, 1992 0.022 117.89 7.50 





12ºC 7.5 Buchanan and Klawitter, 1992 0.018 90.38 7.80 
12ºC 7.5 Buchanan and Klawitter, 1992 0 0 0 
12ºC 7.5 Buchanan et al., 1997 0.012 130.16 7.37 
12ºC 8.0 Buchanan and Klawitter, 1992 0.037 106.46 7.90 
12ºC 8.0 Buchanan and Klawitter, 1992 0.014 131.45 7.90 
12ºC 8.5 Buchanan and Klawitter, 1992 0.020 94.61 7.70 
12ºC 8.5 Buchanan and Klawitter, 1992 0.014 119.10 7.00 
12ºC 8.5 Buchanan et al., 1993 0 0 0 
19ºC 4.5 Buchanan and Klawitter, 1992 0.040 42.33 8.10 
19ºC 4.5 Buchanan and Klawitter, 1992 0.091 94.54 7.80 
19ºC 4.5 Buchanan and Klawitter, 1992 0 0 0 
19ºC 4.5 Buchanan and Klawitter, 1992 0 0 0 
19ºC 4.5 Buchanan and Klawitter, 1992 0.034 47.03 5.90 
19ºC 4.5 Buchanan and Klawitter, 1992 0.020 123.95 4.80 
19ºC 4.5 Buchanan and Klawitter, 1992 0 0 0 
19ºC 4.5 Buchanan and Klawitter, 1992 0 0 0 
19ºC 4.5 Buchanan et al., 1997 0.010 183.42 6.31 
19ºC 5.0 Buchanan and Klawitter, 1992 0.040 35.24 7.90 
19ºC 5.0 Buchanan and Klawitter, 1992 0.048 37.20 7.10 
19ºC 5.0 Rajkowski and Marmer, 1995 0.89 22.70 6.28 
19ºC 5.0 Rajkowski and Marmer, 1995 0.10 14.30 6.10 
19ºC 5.0 Rajkowski and Marmer, 1995 0.068 20.60 6.12 
19ºC 5.0 Rajkowski and Marmer, 1995 0.062 22.10 6.73 
19ºC 5.5 Buchanan and Klawitter, 1992 0.085 23.98 8.20 
19ºC 5.5 Buchanan and Klawitter, 1992 0.034 66.93 7.20 
19ºC 5.5 Coleman et al., 2003 0.056 23.82 8.90 
19ºC 5.5 Coleman et al., 2003 0.059 20.23 10.00 
19ºC 5.5 Coleman et al., 2003 0.058 21.13 8.10 
19ºC 5.5 Coleman et al., 2003 0.055 23.29 7.40 
19ºC 5.5 Buchanan and Klawitter, 1992 0.093 19.55 7.10 
19ºC 5.5 Buchanan and Klawitter, 1992 0.039 67.69 6.80 
19ºC 6.0 Buchanan and Klawitter, 1992 0.093 28.00 7.40 
19ºC 6.0 Buchanan and Klawitter, 1992 0.067 26.68 7.20 
19ºC 6.0 Rajkowski and Marmer, 1995 0.13 11.15 6.76 





19ºC 6.0 Rajkowski and Marmer, 1995 0.13 14.67 6.30 
19ºC 6.0 Rajkowski and Marmer, 1995 0.092 15.48 6.53 
19ºC 6.5 Buchanan and Klawitter, 1992 0.087 21.17 7.70 
19ºC 6.5 Buchanan and Klawitter, 1992 0.073 26.59 8.30 
19ºC 6.5 Buchanan and Klawitter, 1992 0.045 38.43 7.50 
19ºC 6.5 Buchanan and Klawitter, 1992 0.020 70.75 7.60 
19ºC 6.5 Buchanan and Klawitter, 1992 0.085 18.11 7.10 
19ºC 6.5 Buchanan and Klawitter, 1992 0.088 25.54 7.40 
19ºC 6.5 Buchanan and Klawitter, 1992 0.045 38.43 7.50 
19ºC 6.5 Buchanan and Klawitter, 1992 0.019 68.78 6.70 
19ºC 6.5 Buchanan et al., 1997 0.076 18.53 7.16 
19ºC 7.0 Buchanan and Klawitter, 1992 0.095 26.33 7.70 
19ºC 7.0 Buchanan and Klawitter, 1992 0.053 53.24 7.40 
19ºC 7.0 Buchanan and Klawitter, 1992 0.095 27.77 7.30 
19ºC 7.0 Rajkowski and Marmer, 1995 0.081 14.80 6.78 
19ºC 7.0 Rajkowski and Marmer, 1995 0.090 15.50 6.69 
19ºC 7.0 Rajkowski and Marmer, 1995 0.052 36.23 6.57 
19ºC 7.0 Rajkowski and Marmer, 1995 0.032 67.88 6.87 
19ºC 7.0 Buchanan and Klawitter, 1992 0.088 21.98 7.70 
19ºC 7.0 Buchanan and Klawitter, 1992 0.098 17.26 5.54 
19ºC 7.5 Buchanan and Klawitter, 1992 0.093 19.91 7.60 
19ºC 7.5 Buchanan and Klawitter, 1992 0.026 143.62 6.70 
19ºC 7.5 Buchanan and Klawitter, 1992 0.088 17.08 7.30 
19ºC 7.5 Buchanan and Klawitter, 1992 0.011 150.21 6.30 
19ºC 8.0 Buchanan and Klawitter, 1992 0.040 41.94 7.90 
19ºC 8.0 Buchanan and Klawitter, 1992 0.041 45.22 7.70 
19ºC 8.0 Buchanan et al., 1997 0.027 53.25 10.16 
28ºC 4.5 Buchanan and Klawitter, 1992 0.17 10.92 7.30 
28ºC 4.5 Buchanan and Klawitter, 1992 0.98 17.18 7.50 
28ºC 4.5 Buchanan and Klawitter, 1992 0.018 60.38 4.50 
28ºC 4.5 Buchanan and Klawitter, 1992 0.077 54.90 4.70 
28ºC 4.5 Buchanan and Klawitter, 1992 0.14 14.25 6.10 
28ºC 4.5 Buchanan and Klawitter, 1992 0.26 21.00 6.40 
28ºC 4.5 Buchanan and Klawitter, 1992 0.030 45.21 5.40 





28ºC 5.0 Rajkowski and Marmer, 1995 0.23 7.50 5.60 
28ºC 5.0 Rajkowski and Marmer, 1995 0.51 8.40 5.55 
28ºC 5.0 Rajkowski and Marmer, 1995 0.30 8.20 5.14 
28ºC 5.0 Rajkowski and Marmer, 1995 0.17 17.90 5.20 
28ºC 5.5 Buchanan and Klawitter, 1992 0.20 6.87 7.90 
28ºC 5.5 Buchanan and Klawitter, 1992 0.12 50.58 6.70 
28ºC 5.5 Buchanan and Klawitter, 1992 0.26 6.66 7.30 
28ºC 5.5 Buchanan and Klawitter, 1992 0.055 40.69 6.00 
28ºC 6.0 Rajkowski and Marmer, 1995 0.25 6.33 6.03 
28ºC 6.0 Rajkowski and Marmer, 1995 0.27 6.70 6.21 
28ºC 6.0 Rajkowski and Marmer, 1995 0.144 10.55 5.99 
28ºC 6.0 Rajkowski and Marmer, 1995 0.055 23.06 6.53 
28ºC 6.5 Buchanan and Klawitter, 1992 0.19 8.17 7.70 
28ºC 6.5 Buchanan and Klawitter, 1992 0.19 9.14 7.40 
28ºC 6.5 Buchanan and Klawitter, 1992 0.15 14.26 7.50 
28ºC 6.5 Buchanan and Klawitter, 1992 0.11 25.48 7.70 
28ºC 6.5 Buchanan and Klawitter, 1992 0.20 7.61 7.00 
28ºC 6.5 Buchanan and Klawitter, 1992 0.17 8.96 6.90 
28ºC 6.5 Buchanan and Klawitter, 1992 0.16 12.07 7.00 
28ºC 6.5 Buchanan and Klawitter, 1992 0.15 23.55 7.10 
28ºC 7.0 Buchanan and Klawitter, 1992 0.15 11.49 8.00 
28ºC 7.0 Buchanan and Klawitter, 1992 0.20 10.69 7.40 
28ºC 7.0 Buchanan et al., 1997 0.21 9.10 6.55 
28ºC 7.0 Rajkowski and Marmer, 1995 0.29 5.70 6.18 
28ºC 7.0 Rajkowski and Marmer, 1995 0.27 6.47 6.14 
28ºC 7.0 Rajkowski and Marmer, 1995 0.28 10.04 6.20 
28ºC 7.0 Rajkowski and Marmer, 1995 0.20 11.61 6.32 
28ºC 7.0 Buchanan and Klawitter, 1992 0.18 7.86 7.50 
28ºC 7.5 Buchanan and Klawitter, 1992 0.20 7.87 7.40 
28ºC 7.5 Buchanan and Klawitter, 1992 0.12 26.46 7.50 
28ºC 7.5 Buchanan and Klawitter, 1992 0.19 7.63 7.20 
28ºC 7.5 Buchanan and Klawitter, 1992 0.16 24.55 6.90 
28ºC 7.5 Buchanan et al., 1997 0.21 7.26 6.36 
28ºC 8.0 Buchanan and Klawitter, 1992 0.17 7.93 7.60 





28ºC 8.5 Buchanan and Klawitter, 1992 0.16 9.03 7.50 
28ºC 8.5 Buchanan and Klawitter, 1992 0.091 18.62 7.40 
28ºC 8.5 Buchanan and Klawitter, 1992 0.16 8.90 7.40 
28ºC 8.5 Buchanan and Klawitter, 1992 0.15 25.58 7.70 
37ºC 4.5 Buchanan and Klawitter, 1992 0.11 12.61 6.80 
37ºC 4.5 Buchanan and Klawitter, 1992 0 0 0 
37ºC 4.5 Buchanan and Klawitter, 1992 0.28 10.11 5.20 
37ºC 4.5 Buchanan and Klawitter, 1992 0.011 139.34 4.80 
37ºC 5.5 Buchanan and Klawitter, 1992 0.28 4.56 7.30 
37ºC 5.5 Buchanan and Klawitter, 1992 0.10 37.49 6.20 
37ºC 5.5 Coleman et al., 2003 0.27 6.50 9.30 
37ºC 5.5 Coleman et al., 2003 0.26 6.29 9.30 
37ºC 5.5 Coleman et al., 2003 0.13 5.71 6.60 
37ºC 5.5 Coleman et al., 2003 0.13 5.89 6.60 
37ºC 5.5 Buchanan and Klawitter, 1992 0.32 5.50 7.20 
37ºC 5.5 Buchanan and Klawitter, 1992 0.14 22.99 6.30 
37ºC 6.5 Buchanan and Klawitter, 1992 0.36 4.19 7.60 
37ºC 6.5 Buchanan and Klawitter, 1992 0.14 17.60 7.10 
37ºC 6.5 Buchanan and Klawitter, 1992 0.40 4.20 6.90 
37ºC 6.5 Buchanan and Klawitter, 1992 0.10 22.64 6.70 
37ºC 6.5 Buchanan et al., 1997 0.39 3.94 6.92 
37ºC 6.5 Buchanan et al., 1997 0.44 4.18 6.21 
37ºC 7.5 Buchanan and Klawitter, 1992 0.40 4.39 7.60 
37ºC 7.5 Buchanan and Klawitter, 1992 0.17 13.08 7.30 
37ºC 7.5 Buchanan and Klawitter, 1992 0.40 5.54 7.20 
37ºC 7.5 Buchanan and Klawitter, 1992 0.15 18.66 6.60 
37ºC 8.5 Buchanan and Klawitter, 1992 0.34 5.13 7.10 
37ºC 8.5 Buchanan and Klawitter, 1992 0.19 30.86 7.10 
37ºC 8.5 Buchanan and Klawitter, 1992 0.24 11.50 6.80 
42ºC 4.5 Buchanan and Klawitter, 1992 0.19 10.51 6.10 
42ºC 4.5 Buchanan and Klawitter, 1992 0.27 13.57 6.50 
42ºC 6.5 Buchanan and Klawitter, 1992 0.38 4.14 7.50 
42ºC 6.5 Buchanan and Klawitter, 1992 0.15 32.89 7.20 
42ºC 6.5 Buchanan and Klawitter, 1992 0.52 3.71 6.30 





42ºC 8.5 Buchanan and Klawitter, 1992 0.42 4.17 7.00 
42ºC 8.5 Buchanan and Klawitter, 1992 0 0 0 
42ºC 8.5 Buchanan and Klawitter, 1992 0.35 10.59 6.30 
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